畑中 豊 (ハタナカ ユタカ)

北海道大学病院 医療・ヘルスサイエンス研究開発機構特任准教授

研究者基本情報

■ 学位
  • 博士(学術)
■ URL
researchmap URLホームページURL■ ID 各種
研究者番号
  • 30589924
J-Global ID■ 研究キーワード・分野
研究キーワード
  • がん免疫療法
  • ゲノム診断
  • 分子診断学
  • コンパニオン診断
  • 分子標的治療
  • 治療抵抗性
研究分野
  • ライフサイエンス, 人体病理学
  • その他, その他, 病態検査学

経歴

■ 経歴
経歴
  • 2018年 - 現在
    北海道大学, 大学病院, 特任准教授
  • 2012年 - 2017年
    北海道大学 大学病院, 特任講師
  • 2010年 - 2011年
    北海道大学 大学病院, 特任助教
学歴
  • 1999年 - 2002年, 神戸大学大学院 自然科学研究科, Graduate School of Science and Technology, Department of Division of Life Science
委員歴
  • 2017年 - 現在
    日本病理学会, ゲノム病理診断検討委員会委員, 学協会
  • 2016年 - 現在
    日本病理学会, 医療業務委員, 学協会
  • 2014年 - 現在
    日本肺癌学会, バイオマーカー委員, 学協会
  • 2011年 - 現在
    日本病理学会, 学術評議員, 学協会

研究活動情報

■ 論文
  • CD44-targeted near-infrared photoimmunotherapy shows potent anti-tumor effects in an orthotopic lung cancer model
    Hiroshi Yamasaki; Kohei Nakajima; Hideki Ujiie; Ryohei Chiba; Haruhiko Shiiya; Kazuto Ohtaka; Aki Fujiwara-Kuroda; Masato Aragaki; Kanako C. Hatanaka; Yutaka Hatanaka; Mikako Ogawa; Tatsuya Kato
    BMC Cancer, 2026年08月01日, [査読有り]
    英語, 研究論文(学術雑誌), Abstract

    Background
    Lung cancer continues to be associated with a dismal prognosis, despite the recent development of multiple therapeutic modalities. Consequently, there remains an urgent need for the advancement of novel and more efficacious treatment strategies. Cluster of Differentiation 44 (CD44), a cell surface marker associated with cancer stem cells, has been implicated in tumor progression, metastasis, and resistance to therapy, thereby representing a compelling target for oncologic intervention. Near-infrared photoimmunotherapy (NIR-PIT) is an emerging cancer treatment modality that integrates the high specificity of monoclonal antibodies with cytotoxic effects induced by a photosensitizer upon exposure to NIR light. In the present study, we evaluated the therapeutic efficacy of CD44-targeted NIR-PIT utilizing an orthotopic lung cancer mouse model established via transtracheal tumor cell injection, which more faithfully recapitulates the tumor microenvironment compared to conventional subcutaneous models.


    Methods
    An antibody–photoabsorber conjugate was synthesized by conjugating an anti-CD44 monoclonal antibody (IM7) with IRDye700DX (IR700). The cytotoxic effects of CD44-targeted NIR-PIT were assessed in vitro using CD44-expressing lung cancer cell lines. Therapeutic efficacy was subsequently evaluated in an orthotopic lung cancer mouse model established by transtracheal injection of tumor cells. Tumor progression was monitored by bioluminescence imaging, and survival and histopathological changes were analyzed following treatment.


    Results
    In vitro experiments employing CD44-expressing cell lines demonstrated that CD44-targeted NIR-PIT induces cytotoxicity in a light dose-dependent manner. The in vivo therapeutic efficacy was subsequently assessed using the orthotopic lung cancer mouse model. Following CD44-targeted NIR-PIT, bioluminescence imaging revealed a marked reduction in tumor burden, accompanied by an exploratory difference in survival in a small cohort. Histological analysis further demonstrated tumor cell elimination and intratumoral hemorrhage in the treated lesions.


    Conclusions
    CD44-targeted NIR-PIT demonstrated potent antitumor activity in an orthotopic lung cancer model. These findings support the potential clinical translation of CD44-targeted NIR-PIT as a novel therapeutic strategy for lung cancer. Further studies are warranted to optimize clinically feasible light-delivery methods and establish the long-term safety of this approach.
  • Feasibility study of photoimmunotherapy combination with ASP-1929 for vulvar, vaginal, and cervical cancer.
    Ryutaro Yamamoto; Hiroshi Asano; Kanako C Hatanaka; Yoshiki Shinomiya; Hiroyuki Yamazaki; Hiroko Matsumiya; Michiko Nagamine; Yuko Sasajima; Yutaka Hatanaka; Hidemichi Watari
    Journal of gynecologic oncology, 2026年05月21日, [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVE: The aim of this study was to evaluate the feasibility of photoimmunotherapy (PIT) using ASP-1929, an anti-epidermal growth factor receptor (EGFR) antibody-dye conjugate, for vulvar, vaginal, and cervical cancers by validating EGFR expression and establishing immunohistochemistry (IHC)-based eligibility criteria for a phase II trial, HICARi study. METHODS: Cetuximab-binding activity was analyzed in gynecologic cancer cell lines (CaSki, HeLa, and Ishikawa) using flow cytometry and compared with positive controls (A431 and BxPC-3) and a low-EGFR control (MCF-7). IHC was performed on cell blocks and clinical specimens of vulvar, vaginal, and cervical cancers (validation cohort, n=27; screening cohort, n=40). RESULTS: CaSki demonstrated comparable or higher EGFR binding than BxPC-3, whereas HeLa and Ishikawa showed weaker binding. IHC staining intensity correlated with flow cytometry findings. Squamous cell carcinomas consistently exhibited moderate-to-strong EGFR expression, whereas non-squamous carcinomas displayed variable expression. EGFR positivity was defined as >30% of tumor cells with at least moderate membranous staining (2+ or 3+). In the validation cohort, EGFR positivity was observed in 71.4% of the vulvar, 80.0% of the vaginal, and 87.5% of the cervical cancers. The screening cohort showed similar rates: 88.9% of vulvar, 100% of vaginal, and 75.0% of cervical cancers. CONCLUSION: We demonstrated correlation between cetuximab-binding and IHC staining intensity, establishing IHC criteria (≥2+) for patient selection. EGFR positivity (71.4%-87.5%) indicates substantial eligibility for ASP-1929 PIT. Therapeutic efficacy will be evaluated in the HICARi study.
  • High CD73 Expression Is Associated with Poor Prognosis in Biliary Tract Cancer Through Reduced Stromal Tumor-Infiltrating Lymphocytes
    Shoya Shiratori; Kazumichi Kawakubo; Kanako C. Hatanaka; Takuma Kobayashi; Teppei Konishi; Yoshiki Shinomiya; Soichiro Oda; Shunichiro Nozawa; Hiroki Yonemura; Ryo Sugiura; Kazuaki Harada; Yoshitsugu Nakanishi; Takehiro Noji; Shinya Tanaka; Satoshi Hirano; Masaki Kuwatani; Yutaka Hatanaka; Naoya Sakamoto
    Cancers, 18, 6, 975, 975, MDPI AG, 2026年03月18日
    研究論文(学術雑誌), Background: Biliary tract cancer (BTC) is an aggressive malignancy with limited therapeutic options and a poor prognosis. CD73 is upregulated under hypoxic conditions and promotes tumor progression. However, its clinical role in BTC and interaction with tumor-infiltrating lymphocytes (TILs) remain unclear. This study aimed to elucidate the association between CD73 expression and prognosis in BTC, as well as its impact on the tumor microenvironment (TME) and TILs. Methods: This retrospective study included 100 patients who underwent curative BTC surgery at Hokkaido University Hospital between 2018 and 2023. Formalin-fixed tumor specimens were analyzed using DeepPathFinder™ (biomy Inc., Tokyo, Japan), an AI-based digital pathology platform enabling objective quantification of CD73 expression and lymphocyte infiltration within tumoral (T) and stromal (S) compartments. Immunohistochemistry for CD3, CD8, Foxp3, and CD163 was used to identify T-cell subsets and macrophages. Associations between CD73, TIL subsets, and overall survival (OS) were assessed using the Kaplan–Meier, Cox regression, and Spearman correlation analyses. Results: High T-CD73 expression was associated with shorter OS (hazard ratio [HR] = 1.97, p = 0.041), whereas S-CD73 showed no prognostic relevance. Conversely, high S-TIL density was correlated with improved survival (HR = 0.49, p = 0.032). T-CD73 expression was negatively correlated with stromal CD3+ and CD8+ T-cell densities, indicating selective suppression of stromal cytotoxic T-lymphocyte (CTL) infiltration. No significant correlations were observed between Foxp3+ T cells and CD163+ M2 macrophages. Conclusions: CD73 upregulation in tumor cells impairs stromal CTL and TIL activity, leading to a poor prognosis. Spatial distribution, rather than total TIL number, better reflects effective anti-tumor immunity.
  • 気管支鏡による検体採取と治療の最前線 マルチ遺伝子検査に最適な検体とは
    畑中 豊; 四宮 義貴; 横内 浩; 佐々木 高明; 榊原 純; 品川 尚文; 畑中 佳奈子; 大泉 聡史
    肺癌, 65, 5, 346, 346, (NPO)日本肺癌学会, 2025年11月
    日本語
  • がんゲノム診療における細胞検体の取扱い指針
    畑中 佳奈子; 四宮 義貴; 奥村 麻美; 森井 英一; 佐藤 之俊; 畑中 豊
    肺癌, 65, 5, 399, 399, (NPO)日本肺癌学会, 2025年11月
    日本語
  • 全ゲノム解析の臨床実装に向けての現在地 がん全ゲノム解析における検体取扱いと実臨床検体のWGS応用
    四宮 義貴; 畑中 佳奈子; 畑中 豊
    日本臨床細胞学会雑誌, 64, Suppl.2, 455, 455, (公社)日本臨床細胞学会, 2025年11月
    日本語
  • Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer.
    Satoshi Kano; Naomi Kiyota; Ichiro Kinoshita; Yuichiro Tada; Kei Ijichi; Tomoko Yamazaki; Yasushi Shimizu; Yutaka Hatanaka; Hitoshi Tsuda; Shojiroh Morinaga; Yoshihiro Matsuno; Yoichi M Ito; Naoki Nishimoto; Keiko Kobayashi; Toshiyuki Isoe; Takuro Noguchi; Akihiro Homma; Hirotoshi Dosaka-Akita
    Japanese journal of clinical oncology, 55, 10, 1131, 1140, 2025年10月07日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUNDS: Standard systemic chemotherapy remains unestablished for recurrent or metastatic (RM) salivary gland cancer (SGC) due to its rarity. A single institute phase II trial of trastuzumab and docetaxel previously showed efficacy with human epidermal growth factor receptor 2 (HER2)-positive SGC. METHODS: We conducted a multicenter, single-arm, open-label phase II trial of trastuzumab and docetaxel for HER2-positive RM SGC. Patients received trastuzumab 6 mg/kg (loading dose 8 mg/kg) and docetaxel 70 mg/m2 every 3 weeks up to eight cycles. The primary endpoint was the objective response rate (ORR) by a blinded independent review committee. Secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety. Forty-eight patients were screened for HER2 status; 23 were HER2-positive. RESULTS: Eighteen patients were enrolled, with 16 receiving the protocol treatment. Fourteen patients were diagnosed with salivary duct carcinoma. The ORR was 60.0% (95% confidence interval [CI], 32.3 to 83.7). The median PFS was 8.5 months (95% CI, 6.0 to 12.7), the median OS, 33.8 months (95% CI, 16.9 to not estimable), and the DCR, 93.3% (95% CI, 68.1 to 99.8). The most frequent grade ≥3 treatment-emerged adverse events were neutropenia (100%), leukopenia (93.8%), lymphopenia (18.8%), and febrile neutropenia (12.5%). One treatment-related death occurred (6.3%) due to hypoalbuminemia. CONCLUSIONS: These results demonstrate the significant efficacy and predictable toxicities of trastuzumab and docetaxel in patients with HER2-positive RM SGC, leading to the simultaneous approval of trastuzumab and HER2 companion diagnostics assay for this setting in Japan.
  • 胆道癌におけるCD73発現とその進行・予後との関連性
    白鳥 翔也; 川久保 和道; 畑中 佳奈子; 桑谷 将城; 小田 総一郎; 野澤 俊一郎; 米村 洋輝; 杉浦 諒; 畑中 豊; 坂本 直哉
    日本消化器病学会雑誌, 122, 臨増大会, A720, A720, (一財)日本消化器病学会, 2025年10月
    日本語
  • The size of CD8+ infiltrating T cells is a prognostic marker for esophageal squamous cell carcinoma
    Kengo Shigehara; Noriko Kawai; Tomohide Shirosaki; Yuma Ebihara; Aiko Murai; Akari Takaya; Serina Tokita; Kenta Sasaki; Naoki Shijubou; Terufumi Kubo; Kenji Murata; Takayuki Kanaseki; Tomohide Tsukahara; Yutaka Hatanaka; Tomoko Mitsuhashi; Toshiaki Shichinohe; Yoshihiko Hirohashi; Satoshi Hirano; Toshihiko Torigoe
    Scientific Reports, 15, 1, Springer Science and Business Media LLC, 2025年07月22日
    研究論文(学術雑誌)
  • 閉塞性大腸癌の金属ステント留置による病理組織学所見に与える影響の解明
    浜田 卓巳; 今泉 健; 畑中 佳奈子; 畑中 豊; 石黒 友唯; 下國 達志; 松井 博紀; 吉田 雅; 市川 伸樹; 武冨 紹信
    日本消化器外科学会総会, 80回, 2470, 2470, (一社)日本消化器外科学会, 2025年07月
    日本語
  • HR陽性HER2陰性乳癌の早期または晩期再発における網羅的遺伝子発現解析を用いた検討
    萩尾 加奈子; 畑中 佳奈子; 四宮 義貴; 奥村 麻美; 南家 綾江; 松島 由佳; 柏 和哉; 大東 元就; 木下 一郎; 高橋 將人; 畑中 豊
    日本乳癌学会総会プログラム抄録集, 33回, 432, 432, (一社)日本乳癌学会, 2025年07月
    日本語
  • Midkine Promotes Tumor Growth and Attenuates the Effect of Cisplatin in Small Cell Lung Cancer.
    Shotaro Ito; Jun Sakakibara-Konishi; Mineyoshi Sato; Tetsuaki Shoji; Megumi Furuta; Hirofumi Takahashi; Kosuke Tsuji; Daisuke Morinaga; Masahiro Kashima; Hidenori Kitai; Junko Kikuchi; Eiki Kikuchi; Kanako C Hatanaka; Yutaka Hatanaka; Kyoko Hida; Takuro Noguchi; Satoshi Konno
    Cancer medicine, 14, 13, e71034, 2025年07月, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Small cell lung cancer (SCLC) is a highly aggressive disease associated with poor patient survival rates. The addition of an anti-programmed death ligand 1 antibody to platinum combination chemotherapy can improve its prognosis. However, only a few patients achieve a long-term response; thus, establishing new therapies for SCLC is crucial. Midkine (MDK) is a heparin-binding growth factor involved in various biological processes, including cell proliferation and chemotherapeutic resistance, in diverse cancers. MDK has garnered attention as a therapeutic and diagnostic target for several cancers; however, only a few studies have evaluated its expression and function in SCLC. This study aimed to evaluate the MDK expression in human SCLC tissue and human SCLC cell lines, and to clarify its function in tumorigenesis. METHODS: MDK expression was analyzed in vitro and in vivo through ELISA, immunohistochemistry, and western blotting. Its effects on cell proliferation, as well as the effects of cisplatin, were evaluated using the MTT assay. RESULTS: MDK was pathologically expressed in human SCLC tumor tissues but not in normal lung tissues. Serum MDK concentrations in patients with SCLC reflected the SCLC tumor burden and were correlated with response to treatment. Moreover, MDK induced cell proliferation and attenuated the effects of cisplatin in SCLC cell lines. An MDK inhibitor and cisplatin exerted synergistic antitumor effects both in vitro and in vivo. Furthermore, MDK positively regulated the AKT pathway. CONCLUSION: Our findings indicate that MDK promotes cell proliferation and chemotherapeutic resistance by activating the AKT pathway in SCLC cells. Therefore, MDK may be a potential therapeutic and diagnostic target for SCLC.
  • Frequency and Prognostic Impact of Local Ablation Therapy for Oligoprogression in Non-Small Cell Lung Cancer.
    Daisuke Morinaga; Jun Sakakibara-Konishi; Ryohei Kamada; Masahiro Kashima; Kosuke Tsuji; Shotaro Ito; Megumi Furuta; Tetsuaki Shoji; Yuta Takashima; Hidenori Kitai; Yasuyuki Ikezawa; Hiroshi Taguchi; Tatsuya Kato; Yoshiki Shinomiya; Kanako C Hatanaka; Yutaka Hatanaka; Satoshi Konno
    Thoracic cancer, 16, 13, e70119, 2025年07月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: During the systemic treatment of patients with non-small cell lung cancer (NSCLC), oligoprogression (OP), a condition in which most lesions remain controlled while a few progress or develop, has recently attracted attention. Traditionally, systemic therapy is continued after disease progression; however, advancements in local ablation therapy (LAT), such as radiotherapy and surgery, have demonstrated clinical efficacy in patients with OP. The characteristics of patients who may benefit from LAT or their genetic background remain unclear. This study evaluated the frequency, clinicopathological characteristics, and efficacy of LAT in the treatment of OP. METHODS: A retrospective review was conducted of 510 patients with NSCLC who experienced disease progression after systemic therapy. RESULTS: Overall, 106/510 (23.6%) patients exhibited OP; among these, six patients who received only the best supportive care after OP were excluded. Systemic therapy alone was administered to 79 patients (79.0%), while 21 (21.0%) received LAT. Median local progression-free survival was numerically longer in the LAT group than in the systemic therapy-only group (8.3 and 6.7 months, respectively; p = 0.38). In addition, overall survival was also numerically longer in the LAT group than in the systemic therapy-only group (78.1 and 55.1 months, respectively; p = 0.57). Ribonucleic acid sequencing revealed an increase in extracellular matrix-related gene expression after OP, providing potential molecular insights. CONCLUSIONS: Although this study found no significant prognostic benefit of LAT in patients with OP, future research integrating clinical and molecular data may identify patients most likely to benefit from LAT.
  • 筋上皮系マーカーが陽性となったextraskeletal myxoid chondrosarcomaの1例
    姜 博文; 松岡 正剛; 畑中 佳奈子; 中里 信一; 中村 ハルミ; 中村 誠二; 小野寺 智洋; 田中 伸哉; 畑中 豊; 岩崎 倫政
    日本整形外科学会雑誌, 99, 6, S1364, S1364, (公社)日本整形外科学会, 2025年06月
    日本語
  • 細胞検体を用いたゲノム診療の今後と課題 細胞検体を用いたゲノム診療の今後
    畑中 豊; 四宮 義貴; 畑中 佳奈子
    日本臨床細胞学会雑誌, 64, Suppl.1, 118, 118, (公社)日本臨床細胞学会, 2025年06月
    日本語
  • 細胞検体を用いたゲノム診療の今後と課題 細胞検体を用いた全ゲノム解析に関するフィージビリティの検討
    四宮 義貴; 畑中 佳奈子; 奥村 麻美; 南家 綾江; 畑中 豊
    日本臨床細胞学会雑誌, 64, Suppl.1, 119, 119, (公社)日本臨床細胞学会, 2025年06月
    日本語
  • がんゲノム医療の光と影 がんコンパニオン診断の現状 光と影
    畑中 豊; 四宮 義貴; 畑中 佳奈子
    日本臨床細胞学会雑誌, 64, Suppl.1, 173, 173, (公社)日本臨床細胞学会, 2025年06月
    日本語
  • 4種類の組織型を含んだ混合型小細胞肺癌の1切除例
    高木 統一郎; 河井 康孝; 羅 昊; 木村 太俊; 小熊 昂; 牧田 啓史; 四宮 義貴; 畑中 佳奈子; 畑中 豊; 池澤 靖元
    肺癌, 65, 3, 208, 208, (NPO)日本肺癌学会, 2025年06月
    日本語
  • AI-powered quantification of tumor-infiltrating lymphocytes from H&E stained images in ovarian cancer and its association with PARP inhibitor therapy outcomes.
    Hiroshi Asano; Kanako C. Hatanaka; Takuma Kobayashi; Teppei Konishi; Hiroyuki Kurosu; Hiroko Matsumiya; Yoshiki Shinomiya; Ryo Matoba; Daisuke Komura; Shumpei Ishikawa; Shinya Tanaka; Hidemichi Watari; Yutaka Hatanaka
    Journal of Clinical Oncology, 43, 16_suppl, 5575, 5575, American Society of Clinical Oncology (ASCO), 2025年06月
    研究論文(学術雑誌), 5575

    Background: Maintenance therapy with PARP inhibitors improves the prognosis of patients with advanced or recurrent ovarian cancer. However, a simple biomarker detectable at treatment initiation remains unclear. This study evaluated the relationship between prognosis and artificial intelligence (AI)-powered quantification of immune cells in tumor and stroma areas in hematoxylin and eosin (H&E) slides. Methods: We evaluated 28 ovarian cancer patients treated with PARP inhibitors in our institution from 2019 to 2021. We developed an AI model to detect the epithelium and lymphocytes, specifically T cells (CD3+) and B cells (CD20+), from H&E-stained slides. This model was trained using annotated datasets, which included 26,509 images of the epithelium and 12,273 images of lymphocytes. The tumor bed areas were precisely defined by pathologists. Subsequently, the AI model identified epithelial and lymphocyte regions within these predefined areas. Using a treatment duration of PARP inhibitor with 12 months or more as the criterion, we identified the most relevant immune cell type based on the AUCs of the ROC curve and determined cutoff values. Furthermore, tumor BRCA1/2 status was assessed by a custom-targeted NGS testing panel. A log-rank test with a p-value < 0.05, considered statistically significant, examined the relationship between prognosis and tumor characteristics. Results: A total of 61 H&E slides were analyzed by AI: 28 slides before first-line chemotherapy, 25 after first-line chemotherapy, and 8 were the recurrent sample. The highest AUC was the lymphocyte-to-tumor area ratio (tumor-infiltrating lymphocyte score in tumor area, tTIL score) before the initial treatment, with an AUC of 0.73. The cutoff value of the tTIL score was set to 0.000534 based on the Youden index, dividing patients into tTIL-low (n=14) and tTIL-high (n=14) groups. The median follow-up period of the censored cases was 62.5 months vs. 77.3 months (p = 0.71). There were no significant differences in age, histological subtype, initial treatment method, proportion of R0 surgery, or that of tumor BRCA1/2 pathogenic mutations between groups. PARP inhibitors were used as maintenance therapy for recurrent settings in 71.4% of cases in both groups. The 5-year overall survival (5-y OS) rate of tTIL-high was significantly better than that of tTIL-low (84.4% vs. 30.8%, p = 0.0068). The median duration of OS after initiation of PARP inhibitors was significantly longer in the tTIL-high group (23.8 months vs. not reached, p = 0.046), and especially in tumor BRCA1/2-negative cases, tTIL-high had a significantly better 5-y OS rate of 90% vs. 12.5% (p = 0.0015). Conclusions: AI-powered tTIL score may predict the prognosis of ovarian cancer patients treated with PARP inhibitors. Future efforts will focus on increasing sample size and optimizing the tTIL score cutoff to improve accuracy.
  • Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic ductal adenocarcinoma
    Takeaki Nakamura; Kanako C. Hatanaka; Yasuyuki Kawamoto; Shiho Kaneko; Koichi Ishida; Kazuaki Harada; Satoshi Yuki; Yoshito Komatsu; Yutaka Hatanaka; Naoya Sakamoto
    Journal of Cancer Research and Clinical Oncology, 151, 5, Springer Science and Business Media LLC, 2025年05月10日
    研究論文(学術雑誌)
  • HER2陽性唾液腺がんに対するトラスツマブ・デルクステカンの第2相試験
    清田 尚臣; 木下 一郎; 加納 里志; 本間 義崇; 田原 信; 福田 直樹; 伊藤 陽一; 畑中 豊; 松野 吉宏; 秋田 弘俊
    頭頸部癌, 51, 2, 144, 144, (一社)日本頭頸部癌学会, 2025年05月
    日本語
  • 気管支狭窄拡張術後にALK-TKIを導入したHIP1-ALK陽性肺癌の1例
    佐藤 祐麻; 北井 秀典; 田上 敬太; 石田 有莉子; 篠崎 鮎香; 佐藤 峰嘉; 高橋 宏典; 古田 恵; 高島 雄太; 庄司 哲明; 池澤 靖元; 榊原 純; 品川 尚文; 今野 哲; 大川 紘弥; 大塚 紀幸; 畑中 佳奈子; 畑中 豊; 横内 浩
    肺癌, 65, 1, 65, 65, (NPO)日本肺癌学会, 2025年02月
    日本語
  • Effectiveness of afatinib after long-term gefitinib treatment for EGFR L858R and S768I compound mutation-positive lung adenocarcinoma: A case report.
    Ayuka Dai-Shinozaki; Jun Sakakibara-Konishi; Kanako C Hatanaka; Kento Wakabayashi; Naofumi Shinagawa; Yoshihiro Matsuno; Yutaka Hatanaka; Satoshi Konno
    Respiratory medicine case reports, 57, 102249, 102249, 2025年, [国際誌]
    英語, 研究論文(学術雑誌), Afatinib, a second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), irreversibly inhibits the pan-human epidermal growth factor receptor (HER) family. It is effective in patients with lung cancer with various EGFR mutations; however, its efficacy in overcoming resistance following first-line EGFR-TKI treatment remains unclear. Here, we report the case of a 68-year-old woman with lung adenocarcinoma (pStage IA, pT1bN0M0) who underwent surgical resection in March 2012 following several previous lung cancer resections. In November 2012, postoperative recurrence with pleural dissemination led to the detection of the EGFR L858R mutation in the malignant pleural effusion specimen using peptide nucleic acid-locked nucleic acid polymerase chain reaction clamping (PNA-LNA PCR clamp). The patient was treated with gefitinib for 8 years, after disease progression with multiple lung metastases. The metastatic lesions harbored compound EGFR S768I and EGFR L858R mutations, as identified using the Oncomine Dx Target Test Multi-CDx System (ODxTT). Treatment with afatinib resulted in rapid metastatic lesion regression. Reanalysis of the previously resected surgical specimens confirmed the presence of the EGFR S768I and L858R compound mutations in all samples, which suggests that S768I was not an acquired resistance mutation. Furthermore, immunohistochemical analysis revealed an increase in HER2 and HER3 protein expression in the gefitinib-resistant specimens. These findings suggest that HER2 and HER3 upregulation may contribute to gefitinib resistance, and that afatinib may effectively target these resistance mechanisms.
  • Survivin as a Therapeutic Target for Neuroendocrine Neoplasms.
    Yuma Hane; Takahiro Tsuchikawa; Toru Nakamura; Kanako C Hatanaka; Katsunori Sasaki; Noriko Kawai; Shintaro Takeuchi; Kimitaka Tanaka; Yoshitsugu Nakanishi; Toshimichi Asano; Takehiro Noji; Toshiaki Shichinohe; Yutaka Hatanaka; Yoshihiko Hirohshi; Toshihiko Torigoe; Satoshi Hirano
    Neuroendocrinology, 115, 3-4, 295, 307, 2025年, [国際誌]
    英語, 研究論文(学術雑誌), INTRODUCTION: Although neuroendocrine neoplasms (NENs) have a good prognosis, distant metastasis remains a crucial prognostic factor. Survivin, a tumor-associated antigen, is overexpressed in several solid tumors, indicating poor prognosis. We aimed to evaluate the clinical significance and role of survivin as a therapeutic target for NEN. METHODS: We assessed the cytotoxicity of Survivin-2B (a splicing variant of survivin) 80-88 specific CTL clone with HLA-A24 restriction against NEN cell lines using intracellular staining for interferon-γ and assessed the frequency of Survivin-2B 80-88 CTL precursors in nine HLA-A24-positive patients with NEN using tetramer staining and compared it before and after resection. Finally, we evaluated the association between survivin expression and prognosis in 74 patients with pancreatic NEN using immunohistochemistry. RESULTS: Survivin-2B 80-88 CTL clone showed high cytotoxicity against QGP-1 (HLA-A24 positive) cocultured with the Survivin-2B 80-88 peptide. Only three patients were positive for tetramer staining; two showed decreased Survivin-2B 80-88 CTL precursor following resection. The nuclear survivin-low group had a significantly better prognosis than the nuclear survivin-high group. CONCLUSION: Survivin in NEN is antigenic and may induce cellular immunity via the Survivin-2B CTL precursor. Survivin-targeting immunotherapy can be used to treat NEN with highly expressed Survivin-2B.
  • Actionable Gene Alterations Identified in Patients With Malignant Melanoma by Targeted Sequencing in Japan.
    Takuro Noguchi; Shin Ariga; Rika Moku; Junko Kikuchi; Toraji Amano; Takuya Maeda; Kosuke Ishikawa; Taku Maeda; Akihiko Shiiya; Tomohiro Goda; Yoshihito Ohhara; Kanako Hagio; Yusuke Saito; Kanako C Hatanaka; Yutaka Hatanaka; Jun Taguchi; Satoshi Takeuchi; Yasushi Shimizu; Ichiro Kinoshita
    JCO precision oncology, 9, e2400437, 2025年01月, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Precision medicine plays an important role in the treatment of patients with advanced melanoma. Despite its high incidence in White patients, advanced melanoma is rare in Asian countries, hampering prospective clinical trials targeting the Asian population. This retrospective study aimed to elucidate the real-world molecular diagnoses and outcomes of Japanese patients with melanoma using comprehensive genome profiling (CGP). MATERIALS AND METHODS: Patients with melanoma who completed standard anticancer medical treatments (including those expected to complete the treatments) underwent CGP, which is covered by the National Health Insurance. We analyzed the results and clinical annotations of 569 patients registered before August 2023 in a national database. RESULTS: Skin, mucosal, and uveal melanomas accounted for 64%, 28%, and 7% of cases, respectively. Patients with BRAF, NRAS, NF1, and KIT variants represented 25%, 20%, 17%, and 17%, respectively. Eighty-two percent of BRAF, 97% of NRAS, 69% of NF1, and 54% of KIT were actionable alterations (ie, BRAF classes I, II, and III, NRAS Q61, G12, G13, NF1 loss-of-function, KIT gain-of-function variants). BRAF V600E/K variants occurred in 22% of skin and 2% of mucosal melanomas, but not in uveal melanomas. The mean tumor mutation burden in cutaneous melanomas was 4.2 variants/Mb. Patients previously treated with BRAF-targeted therapy harbored amplifications of BRAF and cell cycle genes more frequently than therapy-naive patients. Thirty-six patients (6.3%) were treated following the molecular tumor board (MTB) recommendations. CONCLUSION: Actionable gene alterations in BRAF, NRAS, NF1, and KIT are common in Japanese patients with melanoma. However, few patients were treated according to the MTB recommendations, suggesting that there is an unmet need to increase accessibility to gene-matched clinical trials in Japan.
  • LBCとゲノム[ゲノム診療時代における細胞診のあり方検討WG] 呼吸器領域の細胞検体を用いたゲノム診断の課題と今後の展望
    畑中 佳奈子; 四宮 義貴; 奥村 麻美; 南家 綾江; 田中 佑実; 山本 万美子; 東 学; 石田 裕子; 丸川 活司; 畑中 豊
    日本臨床細胞学会雑誌, 63, Suppl.2, 494, 494, (公社)日本臨床細胞学会, 2024年10月
    日本語
  • 原発不明癌の細胞診 原発不明癌におけるゲノム検査の変遷と今後
    四宮 義貴; 畑中 佳奈子; 畑中 豊
    日本臨床細胞学会雑誌, 63, Suppl.2, 508, 508, (公社)日本臨床細胞学会, 2024年10月
    日本語
  • 肺癌におけるCD73に対する近赤外線免疫療法(NIR-PIT)と抗PD-1抗体の併用療法の有効性(Efficacy of Combined Therapy with Near-Infrared Photoimmunotherapy Targeting CD73 and Anti-PD-1 Antibody in Lung Cancer)
    千葉 龍平; 中島 孝平; 畑中 佳奈子; 氏家 秀樹; 新垣 雅人; 小林 拓馬; 小西 哲平; 畑中 豊; 加藤 達哉; 小川 美香子; 小川 美香子
    日本癌学会総会記事, 83回, P, 1234, (一社)日本癌学会, 2024年09月
    英語
  • Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model.
    Hiroki Niwa; Toru Nakamura; Hiroki Kushiya; Tomotaka Kuraya; Kazuho Inoko; Akihito Inagaki; Tomohiro Suzuki; Katsunori Sasaki; Takahiro Tsuchikawa; Kei Hiraoka; Toshiaki Shichinohe; Yutaka Hatanaka; Douglas J Jolly; Noriyuki Kasahara; Satoshi Hirano
    Cancer gene therapy, 31, 9, 1390, 1401, 2024年09月, [国際誌]
    英語, 研究論文(学術雑誌), Toca 511, a tumor-selective retroviral replicating vector encoding the yeast cytosine deaminase (yCD) gene, exerts direct antitumor effects through intratumoral prodrug 5-fluorocytosine (5-FC) conversion to active drug 5-fluorouracil by yCD, and has demonstrated therapeutic efficacy in preclinical and clinical trials of various cancers. Toca 511/5-FC treatment may also induce antitumor immunity. Here, we first examined antitumor immune responses activated by Toca 511/5-FC treatment in an immunocompetent murine pancreatic cancer model. We then evaluated the therapeutic effects achieved in combination with anti-programmed cell death protein 1 antibody. In the bilateral subcutaneous tumor model, as compared with the control group, enhanced CD8+ T-cell-mediated cytotoxicity and increased T-cell infiltration in Toca 511-untransduced contralateral tumors were observed. Furthermore, the expression levels of T-cell co-inhibitory receptors on CD8+ T-cells increased during treatment. In the bilateral subcutaneous tumor model, combination therapy showed significantly stronger tumor growth inhibition than that achieved with either monotherapy. In an orthotopic tumor and peritoneal dissemination model, the combination therapy resulted in complete regression in both transduced orthotopic tumors and untransduced peritoneal dissemination. Thus, Toca 511/5-FC treatment induced a systemic antitumor immune response, and the combination therapy could be a promising clinical strategy for treating metastatic pancreatic cancer.
  • Epithelioid pleural mesothelioma successfully treated with perioperative immunotherapy: a case report.
    Gaku Yamazaki; Aki Fujiwara-Kuroda; Jun Muto; Hideki Ujiie; Masato Aragaki; Megumi Furuta; Sakurako Ohno; Kanako C Hatanaka; Yutaka Hatanaka; Yoshihiro Matsuno; Tatsuya Kato
    General Thoracic and Cardiovascular Surgery Cases, 3, 1, 31, 31, 2024年06月11日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Pleural mesothelioma, characterized by a dismal prognosis even with multimodal therapy, has seen emerging interest in immune checkpoint inhibitors (ICIs) due to their demonstrated efficacy. Here, we present a case of epithelioid-type pleural mesothelioma with chest wall invasion treated with definitive ICI therapy, resulting in a remarkable pretreatment effect. CASE PRESENTATION: A 46-year-old man was diagnosed with an abnormal chest shadow on a medical check, and a computed tomography scan showed pleural thickening at the dorsal right upper chest wall. One of the nodules was suspected to have invaded the chest wall. A needle biopsy revealed epithelioid-type pleural mesothelioma. After five cycles of nivolumab plus ipilimumab, he underwent right pleurectomy/decortication (P/D). Pathological examination revealed a significant treatment effect, showing numerous lymphocytes infiltrating the tumor nodule and viable tumor cells localized at approximately 6 mm. CONCLUSION: Although further accumulation of cases is required to evaluate the effectiveness and case selection, P/D after immunotherapy is a useful curative treatment option for advanced pleural mesothelioma.
  • Evaluating Cellularity Estimation Methods: Comparing AI Counting with Pathologists' Visual Estimates.
    Tomoharu Kiyuna; Eric Cosatto; Kanako C Hatanaka; Tomoyuki Yokose; Koji Tsuta; Noriko Motoi; Keishi Makita; Ai Shimizu; Toshiya Shinohara; Akira Suzuki; Emi Takakuwa; Yasunari Takakuwa; Takahiro Tsuji; Mitsuhiro Tsujiwaki; Mitsuru Yanai; Sayaka Yuzawa; Maki Ogura; Yutaka Hatanaka
    Diagnostics (Basel, Switzerland), 14, 11, 2024年05月28日, [国際誌]
    英語, 研究論文(学術雑誌), The development of next-generation sequencing (NGS) has enabled the discovery of cancer-specific driver gene alternations, making precision medicine possible. However, accurate genetic testing requires a sufficient amount of tumor cells in the specimen. The evaluation of tumor content ratio (TCR) from hematoxylin and eosin (H&E)-stained images has been found to vary between pathologists, making it an important challenge to obtain an accurate TCR. In this study, three pathologists exhaustively labeled all cells in 41 regions from 41 lung cancer cases as either tumor, non-tumor or indistinguishable, thus establishing a "gold standard" TCR. We then compared the accuracy of the TCR estimated by 13 pathologists based on visual assessment and the TCR calculated by an AI model that we have developed. It is a compact and fast model that follows a fully convolutional neural network architecture and produces cell detection maps which can be efficiently post-processed to obtain tumor and non-tumor cell counts from which TCR is calculated. Its raw cell detection accuracy is 92% while its classification accuracy is 84%. The results show that the error between the gold standard TCR and the AI calculation was significantly smaller than that between the gold standard TCR and the pathologist's visual assessment (p<0.05). Additionally, the robustness of AI models across institutions is a key issue and we demonstrate that the variation in AI was smaller than that in the average of pathologists when evaluated by institution. These findings suggest that the accuracy of tumor cellularity assessments in clinical workflows is significantly improved by the introduction of robust AI models, leading to more efficient genetic testing and ultimately to better patient outcomes.
  • 核酸品質の視点からみた細胞診検体取扱い 呼吸器領域における細胞検体の取扱いと核酸品質
    四宮 義貴; 畑中 佳奈子; 奥村 麻美; 南家 綾江; 田中 佑実; 山本 万美子; 東 学; 石田 裕子; 畑中 豊
    日本臨床細胞学会雑誌, 63, Suppl.1, 138, 138, (公社)日本臨床細胞学会, 2024年05月
    日本語
  • Expression Analysis of Early Metastatic Seeding of Colorectal Cancer.
    Akifumi Sawada; Masafumi Ohira; Kanako C Hatanaka; Hiroki Matsui; Nobuki Ichikawa; Tadashi Yoshida; Moto Fukai; Yoshihiro Matsuno; Shigenori Homma; Yutaka Hatanaka; Akinobu Taketomi
    Annals of surgical oncology, 31, 3, 2101, 2113, 2024年03月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Distant metastasis is the leading cause of death in patients with colorectal cancer (CRC). Tumor dissemination for metastasis formation occurs in advanced cancers and also during early stages of tumorigenesis. Here, we investigated the genes involved in early metastatic seeding of CRC using gene expression analysis. PATIENTS AND METHODS: We performed a cDNA microarray using specimens resected from stages I-II CRC with and without metachronous metastatic recurrence. For the candidate genes, we immunohistochemically validated protein expression using a tissue microarray of stages I-III CRC. RESULTS: The expression of TROP2, VWCE, and BMP7 was upregulated in the recurrence group rather than in the non-recurrence group. Protein expression analysis revealed significant association of these genes with distant metastatic recurrence. The specimens with high expression of BMP7 showed worse recurrence-free survival (RFS; p = 0.02). Those with high expression of TROP2 and VWCE showed worse overall survival (OS) and RFS (TROP2: p = 0.01 and p = 0.03; VWCE: p < 0.05 and p < 0.001, respectively). In the multivariate analysis, high expression of VWCE and BMP7 was an independent predictor of recurrence [VWCE: hazard ratio (HR) 3.41, p < 0.001; BMP7: HR 2.93, p = 0.005]. In contrast, TROP2 was an independent prognostic factor for OS (HR 4.58, p = 0.03). CONCLUSIONS: Gene expression analysis revealed that TROP2, VWCE, and BMP7 were involved in early metastatic seeding. The high expression of these genes may warrant careful surveillance or adjuvant therapy, even in stages I-II CRC cases.
  • Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma
    Junki Fukuda; Shinya Kosuge; Yusuke Satoh; Sho Sekiya; Ryodai Yamamura; Takako Ooshio; Taiga Hirata; Reo Sato; Kanako C. Hatanaka; Tomoko Mitsuhashi; Toru Nakamura; Yoshihiro Matsuno; Yutaka Hatanaka; Satoshi Hirano; Masahiro Sonoshita
    Cancer Science, Wiley, 2024年02月06日
    研究論文(学術雑誌), Abstract

    Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies worldwide. However, drug discovery for PDAC treatment has proven complicated, leading to stagnant therapeutic outcomes. Here, we identify Glycogen synthase kinase 3 (GSK3) as a therapeutic target through a whole‐body genetic screening utilizing a ‘4‐hit’ Drosophila model mimicking the PDAC genotype. Reducing the gene dosage of GSK3 in a whole‐body manner or knocking down GSK3 specifically in transformed cells suppressed 4‐hit fly lethality, similar to Mitogen‐activated protein kinase kinase (MEK), the therapeutic target in PDAC we have recently reported. Consistently, a combination of the GSK3 inhibitor CHIR99021 and the MEK inhibitor trametinib suppressed the phosphorylation of Polo‐like kinase 1 (PLK1) as well as the growth of orthotopic human PDAC xenografts in mice. Additionally, reducing PLK1 genetically in 4‐hit flies rescued their lethality. Our results reveal a therapeutic vulnerability in PDAC that offers a treatment opportunity for patients by inhibiting multiple targets.
  • Impact of the quality of resected thyroid cancer tissue sample on next-generation sequencing testing.
    Kanako C Hatanaka; Kenichi Nakamura; Ryohei Katoh; Koichi Ito; Mitsuyoshi Hirokawa; Akira Miyauchi; Yoshihiro Matsuno; Satoshi Kano; Yui Okada; Joji Mori; Yoichi M Ito; Yutaka Hatanaka
    Pathology international, 74, 2, 77, 86, 2024年02月, [国際誌]
    英語, 研究論文(学術雑誌), Activating rearranged during transfection (RET) proto-oncogene alterations can be identified using next-generation sequencing (NGS) of tumor DNA/RNA. We assessed factors associated with NGS (Oncomine Dx Target Test [ODxTT]) success for resected thyroid cancer (TC) specimens, including sample age, processing conditions, and DNA/RNA quality. TC samples were from three Japanese hospitals, with sample age <1-<10 years, fixative 10%/15% neutralized buffered formalin (NBF), and fixation time ≤48 h/>48 h-≤72 h. NGS success rate was defined as the percentage of samples returning validated NGS results (RET fusion-positive/negative [RNA] or RET mutation-positive/negative [DNA], detected using ODxTT). DNA/RNA quality was assessed with indexes based on electrophoresis (DNA/RNA integrity number, DV200 ) and quantitative polymerase chain reaction (DNA/RNA integrity score [ddCq/ΔCq]). NGS success rate (N = 202) was 90%/93% (DNA/RNA) overall, 98%-100% (DNA and RNA) for samples <3 years old, and 91% (DNA and RNA) for samples ≥3-<5 years old fixed in 10% NBF for ≤48 h. Multivariate logistic regression analysis identified ddCq and ΔCq as significant predictors of DNA and RNA NGS success rates, respectively. Quality assessment of nucleic acid extracted from archival tissue samples is important for achieving high NGS success rates in clinical practice, especially for samples ≥3 years old.
  • KRAS変異陽性大腸癌に対する治療標的分子としてのCD73/NT5E発現に関する分子病理学的検討
    田中 佑実; 畑中 佳奈子; 奥村 麻美; 南家 綾江; 結城 敏志; 本間 重紀; 木下 一郎; 松野 吉宏; 畑中 豊
    日本病理学会会誌, 113, 1, 310, 310, (一社)日本病理学会, 2024年02月
    日本語
  • Polymorphisms of the PD-L1 gene 3'-untranslated region are associated with the expression of PD-L1 in non-small cell lung cancer.
    Yoshihito Ohhara; Utano Tomaru; Ichiro Kinoshita; Kanako C Hatanaka; Takuro Noguchi; Yutaka Hatanaka; Toraji Amono; Yoshihiro Matsuno; Hirotoshi Dosaka-Akita
    Genes, chromosomes & cancer, 63, 1, e23216, 2024年01月, [国際誌]
    英語, 研究論文(学術雑誌), Recent results show that polymorphisms of programmed death ligand 1 (PD-L1, also known as CD274 or B7-H1) might be used as a possible marker for effectiveness of chemotherapy and cancer risk. However, the effect of PD-L1 gene variations on PD-L1 expression remain unclear. Given the post-transcriptional machinery in tumor PD-L1 expression, we investigated single nucleotide polymorphisms (SNPs) in the 3'-untranslated region (3'-UTR) of the PD-L1 gene, rs4143815 and rs4742098, using formalin-fixed paraffin-embedded sections of 154 patients with non-small cell lung cancers (NSCLCs). In rs4143815, the GG genotype showed significant association with PD-L1 expression (P = 0.032). In rs4742098, the AA genotype was significantly associated with histology and PD-L1 expression (P = 0.022 and P = 0.008, respectively). In multivariate logistic regression analysis, the AA genotype in rs4742098 was correlated with PD-L1 expression (odds ratio 0.408, P = 0.048). Interestingly, approximately 10% of the NSCLC cases showed somatic mutation when we compared genotypes of these SNPs between NSCLC tissues and non-tumor tissues from the same patients. In addition, cases with somatic mutation showed higher levels of PD-L1 expression than cases with germline mutation in rs4143815 GG. In conclusion, we demonstrated that the rs4143815 and rs4742098 SNPs in the 3'-UTR of PD-L1 were associated with tumor PD-L1 expression in NSCLCs.
  • Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.
    Yasuyuki Kawamoto; Chigusa Morizane; Yoshito Komatsu; Shunsuke Kondo; Makoto Ueno; Satoshi Kobayashi; Masayuki Furukawa; Lingaku Lee; Taroh Satoh; Daisuke Sakai; Masafumi Ikeda; Hiroshi Imaoka; Arisa Miura; Yutaka Hatanaka; Isao Yokota; Yoshiaki Nakamura; Takayuki Yoshino
    Future oncology (London, England), 20, 26, 1901, 1907, 2024年, [国際誌]
    英語, 研究論文(学術雑誌), Due to the widespread use of cancer genetic testing in gastrointestinal cancer, the BRCA1/2 genetic mutation has been identified in biliary tract cancer as well as pancreatic cancer. Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor, and PARP inhibitors exert their cytotoxicity against cancer cells in the context of homologous recombination deficiency, such as BRCA mutations, via the mechanism of synthetic lethality. The aim of this phase II NIR-B trial is to evaluate the efficacy and safety of niraparib for patients with unresectable advanced or recurrent biliary tract cancer, pancreatic cancer or other gastrointestinal cancers with germline or somatic BRCA1/2 mutations revealed by genetic testing. The primary end point is an investigator-assessed objective response rate in each cohort.Clinical Trial Registration: jRCT2011200023 (ClinicalTrials.gov).
  • Exhaustion, rather than lack of infiltration and persistence, of CAR-T cells hampers the efficacy of CAR-T therapy in an orthotopic PDAC xenograft model.
    Yuta Takeuchi; Yizheng Wang; Katsunori Sasaki; Osamu Sato; Takahiro Tsuchikawa; Linan Wang; Yasunori Amaishi; Sachiko Okamoto; Junichi Mineno; Yoshifumi Hirokawa; Kanako C Hatanaka; Yutaka Hatanaka; Takuma Kato; Hiroshi Shiku; Satoshi Hirano
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 170, 116052, 116052, 2024年01月, [国際誌]
    英語, 研究論文(学術雑誌), Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated impressive success in the treatment of patients with hematologic tumors yet achieved very limited efficacy for solid tumors due to hurdles unique to solid tumors. It is also noted that the tumor microenvironment composition varies between tumor type, which again imposes unique set of hurdles in each solid tumor. Therefore, elucidation of individual hurdles is key to achieving successful CAR-T therapy for solid tumors. In the present study, we employed an orthotopic human PDAC xenograft model, in which quantitative, spatial and functional dynamics of CAR-T cells in tumor tissues were analyzed to obtain insights into ways of overcoming PDAC related hurdles. Contrary to previous studies that demonstrated a limited persistency and infiltration of CAR-T cells in many solid tumors, they persist and accumulated in PDAC tumor tissues. Ex vivo analysis revealed that CAR-T cells that had been recovered at different time points from mice bearing an orthotopic PDAC tumor exhibited a gradual loss of tumor reactivity. This loss of tumor reactivity of CAR-T cells was associated with the increased expression of AMP-activated protein kinase and Mitofusin 1/ Dynamin-related protein 1 ratio.
  • Postoperative Prognosis According to Pathologic Categorization of Desmoplastic Reaction in Patients with Extrahepatic Cholangiocarcinoma.
    Yusuke Yoshida; Yoshitsugu Nakanishi; Tomoko Mitsuhashi; Hiroyuki Yamamoto; Mariko O Hayashi; Mitsunobu Oba; Takeo Nitta; Takashi Ueno; Toru Yamada; Masato Ono; Shota Kuwabara; Yutaka Hatanaka; Satoshi Hirano
    Annals of surgical oncology, 30, 12, 7348, 7357, 2023年11月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Recent studies have demonstrated the importance of desmoplastic reaction (DR) in predicting postoperative prognosis for patients with colorectal carcinoma. However, the impact of DR on the prognosis of extrahepatic cholangiocarcinomas (EHCCs) is not established. This study aimed to clarify the associations of pathologic DR categories with clinicopathologic factors and postoperative prognosis of perihilar cholangiocarcinoma (PHCC) and distal cholangiocarcinoma (DCC). METHODS: A pathologic review of 174 patients with PHCC and 109 patients with DCC who underwent surgical resection was performed. The patients were classified into three DR categories (immature, intermediate, and mature) based on the histologic features within the fibrotic stroma in the invasive front. The association between DR categories and the distribution of fibroblasts with anti-α-smooth muscle actin (SMA) expression, seeming to be tumor-promoting cancer-associated fibroblasts (CAFs), was evaluated in 191 tissue microarray specimens of EHCCs. RESULTS: Intermediate/immature DR categories were significantly associated with a more invasive nature, including higher pT and pN stages and more tumor buds than the mature category in both PHCC and DCC. The DR categories could stratify overall survival (OS) and relapse-free survival (RFS) in both PHCC and DCC patients. In the multivariate analysis, the DR category was an independent prognostic factor for OS and RFS in both PHCC and DCC (p < 0.001). The mature and immature DR categories were significantly associated respectively with the confined and pervasive distribution of fibroblasts with α-SMA expression. CONCLUSION: In patients with EHCCs, DR categorization was an independent prognostic factor reflecting the distribution of tumor-promoting CAFs in the invasive front.
  • Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations
    Nayuta Tsushima; Satoshi Kano; Kanako C. Hatanaka; Takayoshi Suzuki; Seijiro Hamada; Hiroshi Idogawa; Yuji Nakamaru; Masanobu Suzuki; Yutaka Hatanaka; Akihiro Homma
    Auris Nasus Larynx, Elsevier BV, 2023年11月
    研究論文(学術雑誌)
  • 臨床試験に心を込めて:実診療をよりよくするための考え方・取り組み方 HER2陽性唾液腺がんの医師主導治験
    木下 一郎; 加納 里志; 畑中 豊; 松野 吉宏; 磯江 敏幸; 佐藤 典宏; 本間 明宏; 秋田 弘俊
    日本癌治療学会学術集会抄録集, 61回, CCSP10, 1, (一社)日本癌治療学会, 2023年10月
    英語
  • Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel–Trenaunay syndrome in an Asian population
    Yuki Sasaki; Kosuke Ishikawa; Kanako C. Hatanaka; Yumiko Oyamada; Yusuke Sakuhara; Tadashi Shimizu; Tatsuro Saito; Naoki Murao; Tomohiro Onodera; Takahiro Miura; Taku Maeda; Emi Funayama; Yutaka Hatanaka; Yuhei Yamamoto; Satoru Sasaki
    Orphanet Journal of Rare Diseases, 18, 1, Springer Science and Business Media LLC, 2023年09月04日
    研究論文(学術雑誌), Abstract

    Background

    Klippel–Trenaunay syndrome (KTS) is a rare slow-flow combined vascular malformation with limb hypertrophy. KTS is thought to lie on the PIK3CA-related overgrowth spectrum, but reports are limited. PIK3CA encodes p110α, a catalytic subunit of phosphatidylinositol 3-kinase (PI3K) that plays an essential role in the PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathway. We aimed to demonstrate the clinical utility of targeted next-generation sequencing (NGS) in identifying PIK3CA mosaicism in archival formalin-fixed paraffin-embedded (FFPE) tissues from patients with KTS.

    Results

    Participants were 9 female and 5 male patients with KTS diagnosed as capillaro-venous malformation (CVM) or capillaro-lymphatico-venous malformation (CLVM). Median age at resection was 14 years (range, 5–57 years). Median archival period before DNA extraction from FFPE tissues was 5.4 years (range, 3–7 years). NGS-based sequencing of PIK3CA achieved an amplicon mean coverage of 119,000x. PIK3CA missense mutations were found in 12 of 14 patients (85.7%; 6/8 CVM and 6/6 CLVM), with 8 patients showing the hotspot variants E542K, E545K, H1047R, and H1047L. The non-hotspot PIK3CA variants C420R, Q546K, and Q546R were identified in 4 patients. Overall, the mean variant allele frequency for identified PIK3CA variants was 6.9% (range, 1.6–17.4%). All patients with geographic capillary malformation, histopathological lymphatic malformation or macrodactyly of the foot had PIK3CA variants. No genotype–phenotype association between hotspot and non-hotspot PIK3CA variants was found. Histologically, the vessels and adipose tissues of the lesions showed phosphorylation of the proteins in the PI3K/AKT/mTOR signaling pathway, including p-AKT, p-mTOR, and p-4EBP1.

    Conclusions

    The PI3K/AKT/mTOR pathway in mesenchymal tissues was activated in patients with KTS. Amplicon-based targeted NGS could identify low-level mosaicism from low-input DNA extracted from FFPE tissues, potentially providing a diagnostic option for personalized medicine with inhibitors of the PI3K/AKT/mTOR signaling pathway.
  • Correction: Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
    Nobumoto Tomioka; Kanako C Hatanaka; Dai Okuyama; Ken-Ichi Watanabe; Mitsugu Yamamoto; Hideki Maeda; Hanae Tachikawa; Sayuri Kuwahara; Ai Shimizu; Hiroaki Suzuki; Yutaka Hatanaka; Masato Takahashi
    Breast cancer (Tokyo, Japan), 30, 4, 689, 690, 2023年07月, [国内誌]
    英語
  • Drosophila Screening Identifies Dual Inhibition of MEK and AURKB as an Effective Therapy for Pancreatic Ductal Adenocarcinoma
    Sho Sekiya; Junki Fukuda; Ryodai Yamamura; Takako Ooshio; Yusuke Satoh; Shinya Kosuge; Reo Sato; Kanako C. Hatanaka; Yutaka Hatanaka; Tomoko Mitsuhashi; Toru Nakamura; Yoshihiro Matsuno; Satoshi Hirano; Masahiro Sonoshita
    Cancer Research, OF1, OF12, American Association for Cancer Research (AACR), 2023年06月28日
    研究論文(学術雑誌), Abstract

    Significant progress has been made in understanding the pathogenesis of pancreatic ductal adenocarcinoma (PDAC) by generating and using murine models. To accelerate drug discovery by identifying novel therapeutic targets on a systemic level, here we generated a Drosophila model mimicking the genetic signature in PDAC (KRAS, TP53, CDKN2A, and SMAD4 alterations), which is associated with the worst prognosis in patients. The ‘4-hit’ flies displayed epithelial transformation and decreased survival. Comprehensive genetic screening of their entire kinome revealed kinases including MEK and AURKB as therapeutic targets. Consistently, a combination of the MEK inhibitor trametinib and the AURKB inhibitor BI-831266 suppressed the growth of human PDAC xenografts in mice. In patients with PDAC, the activity of AURKB was associated with poor prognosis. This fly-based platform provides an efficient whole-body approach that complements current methods for identifying therapeutic targets in PDAC.

    Significance:

    Development of a Drosophila model mimicking genetic alterations in human pancreatic ductal adenocarcinoma provides a tool for genetic screening that identifies MEK and AURKB inhibition as a potential treatment strategy.
  • Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers.
    Kanako Hagio; Junko Kikuchi; Kohichi Takada; Hiroki Tanabe; Minako Sugiyama; Yoshihito Ohhara; Toraji Amano; Satoshi Yuki; Yoshito Komatsu; Takahiro Osawa; Kanako C Hatanaka; Yutaka Hatanaka; Takashi Mitamura; Ichiro Yabe; Yoshihiro Matsuno; Atsushi Manabe; Akihiro Sakurai; Atsushi Ishiguro; Masato Takahashi; Hiroshi Yokouchi; Hirohito Naruse; Yusuke Mizukami; Hirotoshi Dosaka-Akita; Ichiro Kinoshita
    Cancer science, 2023年05月19日, [国際誌]
    英語, 研究論文(学術雑誌), Comprehensive genomic profiling (CGP) tests have been covered by public insurance in Japan for patients with advanced solid tumors who have completed or are completing standard treatments or do not have them. Therefore, genotype-matched drug candidates are often unapproved or off-label, and improving clinical trial access is critical, involving the appropriate timing of CGP tests. To address this issue, we analyzed the previous treatment data for 441 patients from an observational study on CGP tests discussed by the expert panel at Hokkaido University Hospital between August 2019 and May 2021. The median number of previous treatment lines was two; three or more lines accounted for 49%. Information on genotype-matched therapies was provided to 277 (63%). Genotype-matched clinical trials were ineligible because of an excess number of previous treatment lines or use of specific agents were found in 66 (15%) patients, with the highest proportion in breast and prostate cancers. Many patients met the exclusion criteria of one to two or more treatment lines across cancer types. In addition, previous use of specific agents was a frequent exclusion criterion for breast, prostate, colorectal, and ovarian cancers. The patients with tumor types with a low median number (two or fewer) of previous treatment lines, including most rare cancers, primary unknown cancers, and pancreatic cancers, had significantly fewer ineligible clinical trials. The earlier timing of CGP tests may improve access to genotype-matched clinical trials, with their proportion varying by cancer type. Each relevant society needs to advocate the desirable timing of CGP testing nationwide.
  • 甲状腺腫瘍の病理診断の課題と展望 甲状腺癌切除組織の検体品質が次世代シークエンサーを用いた検査に与える影響の検討
    畑中 佳奈子; 中村 健一; 加藤 良平; 伊藤 公一; 廣川 満良; 宮内 昭; 加納 里志; 岡田 唯; 森 丈治; 畑中 豊
    日本内分泌外科学会雑誌, 40, Suppl.1, S127, S127, (一社)日本内分泌外科学会, 2023年05月
    日本語
  • Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
    Nobumoto Tomioka; Kanako C Hatanaka; Dai Okuyama; Ken-Ichi Watanabe; Mitsugu Yamamoto; Hideki Maeda; Hanae Tachikawa; Sayuri Kuwahara; Ai Shimizu; Hiroaki Suzuki; Yutaka Hatanaka; Masato Takahashi
    Breast cancer (Tokyo, Japan), 30, 3, 497, 505, 2023年05月, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The efficacy of pre-operative systemic treatment (PST) combined with immune checkpoint inhibition (ICI) for triple-negative breast cancer (TNBC) has been recognized recently as being independent of the degree of programmed death ligand-1 (PD-L1) positivity of infiltrating immune cells, especially for patients with axillary lymph node metastasis (ALNM). METHODS: TNBC patients with ALNM were treated surgically between 2002 and 2016 in our facility (n = 109), of whom 38 received PST before resection. The presence of tumor-infiltrating lymphocytes (TILs) expressing CD3, CD8, CD68, PD-L1 (detected by antibody SP142) and FOXP3 at primary and metastatic LN sites was quantified. RESULTS: The size of invasive tumor and the number of metastatic axillary LN were confirmed as prognostic markers. The numbers of both CD8+ and FOXP3+ TILs at primary sites were also recognized as prognostic markers, especially for overall survival (OS) (CD8, p = 0.026; FOXP3, p < 0.001). The presence of CD8+, FOXP3+ and PD-L1+ cells was better maintained in LN after PST and may contribute to improved antitumor immunity. Provided they were present as clusters of ≥ 70 positive cells, even < 1% of immune cells expressing PD-L1 at primary sites predicted a more favorable prognosis for both disease-free survival (DFS) (p = 0.004) and OS (p = 0.020). This was the case not only for 30 matched surgical patients, but also in all 71 surgical only patients (DFS: p < 0.001 and OS: p = 0.002). CONCLUSIONS: PD-L1+ , CD8+ or FOXP3+ immune cells in the tumor microenvironment (TME) at both primary and metastatic sites are significant on prognosis, which could be a clue to expect the potential for better responses to the combination of chemotherapy and ICI, especially for patients with ALNM.
  • CCR7 Mediates Cell Invasion and Migration in Extrahepatic Cholangiocarcinoma by Inducing Epithelial-Mesenchymal Transition.
    Mitsunobu Oba; Yoshitsugu Nakanishi; Tomoko Mitsuhashi; Katsunori Sasaki; Kanako C Hatanaka; Masako Sasaki; Ayae Nange; Asami Okumura; Mariko Hayashi; Yusuke Yoshida; Takeo Nitta; Takashi Ueno; Toru Yamada; Masato Ono; Shota Kuwabara; Keisuke Okamura; Takahiro Tsuchikawa; Toru Nakamura; Takehiro Noji; Toshimichi Asano; Kimitaka Tanaka; Kiyoshi Takayama; Yutaka Hatanaka; Satoshi Hirano
    Cancers, 15, 6, 2023年03月21日, [国際誌]
    英語, 研究論文(学術雑誌), The epithelial-mesenchymal transition (EMT) contributes to the metastatic cascade in various tumors. C-C chemokine receptor 7 (CCR7) interacts with its ligand, chemokine (C-C motif) ligand 19 (CCL19), to promote EMT. However, the association between EMT and CCR7 in extrahepatic cholangiocarcinoma (EHCC) remains unknown. This study aimed to elucidate the prognostic impact of CCR7 expression and its association with clinicopathological features and EMT in EHCC. The association between CCR7 expression and clinicopathological features and EMT status was examined via the immunohistochemical staining of tumor sections from 181 patients with perihilar cholangiocarcinoma. This association was then investigated in TFK-1 and EGI-1 EHCC cell lines. High-grade CCR7 expression was significantly associated with a large number of tumor buds, low E-cadherin expression, and poor overall survival. TFK-1 showed CCR7 expression, and Western blotting revealed E-cadherin downregulation and vimentin upregulation in response to CCL19 treatment. The wound healing and Transwell invasion assays revealed that the activation of CCR7 by CCL19 enhanced the migration and invasion of TFK-1 cells, which were abrogated by a CCR7 antagonist. These results suggest that a high CCR7 expression is associated with an adverse postoperative prognosis via EMT induction and that CCR7 may be a potential target for adjuvant therapy in EHCC.
  • Guidelines for Handling of Cytological Specimens in Cancer Genomic Medicine.
    Eiichi Morii; Yutaka Hatanaka; Noriko Motoi; Akihiko Kawahara; Shinji Hamakawa; Takeshi Kuwata; Tadasuke Nagatomo; Yoshinao Oda; Aikou Okamoto; Ryota Tanaka; Akira Iyoda; Maeda Ichiro; Yukiko Matsuo; Nobuyuki Nakamura; Tokiko Nakai; Mei Fukuhara; Kazuya Tokita; Tomohiko Yamaguchi; Masataka Takenaka; Ayako Kawabata; Kanako C Hatanaka; Kaho Tsubame; Yukitoshi Satoh
    Pathobiology : journal of immunopathology, molecular and cellular biology, 1, 23, 2023年02月08日, [国際誌]
    英語, 研究論文(学術雑誌), Rapid advances are being made in cancer drug therapy. Since molecularly targeted therapy has been introduced, personalized medicine is being practiced, pathological tissue from malignant tumors obtained during routine practice is frequently used for genomic testing. Whereas cytological specimens fixed mainly in alcohol are considered to be more advantageous in terms of preservation of the nucleic acid quality and quantity. This article is aimed to share the information for the proper handling of cytological specimens in practice for genomic medicine based on the findings established in "Guidelines for Handling of Cytological Specimens in Cancer Genomic Medicine (in Japanese)" published by the Japanese Society of Clinical Cytology in 2021. The three-part practical guidelines are based on empirical data analyses; Part 1 describes general remarks on the use of cytological specimens in cancer genomic medicine, then Part 2 describes proper handling of cytological specimens, and Part 3 describes the empirical data related to handling of cytological specimens. The guidelines indicated proper handling of specimens in each fixation, preparation, and evaluation.
  • Identification of antibody against wingless‑type MMTV integration site family member 7B as a biliary cancer tumor marker.
    Mizuna Takahashi; Takahiro Tsuchikawa; Takaki Hiwasa; Toru Nakamura; Koji Hontani; Toshihiro Kushibiki; Kazuho Inoko; Hironobu Takano; Yutaka Hatanaka; Kazuyuki Matsushita; Hisahiro Matsubara; Tyuji Hoshino; Masayuki Ohtsuka; Hideaki Shimada; Kimitaka Tanaka; Yoshitsugu Nakanishi; Toshimichi Asano; Takehiro Noji; Keisuke Okamura; Toshiaki Shichinohe; Satoshi Hirano
    Oncology reports, 49, 2, 2023年02月, [国際誌]
    英語, 研究論文(学術雑誌), Biliary cancer has a poor prognosis due to a lack of specific biomarkers and difficulty in diagnosis. The present study aimed to identify serum tumor markers for the diagnosis of biliary cancer via serological identification of antigens by recombinant cDNA expression cloning. Wingless‑type MMTV integration site family, member 7 (WNT7B) was identified as a target antigen, suggesting the presence of serum antibodies against this antigen. Deletion mutants were then prepared to evaluate the response to serum antibodies. When serum antibody levels against WNT7B deletion mutants (WNT7B-92‑2, -92‑260, 2-260 and 184-260) were examined using amplified luminescence proximity homogeneous assay‑linked immunosorbent assay, the levels of the antibody against WNT7B with amino acids 184‑260 were higher in patients with biliary cancer than in healthy donors. Therefore, the region covering residues 184‑260 of WNT7B was decomposed to generate seven peptides, and the levels of antibodies against these peptides were measured. Among them, the levels of antibodies against WNT7B234‑253 and WNT7B244‑260 were higher in patients with biliary cancers than in healthy donors (WNT7B234‑253, P=0.0009; WNT7B244‑260, P=0.0005). The levels of the antibody against the former were specifically high in patients with biliary cancer but not in those with esophageal, gastric, colorectal, pancreatic, or breast cancer. Furthermore, analysis by the cutoff value of WNT7B234‑253 defined by ROC showed a high sensitivity of 70% in patients with biliary cancer. Therefore, the serum levels of the antibody against WNT7B234‑253 may be useful as a marker for biliary cancer diagnosis.
  • Tumor Growth Suppression of Pancreatic Cancer Orthotopic Xenograft Model by CEA-Targeting CAR-T Cells.
    Osamu Sato; Takahiro Tsuchikawa; Takuma Kato; Yasunori Amaishi; Sachiko Okamoto; Junichi Mineno; Yuta Takeuchi; Katsunori Sasaki; Toru Nakamura; Kazufumi Umemoto; Tomohiro Suzuki; Linan Wang; Yizheng Wang; Kanako C Hatanaka; Tomoko Mitsuhashi; Yutaka Hatanaka; Hiroshi Shiku; Satoshi Hirano
    Cancers, 15, 3, 2023年01月18日, [国際誌]
    英語, 研究論文(学術雑誌), Chimeric antigen receptor engineered T cell (CAR-T) therapy has high therapeutic efficacy against blood cancers, but it has not shown satisfactory results in solid tumors. Therefore, we examined the therapeutic effect of CAR-T therapy targeting carcinoembryonic antigen (CEA) in pancreatic adenocarcinoma (PDAC). CEA expression levels on the cell membranes of various PDAC cell lines were evaluated using flow cytometry and the cells were divided into high, medium, and low expression groups. The relationship between CEA expression level and the antitumor effect of anti-CEA-CAR-T was evaluated using a functional assay for various PDAC cell lines; a significant correlation was observed between CEA expression level and the antitumor effect. We created orthotopic PDAC xenograft mouse models and injected with anti-CEA-CAR-T; only the cell line with high CEA expression exhibited a significant therapeutic effect. Thus, the therapeutic effect of CAR-T therapy was related to the target antigen expression level, and the further retrospective analysis of pathological findings from PDAC patients showed a correlation between the intensity of CEA immunostaining and tumor heterogeneity. Therefore, CEA expression levels in biopsies or surgical specimens can be clinically used as biomarkers to select PDAC patients for anti-CAR-T therapy.
  • Impact of Neutrophil Extracellular Traps Identified by Citrullinated Histone H3 Immunohistochemistry for Postoperative Prognosis in Patients with Extrahepatic Cholangiocarcinomas
    Hiroyuki Yamamoto; Yoshitsugu Nakanishi; Tomoko Mitsuhashi; Yutaka Hatanaka; Kanako Hatanaka; Ayae Nange; Yusuke Yoshida; Norito Ino; Masaru Go; Keisuke Okamura; Takahiro Tsuchikawa; Toru Nakamura; Takehiro Noji; Toshimichi Asano; Aya Matsui; Kimitaka Tanaka; Soichi Murakami; Yuma Ebihara; Yo Kurashima; Toshiaki Shichinohe; Satoshi Hirano
    Annals of Surgical Oncology, 2023年
    研究論文(学術雑誌)
  • Deep fibrous histiocytoma of the index finger: a case report.
    Hiroki Shibayama; Yuichiro Matsui; Daisuke Kawamura; Daisuke Momma; Takeshi Endo; Yuki Matsui; Yasutaka Yawaka; Kanako C Hatanaka; Emi Takakuwa; Hirokazu Sugino; Yutaka Hatanaka; Tadashi Hasegawa; Norimasa Iwasaki
    Case reports in plastic surgery & hand surgery, 10, 1, 2207637, 2207637, 2023年, [国際誌]
    英語, Our patient presented with an elastic soft mass of his left index finger. Hematoxylin and eosin staining showed a high cellular density with spindle-shaped cells in a storiform pattern. Immunohistochemical staining was positive for CD68, factor XIIIa and α-smooth muscle actin, and negative for CD34, STAT6, S100 protein, and desmin.
  • Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer.
    Hirofumi Takahashi; Jun Sakakibara-Konishi; Megumi Furuta; Tetsuaki Shoji; Kosuke Tsuji; Daisuke Morinaga; Eiki Kikuchi; Junko Kikuchi; Takuro Noguchi; Kanako C Hatanaka; Yutaka Hatanaka; Naofumi Shinagawa; Satoshi Konno
    Cancer science, 2022年11月21日, [国際誌]
    英語, 研究論文(学術雑誌), Osimertinib is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that has shown marked antitumor activity in patients with EGFR-mutated non-small-cell lung cancer (NSCLC). However, these effects are transient and most patients develop resistance. Reversible drug-tolerant persister (DTP) cells are defined as a small subpopulation of cells with markedly reduced sensitivity and non-genetic acquired resistance to EGFR-TKIs. Notch is a transmembrane receptor that plays an important role in tumorigenesis. We previously reported that there is significant crosstalk between the Notch and EGFR pathways in NSCLC. Moreover, the Notch pathway is associated with resistance to previous-generation EGFR-TKIs. However, the role of Notch in osimertinib resistance is not fully understood. In this study, we evaluated whether Notch is involved in osimertinib resistance. We show that NOTCH1 and Notch target genes are upregulated in osimertinib DTP cells, and that the addition of a γ-secretase inhibitor (GSI), a Notch inhibitor, impairs drug-tolerant persistence in vitro and in vivo. Compared with osimertinib, combined GSI and osimertinib suppress phospho-ERK partly by enhancing DUSP1 expression. Furthermore, Notch1 and HES1 were upregulated after EGFR-TKI treatment in half of human EGFR-mutated NSCLC tumor tissues. These results suggest that the combination of GSI and osimertinib may be a potential therapy for EGFR-mutated NSCLC.
  • EGFR変異陽性非小細胞肺癌におけるosimertinib耐性とNotch経路の関わり
    高橋 宏典; 榊原 純; 古田 恵; 庄司 哲明; 辻 康介; 森永 大亮; 菊地 英毅; 菊地 順子; 野口 卓郎; 畑中 佳奈子; 畑中 豊; 品川 尚文; 今野 哲
    肺癌, 62, 6, 715, 715, (NPO)日本肺癌学会, 2022年11月
    日本語
  • EBUS-GS-TBB検体の腫瘍細胞含有率に関連する臨床因子についての検討
    高島 雄太; 品川 尚文; 有里 仁希; 嘉島 相裕; 庄司 哲明; 古田 恵; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 畑中 佳奈子; 松野 吉宏; 畑中 豊; 今野 哲
    気管支学, 44, 6, 459, 459, (一社)日本呼吸器内視鏡学会, 2022年11月
    日本語
  • The prognosis of endometrial cancers stratified with conventional risk factors and modified molecular classification.
    Hiroyuki Yamazaki; Hiroshi Asano; Kanako C Hatanaka; Ryosuke Matsuoka; Yosuke Konno; Yoshihiro Matsuno; Yutaka Hatanaka; Hidemichi Watari
    Cancer science, 113, 9, 3134, 3147, 2022年09月, [国際誌]
    英語, 研究論文(学術雑誌), This study aimed to validate the Proactive Molecular Risk Classifier for Endometrial Cancer, a modified version of The Cancer Genome Atlas, using data from 184 patients with endometrial cancer (median age: 57.5 years; median follow-up period: 109 months) who had undergone radical surgery (including systemic lymphadenectomy) and subsequent adjuvant chemotherapy (patients with intermediate or high recurrence risk) from 2003 to 2015. Tissue microarrays were prepared from surgical specimens and classified using the conventional clinical risk classifier. Immunohistochemistry was used to detect mismatch repair proteins, L1 cell adhesion molecule, and p53. Direct sequencing was used to identify hotspot mutations in the polymerase-epsilon gene. Forty-five patients were identified as having high L1 cell adhesion molecule expression, 41 as low risk, 34 as mismatch repair-deficient, 13 as polymerase-epsilon gene-mutated, five as having abnormal p53, and 46 as other. Patients were stratified into significantly different prognostic groups (p < 0.0001): favorable (low risk and polymerase-epsilon gene-mutated), intermediate (mismatch repair-deficient and other), and unfavorable (high L1 cell adhesion molecule expression and abnormal p53) with 5-year disease-specific survival rates of 100%, 93.8%, and 75.1%, respectively (Kaplan-Meier method). The combination of conventional recurrent risk classification, sequencing for polymerase-epsilon gene mutations and immunohistochemistry for L1 cell adhesion molecule, p53, and mismatch repair proteins can be used to determine the prognoses of patients with endometrial cancer.
  • Association of gene mutations with clinicopathologic features in patients with external auditory canal squamous cell carcinoma.
    Shinya Morita; Satoshi Kano; Kanako C Hatanaka; Yutaka Hatanaka; Takayoshi Suzuki; Atsushi Fukuda; Kimiko Hoshino; Keishi Fujiwara; Yuji Nakamaru; Akihiro Homma
    International journal of clinical oncology, 27, 9, 1394, 1403, 2022年09月, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: External auditory canal squamous cell carcinoma (EACSCC) is a rare form of malignant tumor. Due to the extremely limited understanding of the genomic landscape in EACSCC, the association between gene mutations and clinicopathologic features remains unclear. This study aimed to explore somatic gene mutations associated with the clinicopathological features in patients with EACSCC, and to identify the candidate gene mutations for predicting survival outcome in EACSCC. METHODS: Twenty-two tissue samples obtained from patients with EACSCC were analyzed for genetic mutations based on targeted next-generation sequencing and genetic expression based on IHC staining to investigate the driver of tumorigenesis and/or the candidates of genes for predicting clinical outcome in EACSCC. RESULTS: Gene alterations were most frequently observed in TP53 (59.1%), followed by CREBBP (9.1%). TP53 mutations showed significant correlation with T classification (P = 0.027) and p53 expression phenotype (P < 0.001). The 5-year overall survival (OS) rates for EACSCC patients with TP53 mutations and wild-type TP53 were 45.0% and 75.0%, respectively. Multivariable analysis using the Cox proportional hazards model demonstrated that TP53 mutations were independent predictors of OS rates for EACSCC patients (P = 0.007). CONCLUSION: This study has suggested that TP53 mutations have potential for use as a biomarker for identifying individuals at high risk of developing tumors and for predicting survival outcome in EACSCC. IHC staining for p53 might play a useful role as screening tool for detecting TP53 mutations in patients with EACSCC.
  • ASO Visual Abstract: Versican Secreted by Cancer-Associated Fibroblasts Is a Poor Prognostic Factor in Hepatocellular Carcinoma.
    Koichi Kato; Moto Fukai; Kanako C Hatanaka; Akira Takasawa; Tomoyuki Aoyama; Takahiro Hayasaka; Yoshihiro Matsuno; Toshiya Kamiyama; Yutaka Hatanaka; Akinobu Taketomi
    Annals of surgical oncology, 29, 11, 7147, 7148, 2022年07月28日, [国際誌]
    英語, 研究論文(学術雑誌)
  • Efficient multiple treatments including molecular targeting agents in a case of recurrent hepatocellular carcinoma, post-living donor liver transplantation.
    Reimi Suzuki; Ryoichi Goto; Norio Kawamura; Masaaki Watanabe; Yoshikazu Ganchiku; Kanako C Hatanaka; Yutaka Hatanaka; Toshiya Kamiyama; Tsuyoshi Shimamura; Akinobu Taketomi
    Clinical journal of gastroenterology, 15, 4, 755, 764, 2022年05月30日, [国内誌]
    英語, 研究論文(学術雑誌), Despite the promising efficacies of recently developed molecular targeting therapies for hepatocellular carcinoma, their role in liver transplantation is unknown. Here we report that multidisciplinary treatment, including novel molecular targeting therapy with lenvatinib, achieved long-term survival of a patient with post-liver transplantation recurrence of hepatocellular carcinoma. A 62 year-old man with hepatocellular carcinoma beyond the Milan criteria, arising from hepatitis B virus-associated cirrhotic liver, underwent living donor liver transplantation. However, alpha-fetoprotein level increased a month post-transplantation, and pleural dissemination and lung metastasis of hepatocellular carcinoma in the right lung were detected. The patient was initially treated with sorafenib and rapamycin, right pleurectomy and upper and middle lobectomies were attempted as the second treatment. However, remnant tumors started to grow. Subsequently, the newly molecular targeting agents; regorafenib and lenvatinib, approved for recurrent hepatocellular carcinoma in Japan, were administered. Lenvatinib efficiently reduced tumor volumes and the alpha-fetoprotein level, which contributed to maintaining better quality of life for 26 months as an outpatient. Unfortunately, sepsis caused by cholangitis and liver abscess required the discontinuation of lenvatinib, and the patient died 73 months after the recurrence of hepatocellular carcinoma. Multidisciplinary treatment including lenvatinib is potentially acceptable for recurrent hepatocellular carcinoma after liver transplantation.
  • Versican Secreted by Cancer-Associated Fibroblasts is a Poor Prognostic Factor in Hepatocellular Carcinoma.
    Koichi Kato; Moto Fukai; Kanako C Hatanaka; Akira Takasawa; Tomoyuki Aoyama; Takahiro Hayasaka; Yoshihiro Matsuno; Toshiya Kamiyama; Yutaka Hatanaka; Akinobu Taketomi
    Annals of surgical oncology, 29, 11, 7135, 7146, 2022年05月11日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Hepatocellular carcinoma (HCC) is highly recurrent. Cancer-associated fibroblasts (CAFs), a major component of the tumor microenvironment, promote malignancy; however, the mechanisms underlying their actions are obscure. We aimed to identify CAF-specific proteins in HCC and determine whether they could be potential therapeutic targets. METHODS: Using comprehensive proteomic analysis of CAFs and noncancerous fibroblasts (NFs) primary-cultured from resected HCC specimens from the same patients, CAF-specific proteins were identified. Immunohistochemistry for versican (VCAN) was performed on cancerous tissues obtained from 239 patients with HCC. Conditioned medium from CAFs transfected with siRNA for VCAN was analyzed in vitro. RESULTS: CAFs significantly promoted HCC cell proliferation, migration, and invasion (p < 0.01, 0.01, and 0.01, respectively) compared with NFs. VCAN was upregulated in CAFs, and its stromal level correlated with poor differentiation (p = 0.009) and positive vascular invasion (p = 0.003). Stromal VCAN level was also associated with significantly lower overall (p = 0.002) and relapse-free (p < 0.001) survival rates. It also independently predicted prognosis and recurrence. VCAN-knockdown CAFs significantly suppressed HCC cell migration and invasion compared with negative control. CONCLUSIONS: VCAN secreted from CAFs promoted malignant transformation of HCC cells and has potential as a new therapeutic target in HCC.
  • EBUS-GS-TBB検体の腫瘍細胞含有率に関連する臨床因子についての検討
    高島 雄太; 品川 尚文; 有里 仁希; 嘉島 相裕; 庄司 哲明; 古田 恵; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 畑中 佳奈子; 松野 吉宏; 畑中 豊; 今野 哲
    気管支学, 44, Suppl., S250, S250, (NPO)日本呼吸器内視鏡学会, 2022年05月
    日本語
  • 大腸癌浸潤先進部の局所炎症反応と遺伝子発現signature
    松井 博紀; 畑中 佳奈子; 谷 道夫; 本間 重紀; 吉田 雅; 市川 伸樹; 江本 慎; 畑中 豊; 武冨 紹信
    日本外科学会定期学術集会抄録集, 122回, DP, 4, (一社)日本外科学会, 2022年04月
    日本語
  • Clinical Features of Pancreatic Neuroendocrine Microadenoma: A Single-Center Experience and Literature Review.
    Yuki Okawa; Takahiro Tsuchikawa; Kanako C Hatanaka; Aya Matsui; Kimitaka Tanaka; Yoshitsugu Nakanishi; Toshimichi Asano; Takehiro Noji; Toru Nakamura; Tomoko Mitsuhashi; Keisuke Okamura; Yutaka Hatanaka; Satoshi Hirano
    Pancreas, 51, 4, 338, 344, 2022年04月01日, [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVES: Pancreatic neuroendocrine microadenoma (NEMA) is a nonfunctioning neuroendocrine tumor of less than 5 mm. Most studies of NEMA were based on autopsies, and few reports have revealed the clinical frequency of NEMA. We investigated the clinicopathological features of NEMA. METHODS: The pathological results of the pancreatic resection specimens of patients, older than 18 years, who underwent pancreatic resection at Hokkaido University Hospital between April 2008 and December 2020 were retrospectively reviewed. The NEMAs were re-examined in detail and examined by immunohistochemical staining. RESULTS: Among 850 patients enrolled in this study, 24 NEMAs were identified in 12 patients (1.4%). Of the 12 patients, 2 patients had multiple endocrine neoplasia type 1, and the others had no hereditary disease, including 2 patients with multiple NEMAs. A difference in the number of NEMA was observed between patients with multiple endocrine neoplasia type 1 and sporadic NEMA. Intratumoral Ki-67 heterogeneity was correlated with the Ki-67 index. One grade 2 NEMA (Ki-67 index, 4.6%) was detected, but ATRX and DAXX labeling showed intact nuclear protein expression. CONCLUSIONS: Multiple sporadic NEMAs and grade 2 NEMAs were observed, suggesting that NEMA may have malignant potential. Thus, NEMAs should be carefully monitored for lymph node metastasis and postoperative recurrence.
  • Identification of Novel Diagnostic Markers for Malignant Pleural Mesothelioma Using a Reverse Translational Approach Based on a Rare Synchronous Tumor
    Tomoaki Naka; Yutaka Hatanaka; Yukiko Tabata; Akira Takasawa; Hideo Akiyama; Yasuhiro Hida; Hiromi Okada; Kanako C. Hatanaka; Tomoko Mitsuhashi; Kei Kushitani; Vishwa Jeet Amatya; Yukio Takeshima; Kouki Inai; Kichizo Kaga; Yoshihiro Matsuno
    Diagnostics, 12, 2, 2022年02月
    研究論文(学術雑誌)
  • Precision cancer genome testing needs proficiency testing involving all stakeholders.
    Masato Maekawa; Terumi Taniguchi; Kazuto Nishio; Kazuko Sakai; Kazuyuki Matsushita; Kaname Nakatani; Takayuki Ishige; Makoto Ikejiri; Hiroshi Nishihara; Kuniko Sunami; Yasushi Yatabe; Kanako C Hatanaka; Yutaka Hatanaka; Yoshihiro Yamamoto; Keita Fukuyama; Shinya Oda; Kayoko Saito; Mamoru Yokomura; Yuji Kubo; Hiroko Sato; Yoshinori Tanaka; Misa Fuchioka; Tadashi Yamasaki; Koichiro Matsuda; Kiyotaka Kurachi; Kazuhiro Funai; Satoshi Baba; Moriya Iwaizumi
    Scientific reports, 12, 1, 1494, 1494, 2022年01月27日, [国際誌]
    英語, 研究論文(学術雑誌), To implement precision oncology, analytical validity as well as clinical validity and utility are important. However, proficiency testing (PT) to assess validity has not yet been systematically performed in Japan. To investigate the quality of next-generation sequencing (NGS) platforms and cancer genome testing prevalent in laboratories, we performed pilot PT using patient samples. We prepared genomic DNA from the cancer tissue and peripheral blood of 5 cancer patients and distributed these to 15 laboratories. Most participating laboratories successfully identified the pathogenic variants, except for two closely located KRAS variants and 25 bp delins in EGFR. Conversely, the EGFR L858R variant was successfully identified, and the allele frequency was similar for all the laboratories. A high DNA integrity number led to excellent depth and reliable NGS results. By conducting this pilot study using patient samples, we were able to obtain a glimpse of the current status of cancer genome testing at participating laboratories. To enhance domestic cancer genome testing, it is important to conduct local PT and to involve the parties concerned as organizers and participants.
  • Germline PRDM1 Variant rs2185379 in Long-Term Recurrence-Free Survivors of Advanced Ovarian Cancer.
    Takashi Mitamura; Tianyue Zhai; Kanako C Hatanaka; Yutaka Hatanaka; Toraji Amano; Lei Wang; Shinya Tanaka; Hidemichi Watari
    Pharmacogenomics and personalized medicine, 15, 977, 984, 2022年, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: To identify the germline genetic characteristics of long-term recurrence-free survivors that can be applied to establishing a new strategy for curing advanced cancer, we investigated the whole-genome single nucleotide variants of ovarian cancer patients. PATIENTS AND METHODS: DNA specimens were obtained from rare long-term recurrence-free survivors with FIGO stage III-IV ovarian cancer with no recurrence for 8-23 years after primary treatments for a whole-genome analysis of approximately 660,000 single nucleotide variants. We then established a mouse model with a notable gene alteration by CRISPR/Cas9 to confirm the biological role. RESULTS: The long-term recurrence-free survivors more frequently had germline heterozygous variant rs2185379 of the PRDM1 gene exon than patients with early recurrence (6.8-fold, P=0.013) and the general population. In the mouse model, primary intraperitoneal disseminated tumors of allograft ID8 were significantly smaller in the germline heterozygous rs2185379 group than in the wild-type group (57.4% decrease, P=0.008). Immunohistochemistry showed that the area of distribution of infiltrating T lymphocytes with positive CD8 staining was significantly increased in the germline heterozygous rs2185379 group in comparison to the wild-type group. CONCLUSION: Germline heterozygous rs2185379 in PRDM1 is correlated with an excellent prognosis and can be used to establish a new strategy for treating advanced ovarian cancer.
  • Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in Adult T-cell leukemia/lymphoma.
    Takashi Ishio; Sarvesh Kumar; Joji Shimono; Anusara Daenthanasanmak; Sigrid Dubois; Yuquan Lin; Bonita R Bryant; Michael N Petrus; Emmanuel Bachy; Da Wei Huang; Yandan Yang; Patrick L Green; Hiroo Hasegawa; Michiyuki Maeda; Hideki Goto; Tomoyuki Endo; Takashi Yokota; Kanako C Hatanaka; Yutaka Hatanaka; Shinya Tanaka; Yoshihiro Matsuno; Yibin Yang; Satoshi Hashino; Takanori Teshima; Thomas A Waldmann; Louis M Staudt; Masao Nakagawa
    Blood, 2021年11月24日, [国際誌]
    英語, 研究論文(学術雑誌), Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell malignancy with a poor prognosis with current therapy. Here we report genome-wide CRISPR-Cas9 screening of ATLL models, which identified CDK6, CCND2, BATF3, JUNB, STAT3, and IL10RB as genes that are essential for the proliferation and/or survival of ATLL cells. As a single agent, the CDK6 inhibitor palbociclib induced cell cycle arrest and apoptosis in ATLL models with wild type TP53. ATLL models that had inactivated TP53 genetically were relatively resistant to palbociclib owing to compensatory CDK2 activity, and this resistance could be reversed by APR-246, a small molecule activator of mutant TP53. The CRISPR-Cas9 screen further highlighted the dependence of ATLL cells on mTORC1 signaling. Treatment of ATLL cells with palbociclib in combination with mTORC1 inhibitors was synergistically toxic irrespective of the TP53 status. This work defines CDK6 as a novel therapeutic target for ATLL and supports the clinical evaluation of palbociclib in combination with mTORC1 inhibitors in this recalcitrant malignancy.
  • Genetic heterogeneity during breast cancer progression in young patients.
    Kanako Hagio; Kanako C Hatanaka; Toraji Amano; Yoshihiro Matsuno; Yutaka Hatanaka; Hiroko Yamashita
    Breast (Edinburgh, Scotland), 60, 206, 213, 2021年10月28日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Because a number of years may be required for normal cells to develop into carcinoma, genes involved in tumorigenesis and progression might differ among breast cancers in young women and those in older women. The present study sought to analyze subclonality during breast cancer evolution as well as diversity within each individual in our young patients' cohort. METHODS: A total of 13 women aged <35 years at diagnosis with early breast cancer were recruited. Serial sections of breast samples consisting of synchronous invasive carcinoma, adjacent ductal carcinoma in situ (DCIS), normal breast tissue, and metastatic lymph nodes were collected and prepared for immunohistochemical analysis of estrogen receptor, progesterone receptor, HER2, and Ki67, and for extraction of genomic DNA. Germline and somatic gene alterations of genomic DNA were examined by targeted sequencing. RESULTS: Genomic DNA from 13 blood samples and 36 breast tissues consisting of 14 invasive carcinomas, nine adjacent DCIS, 11 normal breast tissues, and two metastatic lymph nodes were successfully sequenced. Germline gene alterations including pathogenic variants and gene alterations that were not yet evaluated for their clinical significance were detected in all patients but one. Somatic gene alterations were identified in eight invasive carcinomas, five DCIS, and one metastatic lymph node. Different somatic gene alterations between invasive carcinoma and DCIS were detected in two patients. Somatic gene mutations were present in non-neoplastic tissues in three patients. No two patients had the same gene alterations. CONCLUSION: Our results reveal diversity within each individual during breast cancer progression.
  • The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine.
    Yutaka Hatanaka; Takeshi Kuwata; Eiichi Morii; Yae Kanai; Hitoshi Ichikawa; Takashi Kubo; Kanako C Hatanaka; Kazuko Sakai; Kazuto Nishio; Satoshi Fujii; Wataru Okamoto; Takayuki Yoshino; Atsushi Ochiai; Yoshinao Oda
    Pathology international, 71, 11, 725, 740, 2021年10月06日, [国際誌]
    英語, 研究論文(学術雑誌), Clinical cancer genomic testing based on next-generation sequencing can help select genotype-matched therapy and provide diagnostic and prognostic information. Pathological tissue from malignant tumors obtained during routine practice are frequently used for genomic testing. This article is aimed to standardize the proper handling of pathological specimens in practice for genomic medicine based on the findings established in "Guidelines on the handling of pathological tissue samples for genomic medicine (in Japanese)" published by The Japanese Society of Pathology (JSP) in 2018. The two-part practical guidelines are based on empirical data analyses; Part 1 describes the standard preanalytic operating procedures for tissue collection, processing, and storage of formalin-fixed paraffin-embedded (FFPE) samples, while Part 2 describes the assessment and selection of FFPE samples appropriate for genomic testing, typically conducted by a pathologist. The guidelines recommend that FFPE sample blocks be used within 3 years from preparation, and the tumor content should be ≥30% (minimum 20%). The empirical data were obtained from clinical studies performed by the JSP in collaboration with leading Japanese cancer genome research projects. The Japanese Ministry of Health, Labour, and Welfare (MHLW) recommended to comply with the JSP practical guidelines in implementing cancer genomic testing under the national health insurance system in over 200 MHLW-designated core and cooperative cancer genome medicine hospitals in Japan.
  • BRAF V600E変異肺癌におけるCDK4の発現によるダブラフェニブ・トラメチニブ併用療法に対する獲得耐性
    佐々木 高明; 平井 理子; 畑中 豊; 畑中 佳奈子; 梅影 泰寛; 南 幸範; 奥村 俊介; 大崎 能伸
    肺癌, 61, 6, 629, 629, (NPO)日本肺癌学会, 2021年10月
    日本語
  • Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in BRAF V600E-mutated lung cancer.
    Noriko Hirai; Yutaka Hatanaka; Kanako C Hatanaka; Yuji Uno; Shin-Ichi Chiba; Yasuhiro Umekage; Yoshinori Minami; Shunsuke Okumura; Yoshinobu Ohsaki; Takaaki Sasaki
    Translational lung cancer research, 10, 9, 3737, 3744, 2021年09月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Combination therapy with the B-Raf inhibitor, dabrafenib, and the MEK inhibitor, trametinib (DT) is commonly used to treat patients with B-Raf proto-oncogene, serine/threonine kinase V600E (BRAF V600E)-mutated non-small cell lung cancer (NSCLC). However, the mechanisms through which cancer develops DT resistance are unclear. Here, we investigated new mechanisms underlying acquired DT-resistant NSCLC with the BRAF V600E mutation. METHODS: We compared genomic signatures before and after DT treatment in patients with NSCLC. RESULTS: Two of four patients treated with DT developed carcinomatous pleuritis within 3 months. Target DNA sequencing and quantitative polymerase chain reaction (PCR) analyses revealed the increased expression level of cyclin-dependent kinase 4 (CDK4). We also found prominent protein expression of CDK4 after DT treatment. Induction of CDK4 expression in a cell line derived from a patient with the BRAF V600E mutation resulted in partial resistance to dabrafenib. CONCLUSIONS: Our findings suggest a possible relationship between CDK4 upregulation and acquired resistance to DT therapy.
  • 浸潤先進部の新規病理所見であるInvasion front gradeによる大腸癌の予後層別化
    松井 博紀; 畑中 佳奈子; 宮岡 陽一; 江本 慎; 市川 伸樹; 吉田 雅; 本間 重紀; 松野 吉宏; 畑中 豊; 武冨 紹信
    日本消化器外科学会総会, 76回, P256, 3, (一社)日本消化器外科学会, 2021年07月
    日本語
  • がん遺伝子パネル検査を用いた乳癌進展における遺伝子異常の検討
    萩尾 加奈子; 竹下 卓志; 押野 智博; 守谷 結美; 李 東; 天野 虎次; 畑中 佳奈子; 畑中 豊; 山下 啓子
    日本乳癌学会総会プログラム抄録集, 29回, 23, 23, (一社)日本乳癌学会, 2021年07月
    日本語
  • Novel Prognostic Stratification Factor Based on the Pathological Profile of the Invasive Front in Colorectal Cancer.
    Hiroki Matsui; Shigenori Homma; Kanako C Hatanaka; Akifumi Sawada; Ken Imaizumi; Tadashi Yoshida; Nobuki Ichikawa; Shin Emoto; Yoichi Miyaoka; Norihiko Takahashi; Yoshihiro Matsuno; Yutaka Hatanaka; Akinobu Taketomi
    Anticancer research, 41, 7, 3429, 3438, 2021年07月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND/AIM: This study aimed to develop a new pathological finding, namely, invasion front grade and verify its clinical usefulness. MATERIALS AND METHODS: We re-examined haematoxylin-eosin-stained specimens in 162 stage II-III colorectal cancer patients who underwent radical resection. We assessed the desmoplastic reaction, Klintrup grade, and poorly differentiated cluster. These three findings were combined to form the invasion front grade (good prognosis group; Grade A, poor prognosis group; Grade B), and its reproducibility and prognostic stratification ability were statistically analysed. RESULTS: Invasion front grade was Grade A in 116 cases and Grade B in 46 cases, and its kappa coefficient was 0.81 for interobserver and 0.74 for intraobserver variability. The 3-year recurrence-free survival rates of Grade A and Grade B were 90.4% and 55.9%. Multivariate analysis showed that invasion front grade was an independent prognostic factor. CONCLUSION: Invasion front grade is useful as a prognostic stratification factor for stage II-III colorectal cancer.
  • Biglycan, tumor endothelial cell secreting proteoglycan, as possible biomarker for lung cancer.
    Hirofumi Morimoto; Yasuhiro Hida; Nako Maishi; Hiroshi Nishihara; Yutaka Hatanaka; Cong Li; Yoshihiro Matsuno; Toru Nakamura; Satoshi Hirano; Kyoko Hida
    Thoracic cancer, 12, 9, 1347, 1357, 2021年05月, [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVES: In lung cancer, surgery remains the most curative treatment and limited resection is beneficial for patients with low cardiopulmonary function and low malignancy tumors. However, there are no biomarkers of low malignancy to select candidates for limited resection without compromising the outcome of treatments. Recently we identified biglycan (BGN) as a tumor endothelial cell (TEC) marker that is associated with tumor progression in various cancers. In this study, we analyzed the association between BGN expression in TECs in lung cancer and cancer progression in patients. MATERIALS AND METHODS: First, we performed immunohistochemistry of BGN with resected lung tumor tissues of 155 patients who had undergone thoracic surgery and analyzed the correlation between BGN-positive vessel density in primary lung tumors and clinicopathological factors. Second, we measured the BGN levels in preoperative serum of other 46 patients with lung cancer by ELISA, and analyzed the correlation between BGN expression in tumor tissues and blood BGN levels. RESULTS: High BGN expression in the TECs was significantly associated with T factor, and was a significant negative predictor. BGN levels in preoperative serum of 46 patients with lung cancer was significantly correlated with BGN expression in the TECs. Preoperative serum BGN level was significantly lower in healthy volunteers and less invasive adenocarcinoma than in invasive adenocarcinoma and other lung carcinomas. These results suggest that low BGN level in preoperative serum in patients with lung cancer might indicate low malignancy. CONCLUSIONS: BGN can be a potential biomarker for lung cancer.
  • Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.
    Junko Kikuchi; Yoshihito Ohhara; Kohichi Takada; Hiroki Tanabe; Kazuteru Hatanaka; Toraji Amano; Kanako C Hatanaka; Yutaka Hatanaka; Takashi Mitamura; Momoko Kato; Yuka Shibata; Ichiro Yabe; Akira Endoh; Yoshito Komatsu; Yoshihiro Matsuno; Minako Sugiyama; Atsushi Manabe; Akihiro Sakurai; Masato Takahashi; Hirohito Naruse; Yoshihiro Torimoto; Hirotoshi Dosaka-Akita; Ichiro Kinoshita
    Japanese journal of clinical oncology, 51, 5, 753, 761, 2021年04月30日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Comprehensive cancer genomic profiling has been used recently for patients with advanced solid cancers. Two cancer genomic profiling tests for patients with no standard treatment are covered by Japanese public health insurance since June 2019. METHODS: We prospectively analyzed data of 189 patients with solid cancers who underwent either of the two-cancer genomic profiling tests at Hokkaido University Hospital and its liaison hospitals and whose results were discussed in molecular tumor board at Hokkaido University Hospital between August 2019 and July 2020. RESULTS: All 189 patients had appropriate results. Actionable gene alterations were identified in 93 patients (49%). Frequent mutations included PIK3CA (12%) mutation, BRCA1/2 alteration (7%), ERBB2 amplification (6%) and tumor mutation burden-High (4%). The median turnaround time from sample shipping to acquisition by the expert panel was 26 days. Although 115 patients (61%) were provided with information for genotype-matched therapies, only 21 (11%) received them. Notably, four of eight patients below the age of 20 years were provided information for genotype-matched therapies, and three received them. Their response rates and disease control rates were 29% and 67%, respectively. Most patients who did not undergo the genotype-matched therapies were provided information for only investigational drugs in phases I and II at distant clinical trial sites in central Japan. Twenty-six patients were informed of suspected germline findings, while 11 patients (42%) received genetic counseling. CONCLUSIONS: The publicly reimbursed cancer genomic profilings may lead to the modest but favorable therapeutic efficacy of genotype-matched therapy for solid cancer patients with no standard therapy. However, poor access to genotype-matched therapy needs to be resolved.
  • 低分化胞巣と局所炎症反応によるStage II大腸癌の予後層別化
    松井 博紀; 畑中 佳奈子; 宮岡 陽一; 江本 慎; 市川 伸樹; 吉田 雅; 本間 重紀; 松野 吉宏; 畑中 豊; 武冨 紹信
    日本外科学会定期学術集会抄録集, 121回, SF, 2, (一社)日本外科学会, 2021年04月
    日本語
  • 低分化胞巣と局所炎症反応によるStage II大腸癌の予後層別化
    松井 博紀; 畑中 佳奈子; 宮岡 陽一; 江本 慎; 市川 伸樹; 吉田 雅; 本間 重紀; 松野 吉宏; 畑中 豊; 武冨 紹信
    日本外科学会定期学術集会抄録集, 121回, SF, 2, (一社)日本外科学会, 2021年04月
    日本語
  • A novel Tn antigen epitope-recognizing antibody for MUC1 predicts clinical outcome in patients with primary lung adenocarcinoma.
    Tatsuya Kato; Hideki Ujiie; Kanako C Hatanaka; Ayae Nange; Asami Okumura; Kaho Tsubame; Kentato Naruchi; Masaharu Sato; Kichizo Kaga; Yoshihiro Matsuno; Satoru Wakasa; Yutaka Hatanaka
    Oncology letters, 21, 3, 202, 202, 2021年03月, [国際誌]
    英語, 研究論文(学術雑誌), Mucin 1 (MUC1) expression is upregulated in multiple types of cancer, including lung cancer. However, the conventional anti-MUC1 antibody is not useful for the differentiation of malignant lung tumors and benign lesions due to its limited specificity. Our previous study screened a novel epitope-defined antibody against cancer-associated sugar chain structures that specifically recognizes the MUC1 Tn antigen (MUC1-Tn ED Ab). In the present study, its potential utility as a diagnostic marker and therapeutic tool for lung adenocarcinoma (ADC) was examined. Immunohistochemical analysis of a lung ADC tissue microarray was performed using the MUC1-Tn ED Ab (clone SN-102), and the results were compared with those of another clone and commercially available MUC1 antibodies. The association between positive immunoreactivity of SN-102 and clinicopathologic factors was analyzed. Furthermore, the association between MUC1-Tn expression and epithelial-mesenchymal transition markers and radiological characteristics was analyzed. Moderate or high MUC1-Tn expression (MUC1-Tn-H) was observed in 138 (78.9%) of the 175 lung ADC cases. MUC1-Tn-H was associated with male sex, cigarette smoking, tumor extension, pleural invasion, and higher preoperative serum carcinoembryonic antigen and cytokeratin 19 fragment levels. Tumors with MUC1-Tn-H had higher consolidation/tumor ratios according to computed tomography and greater uptakes of 18F-fluorodeoxyglucose. A total of 46 (26.9%) of the tumors had mesenchymal features, and MUC1-Tn positivity was higher in the mesenchymal group than in the epithelial and intermediate groups (P<0.01 and P<0.01, respectively). Patients with tumors exhibiting MUC1-Tn-H had significantly shorter 5-year overall and disease-free survival times (P=0.011 and P<0.001, respectively). Additionally, MUC1-Tn-H was identified as an independent prognostic factor in multivariate analysis (P=0.024). MUC1-Tn is specific for lung cancer cells and can improve diagnostic capabilities. Additionally, it may be a potential therapeutic target in lung ADC.
  • Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells.
    Fumihiko Matsuzawa; Hirofumi Kamachi; Tatsuzo Mizukami; Takahiro Einama; Futoshi Kawamata; Yuki Fujii; Moto Fukai; Nozomi Kobayashi; Yutaka Hatanaka; Akinobu Taketomi
    BMC cancer, 21, 1, 200, 200, 2021年02月26日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Mesothelin is a 40-kDa glycoprotein that is highly overexpressed in various types of cancers, however molecular mechanism of mesothelin has not been well-known. Amatuximab is a chimeric monoclonal IgG1/k antibody targeting mesothelin. We recently demonstrated that the combine therapy of Amatuximab and gemcitabine was effective for peritonitis of pancreatic cancer in mouse model. METHODS: We discover the role and potential mechanism of mesothelin blockage by Amatuximab in human pancreatic cells both expressing high or low level of mesothelin in vitro experiment and peritonitis mouse model of pancreatic cancer. RESULTS: Mesothelin blockage by Amatuximab lead to suppression of invasiveness and migration capacity in AsPC-1 and Capan-2 (high mesothelin expression) and reduce levels of pMET expression. The combination of Amatuximab and gemcitabine suppressed proliferation of AsPC-1 and Capan-2 more strongly than gemcitabine alone. These phenomena were not observed in Panc-1 and MIA Paca-2 (Mesothelin low expression). We previously demonstrated that Amatuximab reduced the peritoneal mass in mouse AsPC-1 peritonitis model and induced sherbet-like cancer cell aggregates, which were vanished by gemcitabine. In this study, we showed that the cancer stem cell related molecule such as ALDH1, CD44, c-MET, as well as proliferation related molecules, were suppressed in sherbet-like aggregates, but once sherbet-like aggregates attached to peritoneum, they expressed these molecules strongly without the morphological changes. CONCLUSIONS: Our work suggested that Amatuximab inhibits the adhesion of cancer cells to peritoneum and suppresses the stemness and viability of those, that lead to enhance the sensitivity for gemcitabine.
  • Molecular Classification and Tumor Microenvironment Characterization of Gallbladder Cancer by Comprehensive Genomic and Transcriptomic Analysis.
    Nobutaka Ebata; Masashi Fujita; Shota Sasagawa; Kazuhiro Maejima; Yuki Okawa; Yutaka Hatanaka; Tomoko Mitsuhashi; Ayako Oosawa-Tatsuguchi; Hiroko Tanaka; Satoru Miyano; Toru Nakamura; Satoshi Hirano; Hidewaki Nakagawa
    Cancers, 13, 4, 2021年02月10日, [国際誌]
    英語, 研究論文(学術雑誌), Gallbladder cancer (GBC), a rare but lethal disease, is often diagnosed at advanced stages. So far, molecular characterization of GBC is insufficient, and a comprehensive molecular portrait is warranted to uncover new targets and classify GBC. We performed a transcriptome analysis of both coding and non-coding RNAs from 36 GBC fresh-frozen samples. The results were integrated with those of comprehensive mutation profiling based on whole-genome or exome sequencing. The clustering analysis of RNA-seq data facilitated the classification of GBCs into two subclasses, characterized by high or low expression levels of TME (tumor microenvironment) genes. A correlation was observed between gene expression and pathological immunostaining. TME-rich tumors showed significantly poor prognosis and higher recurrence rate than TME-poor tumors. TME-rich tumors showed overexpression of genes involved in epithelial-to-mesenchymal transition (EMT) and inflammation or immune suppression, which was validated by immunostaining. One non-coding RNA, miR125B1, exhibited elevated expression in stroma-rich tumors, and miR125B1 knockout in GBC cell lines decreased its invasion ability and altered the EMT pathway. Mutation profiles revealed TP53 (47%) as the most commonly mutated gene, followed by ELF3 (13%) and ARID1A (11%). Mutations of ARID1A, ERBB3, and the genes related to the TGF-β signaling pathway were enriched in TME-rich tumors. This comprehensive analysis demonstrated that TME, EMT, and TGF-β pathway alterations are the main drivers of GBC and provides a new classification of GBCs that may be useful for therapeutic decision-making.
  • METex14 skipping testing guidance for lung cancer patients: The guidance from the biomarker committee, the Japan lung cancer society
    Yasushi Yatabe; Koichi Goto; Shingo Matsumoto; Yutaka Hatanaka; Naoko Arakane; Sadakatsu Ikeda; Akira Inoue; Ichiro Kinoshita; Hideharu Kimura; Tomohiro Sakamoto; Miyako Satouchi; Junichi Shimizu; Kuniko Sunami; Koji Tsuta; Shinichi Toyooka; Kazuto Nishio; Kazumi Nishino; Masashi Mikubo; Tomoyuki Yokose; Hirotoshi Dosaka-Akita
    Japanese Journal of Lung Cancer, 61, 5, 361, 370, Japan Lung Cancer Society, 2021年
    英語, 研究論文(学術雑誌)
  • A multi-scale conditional deep model for tumor cell ratio counting
    Eric Cosatto; Kyle Gerard; Hans-Peter Graf; Maki Ogura; Tomoharu Kiyuna; Kanako C. Hatanaka; Yoshihiro Matsuno; Yutaka Hatanaka
    Progress in Biomedical Optics and Imaging - Proceedings of SPIE, 11603, SPIE, 2021年
    英語, 研究論文(国際会議プロシーディングス)
  • A case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma with severe right heart failure.
    Shotaro Ito; Hajime Asahina; Naoko Yamaguchi; Utano Tomaru; Tadashi Hasegawa; Yutaka Hatanaka; Kanako C Hatanaka; Hiroshi Taguchi; Taisuke Harada; Hiroshi Ohira; Daisuke Ikeda; Hidenori Mizugaki; Eiki Kikuchi; Junko Kikuchi; Jun Sakakibara-Konishi; Naofumi Shinagawa; Satoshi Konno
    Respiratory medicine case reports, 32, 101364, 101364, 2021年, [国際誌]
    英語, SMARCA4-deficient thoracic sarcomatoid tumors were characterized by inactivating mutations of SMARCA4 and often found in the chest of young and middle-aged males with a smoking history. Recently, SMARCA4-deficient thoracic sarcomatoid tumors were reported to represent primarily smoking-associated undifferentiated/de-differentiated carcinomas rather than primary thoracic sarcomas. The main complication of this tumor is compression of the respiratory tract and/or blood vessels. A 39-year-old man presented with a 2-month history of fever and dyspnea. Computed tomography revealed a mediastinal tumor invading the right and left pulmonary arteries. Because of severe right heart failure, we considered him ineligible for bronchoscopy. We scheduled palliative irradiation with 40 Gy/20 Fr to improve hemodynamics and perform endobronchial ultrasound transbronchial needle aspiration later. However, irradiation was ineffective, and his general condition deteriorated quickly and he died after a 7-week hospitalization. An autopsy revealed that the diagnosis was SMARCA4-deficient thoracic undifferentiated carcinoma. It has been reported that this tumor is insensitive to radiotherapy and there were some cases which responded to an immune checkpoint inhibitor. Therefore, when caring for patients with mediastinal tumors that invade and compress the trachea and large vessels, it is important to consider this tumor as a differential diagnosis and try to make a pathological diagnosis as soon as possible.
  • Impact of DNA integrity on the success rate of tissue-based next-generation sequencing: Lessons from nationwide cancer genome screening project SCRUM-Japan GI-SCREEN.
    Takeshi Kuwata; Masashi Wakabayashi; Yutaka Hatanaka; Eiichi Morii; Yoshinao Oda; Kenichi Taguchi; Masayuki Noguchi; Yuichi Ishikawa; Takashi Nakajima; Shigeki Sekine; Shogo Nomura; Wataru Okamoto; Satoshi Fujii; Takayuki Yoshino
    Pathology international, 70, 12, 932, 942, 2020年12月, [国際誌]
    英語, 研究論文(学術雑誌), In the nationwide cancer genome screening project SCRUM-Japan GI-SCREEN, 2590 archival formalin-fixed paraffin-embedded (FFPE) tumor tissues from 19 institutions were analyzed with two tissue-based next-generation sequencing (NGS) panels at the Clinical Laboratory Improvement Amendments (CLIA)-certified College of American Pathologists (CAP)-accredited central laboratory. The Oncomine Cancer Research Panel (OCP; 143 genes) succeeded in producing validated results for only 68.3% of the samples (%OCP-success). CE-IVD (25 genes) succeeded in 45.9% of the OCP-failed samples, leading to an overall NGS success (%combined-success) rate as high as 82.9%. Among 2573 samples, the DNA-integrity (ΔCt )-high (ΔCt  < 4.4, n = 1253) samples showed significantly higher %OCP- and %combined-success rates (90.2% and 97.4%, respectively) than the DNA-integrity-intermediate (4.4 < ΔCt  < 6.3, n = 911; 68.9% and 88.7%) and DNA-integrity-low ones (ΔCt  > 6.3 or polymerase chain reaction-failed, n = 409; 5.6% and 24.7%). Other factors associated with NGS success included the FFPE-sample storage period (<4 years), the specimen type (surgical) and the primary tumor site (colorectal). Multivariable analysis revealed DNA integrity as the factor with the strongest independent association with NGS success, although it was suggested that other institution-specific factors contribute to the discordance of inter-institutional NGS success rates. Our results emphasize the importance of DNA quality in FFPE samples for NGS tests and the impact of DNA integrity on quality monitoring of pathology specimens for achieving successful NGS.
  • 大腸癌の新規病理学的因子である線維性癌間質反応の臨床的有用性
    松井 博紀; 畑中 佳奈子; 宮岡 陽一; 今泉 健; 市川 伸樹; 吉田 雅; 本間 重紀; 松野 吉宏; 畑中 豊; 武冨 紹信
    日本消化器外科学会総会, 75回, P196, 3, (一社)日本消化器外科学会, 2020年12月
    日本語
  • Association of Epstein–Barr virus with regression after withdrawal of immunosuppressive drugs and subsequent progression of iatrogenic immunodeficiency‐associated lymphoproliferative disorders in patients with autoimmune diseases
    Katsuya Fujimoto; Kanako C. Hatanaka; Yutaka Hatanaka; Ikumi Kasahara; Satoshi Yamamoto; Takahiro Tsuji; Masanobu Nakata; Yasunari Takakuwa; Yoshihito Haseyama; Yumiko Oyamada; Masakatsu Yonezumi; Hiroaki Suzuki; Hajime Sakai; Hiroko Noguchi; Akio Mori; Hiroshi Nishihara; Takanori Teshima; Yoshihiro Matsuno
    Hematological Oncology, 38, 5, 799, 807, Wiley, 2020年12月
    研究論文(学術雑誌)
  • 腫瘍浸潤リンパ球の局在に注目した肝内胆管癌の臨床病理学的検討
    旭 よう; 畑中 佳奈子; 神山 俊哉; 折茂 達也; 島田 慎吾; 長津 明久; 坂本 譲; 蒲池 浩文; 畑中 豊; 武冨 紹信
    日本消化器外科学会総会, 75回, P220, 3, (一社)日本消化器外科学会, 2020年12月
    日本語
  • 大腸癌の新規病理学的因子である線維性癌間質反応の臨床的有用性
    松井 博紀; 畑中 佳奈子; 宮岡 陽一; 今泉 健; 市川 伸樹; 吉田 雅; 本間 重紀; 松野 吉宏; 畑中 豊; 武冨 紹信
    日本消化器外科学会総会, 75回, P196, 3, (一社)日本消化器外科学会, 2020年12月
    日本語
  • 腫瘍浸潤リンパ球の局在に注目した肝内胆管癌の臨床病理学的検討
    旭 よう; 畑中 佳奈子; 神山 俊哉; 折茂 達也; 島田 慎吾; 長津 明久; 坂本 譲; 蒲池 浩文; 畑中 豊; 武冨 紹信
    日本消化器外科学会総会, 75回, P220, 3, (一社)日本消化器外科学会, 2020年12月
    日本語
  • Multiplex gene-panel testing for lung cancer patients.
    Yasushi Yatabe; Kuniko Sunami; Koichi Goto; Kazuto Nishio; Naoko Aragane; Sadakatsu Ikeda; Akira Inoue; Ichiro Kinoshita; Hideharu Kimura; Tomohiro Sakamoto; Miyako Satouchi; Junichi Shimizu; Koji Tsuta; Shinichi Toyooka; Kazumi Nishino; Yutaka Hatanaka; Shingo Matsumoto; Masashi Mikubo; Tomoyuki Yokose; Hirotoshi Dosaka-Akita
    Pathology international, 70, 12, 921, 931, 2020年12月, [国際誌]
    英語, 研究論文(学術雑誌), The year 2019 was considered to be the first year of cancer genome medicine in Japan, with three gene-panel tests using next-generation sequencing (NGS) techniques being introduced into clinical practice. Among the three tests, the Oncomine CDx Target test was approved under the category of regular molecular testing for lung cancer, which meant that this test could be used to select patients for molecularly targeted drugs. Conversely, the other two tests, NCC OncoPanel and FoundationOne CDx, were assigned to be used under the National Cancer Genome Medicine Network, and implementation was restricted to patients for whom standard treatment was completed or expected to be completed. These NGS tests can detect a series of genetic alterations in individual tumors, which further promotes the development of therapeutic agents and elucidates molecular pathways. The NGS tests require appropriate tissue size and tumor cell content, which can be accessed only by pathologists. In this report, we review the current reimbursement schema in our national healthcare policy and the requirements of the specimens for NGS testing based on the recently published 'Guidance of Gene-panel Testing Using Next-Generation Sequencers for Lung Cancer', by the Japanese Society of Lung Cancer.
  • Predicting the Efficacy and Safety of TACTICs (Tumor Angiogenesis-Specific CAR-T Cells Impacting Cancers) Therapy for Soft Tissue Sarcoma Patients
    Kento Fujiwara; Shigemi Sasawatari; Sho Nakai; Keisuke Imaeda; Seina Nagai; Yoshihiro Matsuno; Kanako Hatanaka; Yutaka Hatanaka; Satoshi Takenaka; Naoki Okada
    CANCERS, 12, 10, 2020年10月
    英語, 研究論文(学術雑誌)
  • Immunological Gene Signature Associated With the Tumor Microenvironment of Pancreatic Cancer After Neoadjuvant Chemotherapy.
    Yuma Hane; Takahiro Tsuchikawa; Toru Nakamura; Kanako C Hatanaka; Tatsuro Saito; Kimitaka Tanaka; Yoshitsugu Nakanishi; Toshimichi Asano; Takehiro Noji; Keisuke Okamura; Toshiaki Shichinohe; Isao Yokota; Yutaka Hatanaka; Satoshi Hirano
    Pancreas, 49, 9, 1240, 1245, 2020年10月, [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVES: Neoadjuvant chemotherapy (NAC) has improved overall survival in patients with pancreatic ductal adenocarcinoma (PDAC), but its effects on immune gene signatures are unknown. Here, we examined the immune transcriptome after NAC for PDAC. METHODS: Resected tumor specimens were obtained from 140 patients with PDAC who received surgery first (n = 93) or NAC (n = 47). Six patients were randomly selected from each group, and RNA was extracted from tumor tissues. We compared 770 immune-related genes among the 2 groups using nCounterPanCancer Immune Profiling (NanoString Technologies, Seattle, Wash). Gene clusters were classified into 14 immune function groups based on gene ontology argolism by nSolver 4.0 software (NanoString Technologies), and corresponding immune cell function scores were compared. RESULTS: Eleven genes (LY86, SH2D1A, CD247, TIGIT, CR2, CD83, LAMP3, CXCR4, DUSP4, SELL, and IL2RA) were significantly downregulated in the NAC group. Gene expression analysis showed that the functions of regulatory T cells, B cells, and natural killer CD56 dim cells were significantly decreased in the NAC group. CONCLUSIONS: Neoadjuvant chemotherapy may suppress regulatory T cells and B-cell function in the PDAC microenvironment. The 11 identified genes could be useful for predicting the efficacy of NAC and could be therapeutic targets for PDAC.
  • Predicting the Efficacy and Safety of TACTICs (Tumor Angiogenesis-Specific CAR-T Cells Impacting Cancers) Therapy for Soft Tissue Sarcoma Patients.
    Kento Fujiwara; Shigemi Sasawatari; Sho Nakai; Keisuke Imaeda; Seina Nagai; Yoshihiro Matsuno; Kanako Hatanaka; Yutaka Hatanaka; Satoshi Takenaka; Naoki Okada
    Cancers, 12, 10, 2020年09月23日, [国際誌]
    英語, 研究論文(学術雑誌), Soft tissue sarcomas (STSs) are heterogeneous and aggressive malignancies with few effective therapies available. We have developed T cells expressing a vascular endothelial growth factor receptor 2 (VEGFR2)-specific chimeric antigen receptor (CAR) to establish a tumor angiogenesis-specific CAR-T cells impacting cancers (TACTICs) therapy. In this study, we optimized the manufacturing and transportation of mRNA-transfected anti-VEGFR2 CAR-T cells and collected information that allowed the extrapolation of the efficacy and safety potential of TACTICs therapy for STS patients. Although 5-methoxyuridines versus uridines did not improve CAR-mRNA stability in T cells, the utilization of CleanCap as a 5' cap-structure extended the CAR expression level, increasing VEGFR2-specific cytotoxicity. Furthermore, 4 °C preservation conditions did not affect the viability/cytotoxicity of CAR-T cells, contrarily to a freeze-thaw approach. Importantly, immunohistochemistry showed that most of the STS patients' specimens expressed VEGFR2, suggesting a great potential of our TACTICs approach. However, VEGFR2 expression was also detected in normal tissues, stressing the importance of the application of a strict monitoring schedule to detect (and respond to) the occurrence of adverse effects in clinics. Overall, our results support the development of a "first in humans" study to evaluate the potential of our TACTICs therapy as a new treatment option for STSs.
  • MUC1がん特異的糖鎖抗原は肺腺癌の有力な新規診断マーカーかつ予後因子となりうる
    加藤 達哉; 畑中 佳奈子; 燕 果歩; 成地 健太郎; 佐藤 正治; 樋田 泰浩; 松野 吉宏; 畑中 豊; 加賀 基知三
    日本外科学会定期学術集会抄録集, 120回, DP, 3, (一社)日本外科学会, 2020年08月
    日本語
  • 大腸癌の新規病理学的因子である低分化胞巣と線維性癌間質反応の予後予測因子としての有用性の検討
    松井 博紀; 畑中 佳奈子; 宮岡 陽一; 今泉 健; 市川 伸樹; 吉田 雅; 本間 重紀; 畑中 豊; 松野 吉宏; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, DP, 7, (一社)日本外科学会, 2020年08月
    日本語
  • 大腸癌の新規病理学的因子である低分化胞巣と線維性癌間質反応の予後予測因子としての有用性の検討
    松井 博紀; 畑中 佳奈子; 宮岡 陽一; 今泉 健; 市川 伸樹; 吉田 雅; 本間 重紀; 畑中 豊; 松野 吉宏; 武冨 紹信
    日本外科学会定期学術集会抄録集, 120回, DP, 7, (一社)日本外科学会, 2020年08月
    日本語
  • CD8の異常発現を示すびまん性大細胞型B細胞リンパ腫(DLBCL)の1症例
    清水 亜衣; 岩口 佳史; 岡田 宏美; 畑中 豊; 岡田 耕平; 松野 吉宏
    日本リンパ網内系学会会誌, 60, 76, 76, (一社)日本リンパ網内系学会, 2020年07月
    日本語
  • Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
    Yoichi Naito; Saori Mishima; Kiwamu Akagi; Ataru Igarashi; Masafumi Ikeda; Susumu Okano; Shunsuke Kato; Tadao Takano; Katsuya Tsuchihara; Keita Terashima; Hiroshi Nishihara; Hiroyki Nishiyama; Eiso Hiyama; Akira Hirasawa; Hajime Hosoi; Osamu Maeda; Yasushi Yatabe; Wataru Okamoto; Shigeru Ono; Hiroaki Kajiyama; Fumio Nagashima; Yutaka Hatanaka; Mitsuru Miyachi; Yasuhiro Kodera; Takayuki Yoshino; Hiroya Taniguchi
    International journal of clinical oncology, 25, 3, 403, 417, 2020年03月, [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we published provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors. Recently, efficacy of tropomyosin receptor kinase inhibitors against neurotrophic receptor tyrosine kinase (NTRK) fusion gene-positive advanced solid tumors have been established as the second tumor-agnostic treatment, making it necessary to develop the guideline prioritized for these patients. METHODS: Clinical questions regarding medical care were formulated for patients with NTRK-positive advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO) and Japanese Society of Medical Oncology (JSMO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and Japanese Society of Pediatric Hematology/Oncology, and the public comments among all Societies' members was done. RESULTS: The current guideline describes 3 clinical questions and 15 recommendations for whom, when, and how NTRK fusion should be tested, and what is recommended for patients with NTRK fusion-positive advanced solid tumors. CONCLUSION: In the NTRK guideline, the committee proposed 15 recommendations for performing NTRK testing properly to select patients who are likely to benefit from tropomyosin receptor kinase inhibitors.
  • 異型上皮の過剰増殖を伴う皮膚未分化大細胞リンパ腫
    清水 亜衣; 大塚 拓也; 高桑 恵美; 岡田 宏美; 柳 輝希; 小野澤 真弘; 畑中 豊; 三橋 智子; 阿南 隆; 松野 吉宏
    日本病理学会会誌, 109, 1, 389, 389, (一社)日本病理学会, 2020年03月
    日本語
  • TTF-1とp40を共発現した肺非小細胞癌の一例
    福井 秀章; 岡崎 ななせ; 高桑 恵美; 岡田 宏美; 清水 亜衣; 椎名 伸行; 加賀 基知三; 畑中 豊; 三橋 智子; 松野 吉宏
    日本病理学会会誌, 109, 1, 415, 415, (一社)日本病理学会, 2020年03月
    日本語
  • Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma.
    Yoh Asahi; Kanako C Hatanaka; Yutaka Hatanaka; Toshiya Kamiyama; Tatsuya Orimo; Shingo Shimada; Akihisa Nagatsu; Yuzuru Sakamoto; Hirofumi Kamachi; Nozomi Kobayashi; Moto Fukai; Akinobu Taketomi
    Surgery today, 2020年02月10日, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), PURPOSE: A lack of effective systemic therapy is one reason for the poor prognosis of intrahepatic cholangiocarcinoma. Newly developed immune checkpoint inhibitors function by minimizing CD8+ T cell suppression to improve tumor-specific responses. This study aimed to examine the characteristics of CD8+ T cells in intrahepatic cholangiocarcinoma. METHODS: Clinicopathological data, including the overall survival, of 69 cases of postoperative intrahepatic cholangiocarcinoma were prospectively investigated. We then immunohistochemically stained for CD8, Foxp3, CD163, PD-L1, and human leukocyte antigen (HLA) class I and counted the number of CD8+ T cells, Foxp3+ T cells, and CD163+ macrophages in different areas (outer border, interborder, and intratumor). RESULTS: A significant difference was found in the 5-year overall survival between the CD8+ T cell high group (45.5%) and low group (24.7%) in the outer border area (p = 0.0103). Furthermore, the number of CD8+ T cells and the high expression of HLA class I were positively correlated (p = 0.0341). CONCLUSION: The number of CD8+ T cells in the outer border area of the tumor correlated with the HLA class I expression of intrahepatic cholangiocarcinoma and may therefore be a prognostic factor for patients with postoperative intrahepatic cholangiocarcinoma.
  • HER2 Gene Amplification in ER-positive HER2 Immunohistochemistry 0 or 1+ Breast Cancer With Early Recurrence.
    Hiroko Yamashita; Naoko Ishida; Yutaka Hatanaka; Kanako Hagio; Tomohiro Oshino; Takashi Takeshita; Hiromi Kanno-Okada; A I Shimizu; Kanako C Hatanaka; Yoshihiro Matsuno
    Anticancer research, 40, 2, 645, 652, 2020年02月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND/AIM: In estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, standard chemotherapies as well as adjuvant endocrine therapy might not be enough for prevention of early relapse. MATERIALS AND METHODS: We focused on ER-positive, HER2 immunohistochemistry (IHC) 0 or 1+ breast cancer, and retrospectively examined HER2 gene amplification and TP53 mutation in breast cancer tissues in patients with or without early recurrence. Post-relapse survival in patients with early recurrence was also analyzed by mutation status of HER2 and TP53. RESULTS: Surprisingly, amplification of the HER2 gene was found in 15% of patients with early recurrence. None of the patients without relapse had HER2-amplified tumors. Post-relapse survival in patients with HER2 gene amplification and/or TP53 mutation in primary tumors was shorter than that in patients without these mutations, especially among postmenopausal women. CONCLUSION: HER2 gene amplification exists in ER-positive, HER2 IHC 0 or 1+ breast cancer in patients who developed early distant metastasis.
  • Enhanced Angiogenesis in Salivary Duct Carcinoma Ex-Pleomorphic Adenoma.
    Takayoshi Suzuki; Satoshi Kano; Masanobu Suzuki; Shinichiro Yasukawa; Takatsugu Mizumachi; Nayuta Tsushima; Kanako C Hatanaka; Yutaka Hatanaka; Yoshihiro Matsuno; Akihiro Homma
    Frontiers in oncology, 10, 603717, 603717, 2020年, [国際誌]
    英語, 研究論文(学術雑誌), Salivary duct carcinoma (SDC) is morphologically similar to breast cancer, with HER2-overexpression reported. With regard to the pattern of disease onset, SDC can arise from de novo or carcinoma ex-pleomorphic adenoma (Ca-ex-PA). Recently, multiple molecular profiles of SDC as well as breast cancer have been reported, with significant differences in HER2 expression between Ca-ex-PA and de novo. We assessed the differences in gene expression between onset classifications. We conducted immunohistochemical analysis and HER2-DISH for 23 patients and classified SDCs into three subtypes as follows: "HER2-positive" (HER2+/any AR), "Luminal-AR" (HER2-/AR+), and "Basal-like" (HER2-/AR-). We assessed the expression levels of 84 functional genes for 19 patients by using a qRT-PCR array. Ten cases were classified as HER2-positive, seven cases as Luminal-AR, and six cases as Basal-like. The gene expression pattern was generally consistent with the corresponding immunostaining classification. The expression levels of VEGFA, ERBB2(HER2), IGF1R, RB1, and XBP1 were higher, while those of SLIT2 and PTEN were lower in Ca-ex-PA than in de novo. The functions of those genes were concentrated in angiogenesis and AKT/PI3K signaling pathway (Fisher's test: p-value = 0.025 and 0.004, respectively). Multiple machine learning methods, OPLS-DA, LASSO, and RandomForest, also show that VEGFA can be a candidate for the characteristic differences between Ca-ex-PA and de novo. In conclusion, the AKT/PI3K signaling pathway leading to angiogenesis was hyper-activated in all SDCs, particularly in those classified into the Ca-ex-PAs. VEGFA was over-expressed significantly in the Ca-ex-PA, which can be a crucial factor in the malignant conversion to SDC.
  • Adenomatous polyposis coli-binding protein end-binding 1 promotes hepatocellular carcinoma growth and metastasis.
    Takeshi Aiyama; Tatsuya Orimo; Hideki Yokoo; Takanori Ohata; Kanako C Hatanaka; Yutaka Hatanaka; Moto Fukai; Toshiya Kamiyama; Akinobu Taketomi
    PloS one, 15, 9, e0239462, 2020年, [国際誌]
    英語, 研究論文(学術雑誌), This study was performed to determine the clinical significance of adenomatous polyposis coli (APC)-binding protein end-binding 1 (EB1) in hepatocellular carcinoma (HCC) and to characterize its biochemical role in comparison with previous reports. We performed immunohistochemical staining to detect EB1 expression in tissues from 235 patients with HCC and investigated its correlations with clinicopathological features and prognosis. We also investigated the roles of EB1 in cell proliferation, migration, and tumorigenesis in vitro and in vivo by siRNA- and CRISPR/Cas9-mediated modulation of EB1 expression in human HCC cell lines. The results showed that EB1 expression was significantly correlated with several important factors associated with tumor malignancy, including histological differentiation, portal vein invasion status, and intrahepatic metastasis. Patients with high EB1 expression in HCC tissue had poorer overall survival and higher recurrence rates than patients with low EB1 expression. EB1 knockdown and knockout in HCC cells reduced cell proliferation, migration, and invasion in vitro and inhibited tumor growth in vivo. Further, genes encoding Dlk1, HAMP, and SLCO1B3 that were differentially expressed in association with EB1 were identified using RNA microarray analysis. In conclusion, elevated expression of EB1 promotes tumor growth and metastasis of HCC. EB1 may serve as a new biomarker for HCC, and genes coexpressed with EB1 may represent potential targets for therapy.
  • Detection of early adenocarcinoma of the esophagogastric junction by spraying an enzyme-activatable fluorescent probe targeting Dipeptidyl peptidase-IV
    Keikokw Yamamoto; Shunsuke Ohnishi; Takeshi Mizushima; Junichi Kodaira; Masayoshi Ono; Yutaka Hatanaka; Kanako C. Hatanaka; Yugo Kuriki; Mako Kamiya; Nobuyuki Ehira; Keisuke Shinada; Hiroaki Takahashi; Yuichi Shimizu; Yasuteru Urano; Naoya Sakamoto
    BMC CANCER, 20, 1, 2020年01月
    英語, 研究論文(学術雑誌)
  • L1CAM Predicts Adverse Outcomes in Patients with Endometrial Cancer Undergoing Full Lymphadenectomy and Adjuvant Chemotherapy.
    Hiroshi Asano; Kanako C Hatanaka; Ryosuke Matsuoka; Peixin Dong; Takashi Mitamura; Yosuke Konno; Tatsuya Kato; Noriko Kobayashi; Kei Ihira; Ayako Nozaki; Akira Oku; Yoshihiro Matsuno; Yutaka Hatanaka; Hidemichi Watari
    Annals of surgical oncology, 2019年12月02日, [査読有り], [国際誌]
    英語, BACKGROUND: L1 cell adhesion molecule (L1CAM) has been established as an important predictor of poor survival of early-stage endometrial cancer patients. We investigated whether L1CAM remains a significant predictor of poor survival of patients with advanced-stage endometrial cancer undergoing extensive surgical staging and adjuvant chemotherapy. METHODS: We prepared tissue microarray (TMA) from surgical tissue specimens of 161 endometrial cancer patients who underwent full lymphadenectomy combined with adjuvant chemotherapy for patients at risk for recurrence, and evaluated expression of L1CAM using immunohistochemistry. The correlation between L1CAM positivity and clinicopathological factors and the prognostic significance of L1CAM expression was investigated. RESULTS: Among 161 cases who had a follow-up duration of over 3 years, 48 cases (29.8%) showed positive staining for L1CAM. L1CAM positivity was significantly correlated with non-endometrioid histology (p < 0.0001), vascular invasion (p = 0.0157), and positive cytology (p = 0.005), and was a significant predictor of poor survival among advanced-stage patients, but not early-stage patients in our cohort. L1CAM-positive patients showed a higher recurrence rate and frequency of distant failure than L1CAM-negative patients. Multivariate analysis revealed that para-aortic lymph node metastasis (PANM) and L1CAM positivity were independent predictors of poor survival. Overall survival can be stratified into three groups by the combination of PANM and L1CAM positivity. CONCLUSION: L1CAM is an independent predictor of poor survival in endometrial cancer patients undergoing full lymphadenectomy and adjuvant chemotherapy, thus indicating that L1CAM can be clinically used as a biomarker to identify those patients at increased risk of recurrence.
  • ロルラチニブ治療後にクリゾチニブ再投与が著効したALK融合遺伝子陽性肺腺癌の1例
    辻 康介; 榊原 純; 北井 秀典; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 品川 尚文; 今野 哲; 池澤 靖元; 畑中 豊; 佐々木 高明; 吉田 遼平; 千葉 伸一; 松本 慎吾; 後藤 功一
    肺癌, 59, 7, 1200, 1200, (NPO)日本肺癌学会, 2019年12月
    日本語
  • 気管支鏡検査におけるFFPE組織検体および細胞検体を用いたROS1融合遺伝子の検査成功率の検証
    辻 康介; 榊原 純; 北井 秀典; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 品川 尚文; 樋田 泰浩; 加賀 基知三; 大井 優子; 中條 聖子; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 今野 哲
    気管支学, 41, 6, 678, 678, (NPO)日本呼吸器内視鏡学会, 2019年11月
    日本語
  • Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer.
    Jun Sakakibara-Konishi; Hidenori Kitai; Yasuyuki Ikezawa; Yutaka Hatanaka; Takaaki Sasaki; Ryohei Yoshida; Shinichi Chiba; Shingo Matsumoto; Koichi Goto; Hidenori Mizugaki; Naofumi Shinagawa
    Clinical lung cancer, 20, 5, e555-e559, 2019年09月, [査読有り], [国際誌]
    英語
  • 乳癌における腫瘍関連MUC1の発現変化とその臨床的意義
    清水 亜衣; 畑中 佳奈子; 畑中 豊; 南家 綾江; 奥村 麻美; 燕 果歩; 成地 健太郎; 佐藤 正治; 加瀬 廣; 小野寺 康仁; 三橋 智子; 山下 啓子; 松野 吉宏
    日本乳癌学会総会プログラム抄録集, 27回, 593, 593, (一社)日本乳癌学会, 2019年07月
    日本語
  • Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
    Kuwabara S; Tsuchikawa T; Nakamura T; Hatanaka Y; Hatanaka KC; Sasaki K; Ono M; Umemoto K; Suzuki T; Sato O; Hane Y; Nakanishi Y; Asano T; Ebihara Y; Kurashima Y; Noji T; Murakami S; Okamura K; Shichinohe T; Hirano S
    Cancer science, 110, 6, 1853, 1862, 2019年06月, [査読有り]
  • Desmoplastic small round cell tumor of the parotid gland-report of a rare case and a review of the literature.
    Hatanaka KC; Takakuwa E; Hatanaka Y; Suzuki A; IIzuka S; Tsushima N; Mitsuhashi T; Sugita S; Homma A; Morinaga S; Hashegawa T; Matsuno Y
    Diagnostic pathology, 14, 1, 43, 2019年05月, [査読有り]
  • 乳癌の進展過程における腫瘍関連MUC1の発現変化
    清水 亜衣; 畑中 佳奈子; 畑中 豊; 南家 綾江; 奥村 麻美; 燕 果歩; 小野寺 康仁; 三橋 智子; 山下 啓子; 松野 吉宏
    日本病理学会会誌, 108, 1, 393, 393, (一社)日本病理学会, 2019年04月
    日本語
  • 肝外胆管癌におけるtumor buddingの臨床応用に向けた検討
    荻野 真理子; 中西 喜嗣; 三橋 智子; 畑中 豊; 田中 公貴; 浅野 賢道; 野路 武寛; 倉島 庸; 海老原 裕磨; 村上 壮一; 中村 透; 土川 貴裕; 岡村 圭祐; 七戸 俊明; 平野 聡
    日本外科学会定期学術集会抄録集, 119回, SF, 3, (一社)日本外科学会, 2019年04月
    日本語
  • 下部直腸癌に対する術前治療 切除可能局所進行性直腸癌患者における術前化学放射線療法後のnivolumab単剤療法とその後の広汎切除術に関する多施設共同第Ib/II相研究 VOLTAGE試験(Multicenter phase Ib/II study of nivolumab monotherapy and subsequent radical surgery following pre-operative chemoradiotherapy in patients with resectable locally advanced rectal cancer:VOLTAGE trial)
    塚田 祐一郎; 坂東 英明; 稲守 宏治; 佐々木 剛志; 西澤 祐吏; 若林 将史; 小嶋 基寛; 結城 敏志; 小松 嘉人; 吉田 雅; 市川 伸樹; 本間 重紀; 畑中 豊; 松野 吉宏; 植村 守; 三宅 正和; 加藤 健志; 関本 貢嗣; 佐藤 暁洋; 伊藤 雅昭; 吉野 孝之
    日本外科学会定期学術集会抄録集, 119回, PD, 7, (一社)日本外科学会, 2019年04月
    英語
  • Formation and Disordered Degradation of Neutrophil Extracellular Traps in Necrotizing Lesions of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Sakiko Masuda; Mayu Nonokawa; Emika Futamata; Yuka Nishibata; Sari Iwasaki; Takahiro Tsuji; Yutaka Hatanaka; Daigo Nakazawa; Satoshi Tanaka; Utano Tomaru; Tamihiro Kawakami; Tatsuya Atsumi; Akihiro Ishizu
    The American journal of pathology, 189, 4, 839, 846, 2019年04月, [査読有り], [国際誌]
    英語, Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is characterized by the production of ANCAs and systemic necrotizing vasculitis in small vessels. Disordered regulation of neutrophil extracellular traps (NETs) is critically involved in the pathogenesis of AAV. NETs are web-like DNA decorated with antimicrobial proteins; they are extruded from activated neutrophils. The principal degradation factor of NETs in vivo is DNase I; however, NETs resistant to DNase I can persist in tissues and can lead to the production of ANCAs. Deposition of NETs has been demonstrated in glomerular crescents and necrotizing vasculitis in AAV. Here, the amount of NETs in formalin-fixed, paraffin-embedded tissue sections was examined, and the results for AAV were compared with the results for diseases that should be distinguished from AAV. NETs were more abundant in necrotizing vasculitis of AAV than in non-ANCA-associated vasculitis, or in granulomatous angiitis. Pulmonary granulomas in AAV and non-ANCA-associated diseases were further studied. The amount of NETs was significantly greater in necrotizing granulomas of AAV than in granulomas of sarcoidosis without necrosis. Although NETs were formed in necrotizing granulomas of tuberculosis equivalently to those formed in AAV, they were more susceptible to degradation by DNase I than were NETs in AAV. The formation and disordered degradation of NETs in necrotizing lesions are characteristics of AAV and are possibly related to its pathogenesis.
  • 当院におけるFFPE検体、細胞診検体を用いたROS1融合遺伝子の検査成功率の検証
    北井 秀典; 榊原 純; 高橋 宏典; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 品川 尚文; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 大井 優子
    肺癌, 59, 1, 112, 112, (NPO)日本肺癌学会, 2019年02月, [査読有り]
    日本語
  • Impact of tumour budding grade in 310 patients who underwent surgical resection for extrahepatic cholangiocarcinoma.
    Ogino M; Nakanishi Y; Mitsuhashi T; Hatanaka Y; Amano T; Marukawa K; Nitta T; Ueno T; Ono M; Kuwabara S; Yamada T; Hirano S
    Histopathology, 74, 6, 861, 872, Wiley, 2019年01月, [査読有り]
    研究論文(学術雑誌)
  • Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.
    Kato T; Jin CS; Lee D; Ujiie H; Fujino K; Hu HP; Wada H; Wu L; Chen J; Weersink RA; Kanno H; Hatanaka Y; Hatanaka KC; Kaga K; Matsui Y; Matsuno Y; De Perrot M; Wilson BC; Zheng G; Yasufuku K
    International journal of oncology, 53, 5, 2034, 2046, 2018年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Cytoplasmic CD133 expression correlates with histologic differentiation and is a significant prognostic factor in extrahepatic bile duct cancer and gallbladder cancer.
    Mizukami T; Kamachi H; Mitsuhashi T; Einama T; Hatanaka Y; Kamiyama T; Taketomi A
    Oncology letters, 16, 5, 6423, 6430, 2018年11月, [査読有り]
  • EGFR-TKI初期耐性におけるPD-L1発現や腫瘍浸潤Tリンパ球についての検討
    高島 雄太; 榊原 純; 畑中 豊; 畑中 佳奈子; 大原 克仁; 大泉 聡史; 樋田 泰浩; 加賀 基知三; 木下 一郎; 秋田 弘俊; 松野 吉宏; 品川 尚文
    肺癌, 58, 6, 633, 633, (NPO)日本肺癌学会, 2018年10月, [査読有り]
    日本語
  • 酵素活性により蛍光を発するプローブの局所散布による早期胃食道接合部癌の検出(Detection of carcinoma of the esophagogastric junction by topically spraying enzymatically activatable fluorescent probe)
    大西 俊介; 山本 桂子; 清水 勇一; 水島 健; 畑中 豊; 畑中 佳奈子; 栗木 優五; 神谷 真子; 浦野 泰照; 坂本 直哉
    日本癌学会総会記事, 77回, 786, 786, 日本癌学会, 2018年09月
    英語
  • The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model.
    Mizukami T; Kamachi H; Fujii Y; Matsuzawa F; Einama T; Kawamata F; Kobayashi N; Hatanaka Y; Taketomi A
    Oncotarget, 9, 73, 33844, 33852, 2018年09月, [査読有り]
  • Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Yuta Takashima; Jun Sakakibara-Konishi; Yutaka Hatanaka; Kanako C Hatanaka; Yoshihito Ohhara; Satoshi Oizumi; Yasuhiro Hida; Kichizo Kaga; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Yoshihiro Matsuno; Masaharu Nishimura
    Clinical lung cancer, 19, 4, 352, 359, 2018年07月, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Approximately 20% to 30% of non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-activating mutations are not responsive to EGFR tyrosine kinase inhibitors (TKIs). Although primary resistance to EGFR-TKIs has been attributed to various genetic alterations, little is known about the clinical and immunopathologic features of patients with primary resistance. The tumor immune microenvironment, including tumor-infiltrating lymphocytes (TILs) and programmed cell death ligand 1 (PD-L1), has been reported to play an important role in tumor progression in those with NSCLC. However, few studies have directly focused on the relationship between the tumor immune microenvironment and primary resistance to EGFR-TKIs. MATERIALS AND METHODS: The characteristics of 124 NSCLC patients with EGFR mutations who had received EGFR-TKIs were analyzed. Primary resistance was defined as disease progression within 3 months after EGFR-TKI treatment. Tumor specimens obtained before EGFR-TKI treatment were assessed for the density of TILs expressing CD4 or CD8 and for the expression rate of PD-L1 on tumor cells and tumor-infiltrating immune cells, immunohistochemically. RESULTS: Primary resistance was observed in 13.7% of the patients (17 of 124). A significant difference in smoking history was observed between patients with primary resistance and those with non-primary resistance. A lower density of total TILs and negative PD-L1 expression on immunohistochemical analysis correlated significantly with primary resistance, in contrast to that with non-primary resistance. Moreover, the negative PD-L1 expression with low TIL density, indicating immune ignorant phenotype of tumor microenvironment, was observed in those with primary resistance with a significant difference. CONCLUSION: Smoking and immune ignorance in the tumor microenvironment might result in primary resistance to EGFR-TKIs.
  • DJ-1 is a useful biomarker for invasive extrahepatic cholangiocarcinoma
    Yukiko Tabata; Yoshitsugu Nakanishi; Kanako C. Hatanaka; Yutaka Hatanaka; Takahiro Tsuchikawa; Keisuke Okamura; Takehiro Noji; Toshiaki Shichinohe; Yoshihiro Matsuno; Satoshi Hirano
    Human Pathology, 76, 28, 36, W.B. Saunders, 2018年06月01日
    英語, 研究論文(学術雑誌)
  • 唾液腺導管癌における免疫染色およびRT-PCR法を用いた分子生物学的プロファイルの検討
    鈴木 崇祥; 加納 里志; 畑中 佳奈子; 鈴木 正宣; 安川 真一郎; 中薗 彬; 水町 貴諭; 畑中 豊; 松野 吉宏; 本間 明宏
    頭頸部癌, 44, 2, 179, 179, (一社)日本頭頸部癌学会, 2018年05月
    日本語
  • 唾液腺導管癌における免疫染色およびRT-PCR法を用いた分子生物学的プロファイルの検討
    鈴木 崇祥; 加納 里志; 畑中 佳奈子; 鈴木 正宣; 安川 真一郎; 中薗 彬; 水町 貴諭; 畑中 豊; 松野 吉宏; 本間 明宏
    頭頸部癌, 44, 2, 179, 179, (一社)日本頭頸部癌学会, 2018年05月
    日本語
  • Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations
    Christopher P. Wardell; Masashi Fujita; Toru Yamada; Michele Simbolo; Matteo Fassan; Rosa Karlic; Paz Polak; Jaegil Kim; Yutaka Hatanaka; Kazuhiro Maejima; Rita T. Lawlor; Yoshitsugu Nakanishi; Tomoko Mitsuhashi; Akihiro Fujimoto; Mayuko Furuta; Andrea Ruzzenente; Simone Conci; Ayako Oosawa; Aya Sasaki-Oku; Kaoru Nakano; Hiroko Tanaka; Yujiro Yamamoto; Kubo Michiaki; Yoshiiku Kawakami; Hiroshi Aikata; Masaki Ueno; Shinya Hayami; Kunihito Gotoh; Shun-ichi Ariizumi; Masakazu Yamamoto; Hiroki Yamaue; Kazuaki Chayama; Satoru Miyano; Gad Getz; Aldo Scarpa; Satoshi Hirano; Toru Nakamura; Hidewaki Nakagawa
    Journal of Hepatology, 68, 5, 959, 969, Elsevier B.V., 2018年05月01日
    英語, 研究論文(学術雑誌)
  • Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma
    Takashi Ueno; Takahiro Tsuchikawa; Kanako C. Hatanaka; Yutaka Hatanaka; Tomoko Mitsuhashi; Yoshitsugu Nakanishi; Takehiro Noji; Toru Nakamura; Keisuke Okamura; Yoshihiro Matsuno; Satoshi Hirano
    Oncotarget, 9, 28, 20034, 20047, Impact Journals LLC, 2018年04月13日
    英語, 研究論文(学術雑誌)
  • 乳癌前癌病変におけるMUC1癌関連糖鎖の免疫組織化学的変化
    清水 亜衣; 畑中 佳奈子; 畑中 豊; 南家 綾江; 奥村 麻美; 成地 健太郎; 佐藤 正治; 三橋 智子; 山下 啓子; 松野 吉宏
    日本病理学会会誌, 107, 1, 430, 430, (一社)日本病理学会, 2018年04月
    日本語
  • 胸膜中皮腫・肺腺癌の同時性重複腫瘍の遺伝子発現プロファイルに基づく新規中皮腫マーカーの探索
    中 智昭; 畑中 豊; 岡田 宏美; 畑中 佳奈子; 樋田 泰浩; 加賀 基知三; 武島 幸男; 井内 康輝; 三橋 智子; 松野 吉宏
    日本病理学会会誌, 107, 1, 417, 417, (一社)日本病理学会, 2018年04月, [査読有り]
    日本語
  • PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ERα serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive early breast cancer.
    Ishida N; Baba M; Hatanaka Y; Hagio K; Okada H; Hatanaka KC; Togashi K; Matsuno Y; Yamashita H
    Oncotarget, 9, 25, 17711, 17724, Impact Journals LLC, 2018年04月01日
    英語, 研究論文(学術雑誌)
  • Detection of Superficial Head and Neck Squamous Cell Carcinoma by Topically Spraying Fluorescent Probe Targeting DPP-IV
    Ohnishi Shunsuke; Mizushima Takeshi; Shimizu Yuichi; Hatanaka Yutaka; Hatanaka Kanako; Yamamoto Keiko; Homma Akihiro; Kuriki Yugo; Kamiya Mako; Urano Yasuteru; Sakamoto Naoya
    CANCER SCIENCE, 109, 730, 2018年01月, [査読有り]
  • Image analysis is an excellent tool for quantifying Ki-67 to predict the prognosis of gastrointestinal stromal tumor patients
    Shintaro Sugita; Hiroshi Hirano; Yutaka Hatanaka; Hiromi Fujita; Terufumi Kubo; Noriaki Kikuchi; Yumika Ito; Taro Sugawara; Keiko Segawa; Hiroyuki Hisai; Kentaro Yamashita; Takayuki Nobuoka; Yoshihiro Matsuno; Tadashi Hasegawa
    Pathology International, 68, 1, 7, 11, Blackwell Publishing, 2018年01月01日
    英語, 研究論文(学術雑誌)
  • Rapid detection of superficial head and neck squamous cell carcinoma by topically spraying fluorescent probe targeting dipeptidyl peptidase-IV.
    Mizushima T; Ohnishi S; Shimizu Y; Hatanaka Y; Hatanaka KC; Kuriki Y; Kamiya M; Homma A; Yamamoto K; Ono S; Urano Y; Sakamoto N
    Head Neck, 40, 7, 1466, 1475, 2018年
    英語, 研究論文(学術雑誌)
  • The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma In Vitro and In Vivo
    Makiko Nakatani; Hidemichi Watari; Takashi Mitamura; Lei Wang; Yutaka Hatanaka; Kanako C. Hatanaka; Kohei Honda; Toshiyuki Nomura; Hiroshi Nishihara; Shinya Tanaka; Noriaki Sakuragi
    ANTICANCER RESEARCH, 37, 11, 6125, 6132, 2017年11月
    英語, 研究論文(学術雑誌)
  • Dipeptidylpeptidase-IVの酵素活性により蛍光を発するプローブによる頭頸部表在癌の検出
    大西 俊介; 水島 健; 清水 勇一; 畑中 豊; 畑中 佳奈子; 山本 桂子; 本間 明宏; 栗木 優五; 神谷 真子; 浦野 泰照; 坂本 直哉
    日本癌学会総会記事, 76回, P, 2320, 日本癌学会, 2017年09月
    英語
  • Dipeptidylpeptidase-IVの酵素活性により蛍光を発するプローブによる頭頸部表在癌の検出
    大西 俊介; 水島 健; 清水 勇一; 畑中 豊; 畑中 佳奈子; 山本 桂子; 本間 明宏; 栗木 優五; 神谷 真子; 浦野 泰照; 坂本 直哉
    日本癌学会総会記事, 76回, P, 2320, 日本癌学会, 2017年09月
    英語
  • Cytopathologic findings of cell block materials from the vitreous: Diagnostic distinction between intraocular lymphoma and non-lymphomatous diseases
    Hiromi Kanno-Okada; Emi Takakuwa; Yoshiaki Tagawa; Satoru Kase; Kanako C. Hatanaka; Yutaka Hatanaka; Kenichi Namba; Tomoko Mitsuhashi; Yoshihiro Matsuno
    PATHOLOGY INTERNATIONAL, 67, 7, 342, 349, 2017年07月
    英語, 研究論文(学術雑誌)
  • Rapid Detection of Superficial Head and Neck Squamous Cell Carcinoma by Topically Spraying Fluorescent Probe Targeting Dipeptidylpeptidase-Iv
    Shunsuke Ohnishi; Takeshi Mizushima; Yuichi Shimizu; Yutaka Hatanaka; Kanako Hatanaka; Keiko Yamamoto; Akihiro Homma; Yugo Kuriki; Mako Kamiya; Yasuteru Urano; Naoya Sakamoto
    GASTROINTESTINAL ENDOSCOPY, 85, 5, AB530, AB530, 2017年05月, [査読有り]
    英語
  • Fatty acid-binding protein 5 function in hepatocellular carcinoma through induction of epithelial-mesenchymal transition
    Takanori Ohata; Hideki Yokoo; Toshiya Kamiyama; Moto Fukai; Takeshi Aiyama; Yutaka Hatanaka; Kanako Hatanaka; Kenji Wakayama; Tatsuya Orimo; Tatsuhiko Kakisaka; Nozomi Kobayashi; Yoshihiro Matsuno; Akinobu Taketomi
    CANCER MEDICINE, 6, 5, 1049, 1061, 2017年05月
    英語, 研究論文(学術雑誌)
  • Identification of novel serum autoantibodies against EID3 in non-functional pancreatic neuroendocrine tumors
    Koji Hontani; Takahiro Tsuchikawa; Takaki Hiwasa; Toru Nakamura; Takashi Ueno; Toshihiro Kushibiki; Mizuna Takahashi; Kazuho Inoko; Hironobu Takano; Satoshi Takeuchi; Hirotoshi Dosaka-Akita; Masaki Kuwatani; Naoya Sakamoto; Yutaka Hatanaka; Tomoko Mitsuhashi; Hideaki Shimada; Toshiaki Shichinohe; Satoshi Hirano
    Oncotarget, 8, 63, 106206, 106221, Impact Journals LLC, 2017年
    英語, 研究論文(学術雑誌)
  • SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma
    Tatsuya Kato; Daiyoon Lee; Licun Wu; Priya Patel; Jin Young; Hironobu Wada; Hsin-Pei Hu; Hideki Ujiie; Mitsuhito Kaji; Satoshi Kano; Shinichi Matsuge; Hiromitsu Domen; Hiromi Kanno; Yutaka Hatanaka; Kanako C. Hatanaka; Kichizo Kaga; Yoshiro Matsui; Yoshihiro Matsuno; Marc De Perrot; Kazuhiro Yasufuku
    INTERNATIONAL JOURNAL OF ONCOLOGY, 49, 6, 2411, 2420, 2016年12月
    英語, 研究論文(学術雑誌)
  • High expression of EPB41L5, an integral component of the Arf6-driven mesenchymal program, correlates with poor prognosis of squamous cell carcinoma of the tongue
    Yutaro Otsuka; Hiroki Sato; Tsukasa Oikawa; Yasuhito Onodera; Jin-Min Nam; Ari Hashimoto; Kiyoshi Fukunaga; Kanako C. Hatanaka; Yutaka Hatanaka; Yoshihiro Matsuno; Satoshi Fukuda; Hisataka Sabe
    CELL COMMUNICATION AND SIGNALING, 14, 1, 28, 2016年11月
    英語, 研究論文(学術雑誌)
  • 頭頸・口腔 頭頸部がんの集学的治療 表在性頭頸部扁平上皮癌のGGT活性化標的薬を用いた蛍光イメージング(Fluorescent imaging of superficial head and neck squamous cell carcinoma using a GGT-Activated targeting agent)
    大西 俊介; 水島 健; 清水 勇一; 畑中 豊; 畑中 佳奈子; 本間 明宏; 浦野 泰照; 坂本 直哉
    日本癌治療学会学術集会抄録集, 54回, WS81, 6, (一社)日本癌治療学会, 2016年10月
    英語
  • Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma
    Tatsuya Kato; Daiyoon Lee; Licun Wu; Priya Patel; Ahn Mn Young; Hironobu Wada; Hsin-Pei Hu; Hideki Ujiie; Mitsuhito Kaji; Satoshi Kano; Shinichi Matsuge; Hiromitsu Domen; Kichizo Kaga; Yoshiro Matsui; Hiromi Kanno; Yutaka Hatanaka; Kanako C. Hatanaka; Yoshihiro Matsun; Marc de Perrot; Kazuhiro Yasufuku
    INTERNATIONAL JOURNAL OF ONCOLOGY, 49, 2, 448, 456, 2016年08月
    英語, 研究論文(学術雑誌)
  • ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma
    Katsumi Terashita; Makoto Chuma; Yutaka Hatanaka; Kanako Hatanaka; Tomoko Mitsuhashi; Hideki Yokoo; Takumi Ohmura; Hiroyuki Ishizu; Shunji Muraoka; Atsushi Nagasaka; Takahiro Tsuji; Yoshiya Yamamoto; Nobuaki Kurauchi; Norihiko Shimoyama; Hidenori Toyoda; Takashi Kumada; Yuji Kaneoka; Atsuyuki Maeda; Koji Ogawa; Mitsuteru Natsuizaka; Hirofumi Kamachi; Tatsuhiko Kakisaka; Toshiya Kamiyama; Akinobu Taketomi; Yoshihiro Matsuno; Naoya Sakamoto
    JOURNAL OF CLINICAL PATHOLOGY, 69, 7, 593, 599, 2016年07月
    英語, 研究論文(学術雑誌)
  • Fluorescent imaging of superficial head and neck squamous cell carcinoma using a γ-glutamyltranspeptidase-activated targeting agent: a pilot study.
    Mizushima T; Ohnishi S; Shimizu Y; Hatanaka Y; Hatanaka KC; Hosono H; Kubota Y; Natsuizaka M; Kamiya M; Ono S; Homma A; Kato M; Sakamoto N; Urano Y
    BMC Cancer, 16, 411, 2016年07月
    英語, 研究論文(学術雑誌)
  • Feasibility of Using an Enzymatically Activatable Fluorescence Probe for the Rapid Evaluation of Pancreatic Tissue Obtained Using Endoscopic Ultrasound-Guided Fine Needle Aspiration: a Pilot Study
    Kazumichi Kawakubo; Shunsuke Ohnishi; Yutaka Hatanaka; Kanako C. Hatanaka; Hidetaka Hosono; Yoshimasa Kubota; Mako Kamiya; Masaki Kuwatani; Hiroshi Kawakami; Yasuteru Urano; Naoya Sakamoto
    MOLECULAR IMAGING AND BIOLOGY, 18, 3, 463, 471, 2016年06月
    英語, 研究論文(学術雑誌)
  • Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.
    Tomoaki Naka; Yutaka Hatanaka; Katsuji Marukawa; Hiromi Okada; Kanako C Hatanaka; Jun Sakakibara-Konishi; Satoshi Oizumi; Yasuhiro Hida; Kichizo Kaga; Tomoko Mitsuhashi; Yoshihiro Matsuno
    Diagnostic pathology, 11, 38, 38, 2016年04月18日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Although asbestos acts as a potent carcinogen in pleural mesothelial and pulmonary epithelial cells, it still remains unclear whether asbestos causes specific and characteristic gene alterations in these different kinds of target cells, because direct comparison in an identical patient is not feasible. We experienced a rare synchronous collision tumor composed of malignant pleural mesothelioma (MPM) and primary pulmonary adenocarcinoma (PAC) in a 77-year-old man with a history of long-term smoking and asbestos exposure, and compared the DNA copy number alteration (CNA) and somatic mutation in these two independent tumors. METHODS: Formalin-fixed paraffin-embedded (FFPE) tissues of MPM and PAC lesions from the surgically resected specimen were used. Each of these MPM and PAC lesions exhibited a typical histology and immunophenotype. CNA analysis using SNP array was performed using the Illumina Human Omni Express-12_FFPE (Illumina, San Diego, CA, USA) with DNA extracts from each lesion. Somatic mutation analysis using next-generation sequencing was performed using the TruSeq Amplicon Cancer Panel (Illumina). RESULTS: The CNA analysis demonstrated a marked difference in the frequency of gain and loss between MPM and PAC. In PAC, copy number (CN) gain was detected more frequently and widely than CN loss, whereas in MPM there was no such obvious difference. PAC did not harbor CNAs that have been identified in asbestos-associated lung cancer, but did harbor some of the CNAs associated with smoking. MPM exhibited CN loss at 9p21.2-3, which is the most common genetic alteration in mesothelioma. CONCLUSION: In this particular case, asbestos exposure may not have played a primary role in PAC carcinogenesis, but cigarette smoking may have contributed more to the occurrence of CN gains in PAC. This comparative genetic analysis of two different lesions with same amount of asbestos exposure and cigarette smoke exposure has provided information on differences in the cancer genome related to carcinogenesis.
  • 組織マイクロアレイを用いた非小細胞肺癌における抗PD-L1抗体の比較検討
    清水 知浩; 岡田 宏美; 畑中 豊; 桑原 健; 清水 亜衣; 中 智昭; 藤澤 孝志; 高桑 恵美; 畑中 佳奈子; 松野 吉宏
    日本病理学会会誌, 105, 1, 455, 455, (一社)日本病理学会, 2016年04月
    日本語
  • 非小細胞肺癌におけるPD-L1とAKR1B10発現の関連性に関する検討
    桑原 健; 畑中 豊; 岡田 宏美; 清水 知浩; 奥村 麻未; 平野 裕子; 畑中 佳奈子; 樋田 泰浩; 加賀 基知三; 松野 吉宏
    日本病理学会会誌, 105, 1, 532, 532, (一社)日本病理学会, 2016年04月, [査読有り]
    日本語
  • Stromal Palladin Expression Is an Independent Prognostic Factor in Pancreatic Ductal Adenocarcinoma
    Daisuke Sato; Takahiro Tsuchikawa; Tomoko Mitsuhashi; Yutaka Hatanaka; Katsuji Marukawa; Asami Morooka; Toru Nakamura; Toshiaki Shichinohe; Yoshihiro Matsuno; Satoshi Hirano
    PLOS ONE, 11, 3, e0152523, 2016年03月
    英語, 研究論文(学術雑誌)
  • Usefulness of the octreotide test in Japanese patients for predicting the presence/absence of somatostatin receptor 2 expression in insulinomas
    Akinobu Nakamura; Tomoko Mitsuhashi; Yoshinari Takano; Hideaki Miyoshi; Hiraku Kameda; Hiroshi Nomoto; So Nagai; Yutaka Hatanaka; Chikara Shimizu; Yasuo Terauchi; Tatsuya Atsumi
    ENDOCRINE JOURNAL, 63, 2, 135, 142, 2016年02月
    英語, 研究論文(学術雑誌)
  • Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer
    Seiji Oguro; Yoshinori Ino; Kazuaki Shimada; Yutaka Hatanaka; Yoshihiro Matsuno; Minoru Esaki; Satoshi Nara; Yoji Kishi; Tomoo Kosuge; Nobuyoshi Hiraoka
    CANCER SCIENCE, 106, 12, 1750, 1760, 2015年12月
    英語, 研究論文(学術雑誌)
  • γ-Glutamyltranspeptidaseにより蛍光を発するprobeによる早期頭頸部がんの検出
    大西 俊介; 清水 勇一; 水島 健; 畑中 豊; 畑中 佳奈子; 久保田 良政; 夏井坂 光輝; 神谷 真子; 本間 明宏; 加藤 元嗣; 浦野 泰照; 坂本 直哉
    日本癌学会総会記事, 74回, P, 3308, 日本癌学会, 2015年10月
    英語
  • EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition
    Fumiyuki Sato; Yoshimasa Kubota; Mitsuteru Natsuizaka; Osamu Maehara; Yutaka Hatanaka; Katsuji Marukawa; Katsumi Terashita; Goki Suda; Shunsuke Ohnishi; Yuichi Shimizu; Yoshito Komatsu; Shinya Ohashi; Shingo Kagawa; Hideaki Kinugasa; Kelly A. Whelan; Hiroshi Nakagawa; Naoya Sakamoto
    CANCER BIOLOGY & THERAPY, 16, 6, 933, 940, 2015年06月
    英語, 研究論文(学術雑誌)
  • A Novel Technique for the Detection of Endoscopic Ultrasound-Guided Fine Needle Pancreatic Tissue Acquisition by an Enzymatically Rapid-Activatable Fluorescent Probe
    Kawakubo Kazumichi; Ohnishi Shunsuke; Urano Yasuteru; Hatanaka Yutaka; Hatanaka Kanako C; Kawakami Hiroshi; Kuwatani Masaki; Kawahata Shuhei; Abe Yoko; Kubota Yoshimasa; Kubo Kimitoshi; Sakamoto Naoya
    GASTROINTESTINAL ENDOSCOPY, 81, 5, AB536, AB537, 2015年05月, [査読有り]
  • 唾液腺癌を対象としたHER2タンパク過剰発現および遺伝子増幅検査法の臨床的バリデーションに関する検討
    加納 里志; 畑中 豊; 松野 吉宏; 本間 明宏; 秋田 弘俊; 福田 諭
    頭頸部癌, 41, 2, 257, 257, (一社)日本頭頸部癌学会, 2015年05月
    日本語
  • 肺を含む多臓器腺癌症例における原発性診断の根拠に関する検討
    清水 亜衣; 菅野 宏美; 畑中 豊; 畑中 佳奈子; 三橋 智子; 加賀 基知三; 松野 吉宏
    日本病理学会会誌, 104, 1, 409, 409, (一社)日本病理学会, 2015年03月
    日本語
  • 本邦において市販されている標準化免疫組織化学染色システムに関する実態調査
    畑中 豊; 畑中 佳奈子; 高桑 恵美; 平野 裕子; 森谷 純; 高桑 康成; 山本 宏司; 松野 吉宏
    日本病理学会会誌, 104, 1, 465, 465, (一社)日本病理学会, 2015年03月
    日本語
  • 所属リンパ節転移を伴う胃plexiform fibromyxomaの一例
    中 智昭; 畑中 佳奈子; 九嶋 亮治; 吉田 朗彦; 畑中 豊; 間部 克裕; 七戸 俊明; 三橋 智子; 松野 吉宏
    日本病理学会会誌, 104, 1, 364, 364, (一社)日本病理学会, 2015年03月
    日本語
  • Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer
    Tatsuya Yoshioka; Mitsuchika Hosoda; Mitsugu Yamamoto; Kazunori Taguchi; Kanako C. Hatanaka; Emi Takakuwa; Yutaka Hatanaka; Yoshihiro Matsuno; Hiroko Yamashita
    BREAST CANCER, 22, 2, 185, 191, 2015年03月
    英語, 研究論文(学術雑誌)
  • Immunohistochemical validation and expression profiling of NKG2D ligands in a wide spectrum of human epithelial neoplasms.
    Hiromi Fujita; Yutaka Hatanaka; Yoichi Sutoh; Yuta Suzuki; Koji Oba; Kanako C Hatanaka; Tomoko Mitsuhashi; Noriyuki Otsuka; Kazunori Fugo; Masanori Kasahara; Yoshihiro Matsuno
    The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 63, 3, 217, 27, 2015年03月, [国際誌]
    英語, 研究論文(学術雑誌), The MHC class I-chain-related proteins (MICs) and the UL16-binding proteins (ULBPs) are inducible stress response molecules that work as activators of a specific receptor, NKG2D, which is expressed on effector cells, such as NK cells and subsets of T cells. In this study, we sought to explore the biological significance of NKG2D ligands in human neoplasms by comprehensively examining the immunohistochemical expression profile of NKG2D ligands in a variety of human epithelial neoplasms. Following careful validation of the immunohistochemical specificity and availability of anti-human ULBP antibodies for formalin-fixed paraffin-embedded (FFPE) materials, the expression of NKG2D ligands was analyzed in FFPE tissue microarrays comprising 22 types of epithelial neoplastic tissue with their non-neoplastic counterpart from various organs. Hierarchical cluster analysis demonstrated a positive relationship among ULBP2/6, ULBP3, ULBP1, and ULBP5, whose expression patterns were similar across all of the neoplastic tissues examined. In contrast, MICA/B, as well as ULBP4, did not appear to be related to any other ligand. These expression profiles of NKG2D ligands in human neoplasms based on well-validated specific antibodies, followed by hierarchical cluster analysis, should help to clarify some functional aspects of these molecules in cancer biology, and also provide a path to the development of novel tumor-type-specific treatment strategies.
  • CTNNB1 mutational analysis of solid-pseudopapillary neoplasms of the pancreas using endoscopic ultrasound-guided fine-needle aspiration and next-generation deep sequencing
    Yoshimasa Kubota; Hiroshi Kawakami; Mitsuteru Natsuizaka; Kazumichi Kawakubo; Katsuji Marukawa; Taiki Kudo; Yoko Abe; Kimitoshi Kubo; Masaki Kuwatani; Yutaka Hatanaka; Tomoko Mitsuhashi; Yoshihiro Matsuno; Naoya Sakamoto
    JOURNAL OF GASTROENTEROLOGY, 50, 2, 203, 210, 2015年02月
    英語, 研究論文(学術雑誌)
  • 変異p53蛋白発現がアロマターゼ阻害剤投与後再発乳癌症例の予後に及ぼす影響の検討
    山本 貢; 石田 直子; 市之川 一臣; 細田 充主; 山下 啓子; 畑中 佳奈子; 高桑 恵美; 畑中 豊; 松野 吉宏
    北海道外科雑誌, 59, 2, 221, 221, 北海道外科学会, 2014年12月
    日本語
  • 肝細胞癌におけるAPC-binding protein EB1の予後・再発予測因子としての有用性(APC-binding protein EB1 is an important predictive factor for the prognosis and recurrence in hepatocellular carcinoma)
    相山 健; 折茂 達也; 横尾 英樹; 大畑 多嘉宣; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 神山 俊哉; 武冨 紹信
    日本癌学会総会記事, 73回, P, 2310, 日本癌学会, 2014年09月
    英語
  • Prognostic significance of epithelial-mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: comprehensive immunohistochemical study using a tissue microarray
    T. Nitta; T. Mitsuhashi; Y. Hatanaka; M. Miyamoto; K. Oba; T. Tsuchikawa; Y. Suzuki; K. C. Hatanaka; S. Hirano; Y. Matsuno
    BRITISH JOURNAL OF CANCER, 111, 7, 1363, 1372, 2014年09月
    英語, 研究論文(学術雑誌)
  • Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy
    Tatsuzo Mizukami; Hirofumi Kamachi; Tomoko Mitsuhashi; Yosuke Tsuruga; Yutaka Hatanaka; Toshiya Kamiyama; Yoshihiro Matsuno; Akinobu Taketomi
    BMC CANCER, 14, 687, 2014年09月
    英語, 研究論文(学術雑誌)
  • EGFR Inhibitors Eliminate Esophageal Cancer Stem Cells by Suppressing Epithelial-Mesenchymal Transition
    Mitsuteru Natsuizaka; Bongani Kaimila; Yoshimasa Kubota; Yutaka Hatanaka; Katsuji Marukawa; Katsumi Terashita; Fumiyuki Satou; Shunsuke Ohnishi; Goki Suda; Shinya Ohashi; Shingo Kagawa; Kelly A. Whelan; Anil K. Rustgi; Hiroshi Nakagawa; Naoya Sakamoto
    GASTROENTEROLOGY, 146, 5, S821, S821, 2014年05月, [査読有り]
    英語
  • Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer
    Mitsuchika Hosoda; Mitsugu Yamamoto; Kiichiroh Nakano; Kanako C. Hatanaka; Emi Takakuwa; Yutaka Hatanaka; Yoshihiro Matsuno; Hiroko Yamashita
    BREAST CANCER RESEARCH AND TREATMENT, 144, 2, 249, 261, 2014年04月
    英語, 研究論文(学術雑誌)
  • 中枢神経系原発びまん性大細胞型B細胞性リンパ腫におけるDNAメチル化に関する解析
    畑中佳奈子; 畑中豊; 小林浩之; 菅野宏美; 西原広史; 田中伸哉; 三橋智子; 松野吉宏
    日本病理学会会誌, 103, 1, 211, 2014年03月26日
    日本語
  • 胆道乳頭状腫瘍におけるIPNB、ICPNの診断基準の検討
    佐藤 大介; 三橋 智子; 畑中 豊; 中西 喜嗣; 平野 聡; 松野 吉宏
    日本病理学会会誌, 103, 1, 263, 263, (一社)日本病理学会, 2014年03月
    日本語
  • High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients
    Hiroki Sato; Kanako C. Hatanaka; Yutaka Hatanaka; Hiromitsu Hatakeyama; Ari Hashimoto; Yoshihiro Matsuno; Satoshi Fukuda; Hisataka Sabe
    CELL COMMUNICATION AND SIGNALING, 12, 17, 2014年03月
    英語, 研究論文(学術雑誌)
  • p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
    Yamamoto M; Hosoda M; Nakano K; Jia S; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Cancer science, 105, 1, 81, 88, Wiley-blackwell, 2014年01月, [査読有り]
    英語, Aromatase inhibitors have played a central role in endocrine therapy for estrogen receptor (ER)-positive breast cancer in postmenopausal women. However, factors predictive of the efficacy of aromatase inhibitors, and prognostic factors, both for early and late recurrence in women treated with adjuvant aromatase inhibitors have not been identified. Whole genome analysis identified that a TP53 gene mutation exists in ER-positive breast cancers, although the frequency of TP53 gene mutation in luminal tumors is lower compared with basal-like or human epidermal growth factor receptor type 2 (HER2)-positive breast cancers. We examined expression of p53, as well as ER, progesterone receptor, HER2 and Ki-67 using immunohistochemistry in postmenopausal ER-positive breast cancer patients who were treated with aromatase inhibitors as adjuvant endocrine therapy. There were 53 (21%) tumors that contained 10% or more p53-positive cells. High p53 expression was positively correlated with tumor grade, HER2 score and Ki-67 expression. Significant association was observed between disease-free survival and high p53 expression in multivariate analysis (P<0.0001). Compared with women without recurrence, women with early recurrence had significantly higher p53 expression (P<0.0001), as did women with late recurrence (P=0.037). The present study demonstrates that p53 accumulation is a strong predictor of both early and late recurrence in ER-positive breast cancer patients treated with aromatase inhibitors as adjuvant endocrine therapy. TP53 gene alteration might be a key biological characteristic of ER-positive breast cancer.
  • p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors
    Mitsugu Yamamoto; Mitsuchika Hosoda; Kiichiroh Nakano; Shusheng Jia; Kanako C. Hatanaka; Emi Takakuwa; Yutaka Hatanaka; Yoshihiro Matsuno; Hiroko Yamashita
    CANCER SCIENCE, 105, 1, 81, 88, 2014年01月
    英語, 研究論文(学術雑誌)
  • Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma
    Shingo Soma; Koji Tsuta; Toshimi Takano; Yutaka Hatanaka; Akihiko Yoshida; Kenji Suzuki; Hisao Asamura; Hitoshi Tsuda
    PATHOLOGY RESEARCH AND PRACTICE, 210, 3, 155, 160, 2014年
    英語, 研究論文(学術雑誌)
  • Epstein-Barr Virus-Associated Smooth Muscle Tumors After Bone Marrow Transplantation
    Eiko Hayase; Katsuya Fujimoto; Tomoko Mitsuhashi; Yutaka Hatanaka; Miho Yoshida; Ryo Takemura; Junko Iwasaki; Souichi Shiratori; Junichi Sugita; Takeshi Kondo; Junji Tanaka; Masahiro Imamura; Yoshihiro Matsuno; Takanori Teshima
    TRANSPLANTATION, 97, 1, E1, +, 2014年01月
    英語, 研究論文(学術雑誌)
  • Histopathologic Characterization of Lung Adenocarcinoma in Relation to Fluorine-18-fluorodeoxyglucose Uptake on Positron Emission Tomography
    Hiromitsu Domen; Yasuhiro Hida; Shozo Okamoto; Kanako C. Hatanaka; Yutaka Hatanaka; Kichizo Kaga; Nagara Tamaki; Satoshi Hirano; Yoshihiro Matsuno
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 43, 9, 874, 882, 2013年09月
    英語, 研究論文(学術雑誌)
  • A case of lymphomatoid gastropathy: A self-limited pseudomalignant natural killer (NK)-cell proliferative disease mimicking NK/T-cell lymphomas
    Yoko Ishibashi; Emi Matsuzono; Fumiaki Yokoyama; Yoshihito Ohara; Nozomu Sugai; Hideyuki Seki; Atsuhiko Miura; Jun Fujita; Junichi Suzuki; Takashi Fujisawa; Akira Suzuki; Yutaka Hatanaka
    Clinical Journal of Gastroenterology, 6, 4, 287, 290, 2013年08月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine
    Yasutaka Kato; Hiroshi Nishihara; Sayaka Yuzawa; Hiromi Mohri; Hiromi Kanno; Yutaka Hatanaka; Taichi Kimura; Mishie Tanino; Shinya Tanaka
    Brain Tumor Pathology, 30, 3, 167, 174, 2013年07月
    英語, 研究論文(学術雑誌)
  • 自動薄切装置により作製した薄切標本を用いた乳癌Ki-67免疫組織化学検索の染色サーベイに関する報告
    森谷 純; 畑中 豊; 加藤 隆; 後藤田 裕子; 藤田 裕美; 高桑 恵美; 畑中 佳奈子; 三橋 智子; 山崎 恭詩; 村岡 俊二; 松野 吉宏; 札幌臨床検査技師会データ統一化プロジェクト委員会
    日本病理学会会誌, 102, 1, 368, 368, (一社)日本病理学会, 2013年04月
    日本語
  • 性分化疾患に発症した性腺腫瘍の1例
    高桑 恵美; 山田 洋介; 畑中 佳奈子; 畑中 豊; 中 智昭; 藤田 裕美; 西村 陽子; 守屋 仁彦; 野々村 克也; 三橋 智子; 松野 吉宏
    日本病理学会会誌, 102, 1, 414, 414, (一社)日本病理学会, 2013年04月, [査読有り]
    日本語
  • Pancreatic Ductal Adenocarcinomas with Multiple Large Cystic Structures:A Clinicopathologic and Immunohistochemical Study of Seven Cases
    T. Nitta; T. Mitsuhashi; Y. Hatanaka; S. Hirano; Y. Matsuno
    MODERN PATHOLOGY, 26, 4, 429A, 429A, 2013年02月
    英語, 研究論文(学術雑誌)
  • Validity and reproducibility of Ki-67 assessment in gastrointestinal stromal tumors and leiomyosarcomas
    Jiro Ogino; Hiroko Asanuma; Yutaka Hatanaka; Yoshihiro Matsuno; Hiroko Gotoda; Shunji Muraoka; Takayuki Tsuji; Yuichiro Fukazawa; Katsushige Yamashiro; Nobuo Kondo; Hiroyuki Iwaki; Naoyuki Miyokawa; Tadashi Hasegawa
    PATHOLOGY INTERNATIONAL, 63, 2, 102, 107, 2013年02月
    英語, 研究論文(学術雑誌)
  • Pancreatic ductal adenocarcinomas with multiple large cystic structures: A clinicopathologic and immunohistochemical study of seven cases
    Takeo Nitta; Tomoko Mitsuhashi; Yutaka Hatanaka; Satoshi Hirano; Yoshihiro Matsuno
    Pancreatology, 13, 4, 401, 408, Elsevier B.V., 2013年, [査読有り]
    英語, 研究論文(学術雑誌)
  • Ultrastaging of para-aortic lymph nodes in stage IIIC1 endometrial cancer: A preliminary report
    Yukiharu Todo; Yoshihiro Suzuki; Manabu Azuma; Yutaka Hatanaka; Yosuke Konno; Hidemichi Watari; Hidenori Kato; Yoshihiro Matsuno; Katsushige Yamashiro; Noriaki Sakuragi
    GYNECOLOGIC ONCOLOGY, 127, 3, 532, 537, 2012年12月
    英語, 研究論文(学術雑誌)
  • 膵腺房細胞・内分泌混合癌の細胞像の比較検討
    仁木涼子; 丸川活司; 恩田千景; 山谷幸恵; 森谷純; 高桑恵美; 久保田佳奈子; 畑中豊; 三橋智子; 松野吉宏
    日本臨床細胞学会雑誌, 51, Suppl.2, 780, 780, (公社)日本臨床細胞学会, 2012年09月22日
    日本語
  • 免疫細胞化学法による肺癌EGFR遺伝子変異検索の標準化およびそのバリデーション
    森谷純; 畑中豊; 畑中豊; 仁木涼子; 恩田千景; 山谷幸恵; 丸川活司; 高桑恵美; 高桑恵美; 久保田佳奈子; 三橋智子; 松野吉宏; 松野吉宏
    日本臨床細胞学会雑誌, 51, Suppl.2, 800, 800, (公社)日本臨床細胞学会, 2012年09月22日
    日本語
  • 多発性大型嚢胞形成を伴う通常型膵癌7例の臨床病理学的検討
    新田 健雄; 三橋 智子; 畑中 豊; 山田 洋介; 高桑 恵美; 久保田 佳奈子; 平野 聡; 松野 吉宏
    日本病理学会会誌, 101, 1, 263, 263, (一社)日本病理学会, 2012年03月, [査読有り]
    日本語
  • 眼窩IgG4関連疾患を背景に発生したと考えたIgG4陽性形質細胞を伴う節外性濾胞辺縁帯B細胞性リンパ腫の1例
    久保田 佳奈子; ヘールナンデス 真子; 藤田 裕美; 山田 洋介; 加瀬 諭; 畑中 豊; 高桑 恵美; 三橋 智子; 松野 吉宏
    日本病理学会会誌, 101, 1, 381, 381, (一社)日本病理学会, 2012年03月, [査読有り]
    日本語
  • Bright-Field Dual-Color Chromogenic In Situ Hybridization for Diagnosing Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinomas
    Akihiko Yoshida; Koji Tsuta; Hiroaki Nitta; Yutaka Hatanaka; Hisao Asamura; Ikuo Sekine; Thomas M. Grogan; Masashi Fukayama; Tatsuhiro Shibata; Koh Furuta; Takashi Kohno; Hitoshi Tsuda
    JOURNAL OF THORACIC ONCOLOGY, 6, 10, 1677, 1686, 2011年10月
    英語, 研究論文(学術雑誌)
  • Contrasting prognostic implications of platelet-derived growth factor receptor-β and vascular endothelial growth factor receptor-2 in patients with angiosarcoma.
    Yonemori K; Tsuta K; Ando M; Hirakawa A; Hatanaka Y; Matsuno Y; Chuman H; Yamazaki N; Fujiwara Y; Hasegawa T
    Ann Surg Oncol, 18, 10, 2841, 2850, 2011年10月
    英語, 研究論文(学術雑誌)
  • 抗体治療薬セツキシマブを用いた標的分子EGFRの組織発現分布に関する検討
    畑中 豊; 山田 康秀; 谷口 浩和; 福岡 みどり; 久保田 佳奈子; 松野 吉宏
    日本病理学会会誌, 100, 1, 310, 310, (一社)日本病理学会, 2011年03月, [査読有り]
    日本語
  • 細葉中心性間質性肺炎像を呈した超硬合金肺の一例
    久保田 佳奈子; 細川 剛; 照井 浩也; ヘールナンデス 真子; 藤田 裕美; 山田 洋介; 畑中 豊; 松野 吉宏
    日本病理学会会誌, 100, 1, 375, 375, (一社)日本病理学会, 2011年03月, [査読有り]
    日本語
  • 生検診断された血管内大細胞型B細胞リンパ腫の臨床病理学的検討
    川名 聡; 久保田 加奈子; 畑中 豊; ヘールナンデス 真子; 藤田 裕美; 山田 洋介; 松野 吉宏
    日本病理学会会誌, 100, 1, 413, 413, (一社)日本病理学会, 2011年03月, [査読有り]
    日本語
  • 肺癌切除標本の術後病理検索手順の標準化
    松野 吉宏; 山田 洋介; ヘールナンデス 真子; 藤田 裕美; 畑中 豊; 久保田 佳奈子; 田畑 佑希子; 道免 寛充; 津田 均
    肺癌, 50, 7, 950, 951, (NPO)日本肺癌学会, 2010年12月, [査読有り]
    日本語
  • 原発性肺癌と胸膜悪性中皮腫の合併症例における遺伝子発現に関する検討(Array-based analysis of a collision tumor composed of malignant pleural mesothelioma and primary lung cancer)
    田畑 佑希子; 高澤 啓; 畑中 豊; 久保田 佳奈子; 羽賀 博典; 樋田 泰浩; 松野 吉宏
    日本癌学会総会記事, 69回, 453, 454, 日本癌学会, 2010年08月, [査読有り]
    英語
  • Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH)
    Nobuaki Kato; Hitoshi Itoh; Akihiko Serizawa; Yutaka Hatanaka; Shinobu Umemura; R. Yoshiyuki Osamura
    PATHOLOGY INTERNATIONAL, 60, 7, 510, 515, 2010年07月
    英語, 研究論文(学術雑誌)
  • 菌状息肉症における、病期の進行と形態形質学的変化の関係に関する検討
    山田 洋介; ヘールナンデス 真子; 藤田 裕美; 畑中 豊; 久保田 佳奈子; 羽賀 博典; 松野 吉宏
    日本リンパ網内系学会会誌, 50, 110, 110, (一社)日本リンパ網内系学会, 2010年05月, [査読有り]
    日本語
  • Immunohistochemical Expression of HER1, HER3, and HER4 in HER2-Positive Breast Cancer Patients Treated With Trastuzumab-Containing Neoadjuvant Chemotherapy
    Kan Yonemori; Koji Tsuta; Chikako Shimizu; Yutaka Hatanaka; Akihiro Hirakawa; Makiko Ono; Tsutomu Kouno; Noriyuki Katsumata; Masashi Ando; Kenji Tamura; Tadashi Hasegawa; Takayuki Kinoshita; Yasuhiro Fujiwara
    JOURNAL OF SURGICAL ONCOLOGY, 101, 3, 222, 227, 2010年03月
    英語, 研究論文(学術雑誌)
  • Disruption of the Blood Brain Barrier by Brain Metastases of Triple-Negative and Basal-Type Breast Cancer But Not HER2/neu-Positive Breast Cancer
    Kan Yonemori; Koji Tsuta; Makiko Ono; Chikako Shimizu; Akihiro Hirakawa; Tadashi Hasegawa; Yutaka Hatanaka; Yoshitaka Narita; Soichiro Shibui; Yasuhiro Fujiwara
    CANCER, 116, 2, 302, 308, 2010年01月
    英語, 研究論文(学術雑誌)
  • Immunohistochemical profiles of brain metastases from breast cancer
    Kan Yonemori; Koji Tsuta; Chikako Shimizu; Yutaka Hatanaka; Kaoru Hashizume; Makiko Ono; Yukihiro Nakanishi; Tadashi Hasegawa; Yasuji Miyakita; Yoshitaka Narita; Soichiro Shibui; Yasuhiro Fujiwara
    JOURNAL OF NEURO-ONCOLOGY, 90, 2, 223, 228, 2008年11月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Cotransduction of CCL27 gene can improve the efficacy and safety of IL-12 gene therapy for cancer
    Jian-Qing Gao; Naoko Kanagawa; Yoshiaki Motomura; Tatsuya Yanagawa; Toshiki Sugita; Yutaka Hatanaka; Yoichi Tani; Hiroyuki Mizuguchi; Yasuo Tsutsumi; Tadanori Mayumi; Naoki Okada; Shinsaku Nakagawa
    Gene Ther., 14, 6, 491, 502, 2007年03月, [査読有り]
    英語, 研究論文(学術雑誌)
■ その他活動・業績
  • Identification of TROP2 as an adaptive resistance mechanism in KRAS G12C inhibition and its therapeutic targeting.
    Masahiro Kashima; Hidenori Kitai; Yukiko Yoshida; Yuriko Ishida; Yuma Sato; Daisuke Morinaga; Kosuke Tsuji; Shotaro Ito; Kanako C. Hatanaka; Takuma Kobayashi; Yoshiki Shinomiya; Teppei Konishi; Yutaka Hatanaka; Jun Sakakibara-Konishi; Satoshi Konno, CANCER RESEARCH, 86, 7, 2026年04月03日
    英語, 研究発表ペーパー・要旨(国際会議)
  • 広範なSMARCA4/BRG1欠損成分を伴うHPV関連子宮頸部腺癌の1例
    馬詰 知佐; 畑中 佳奈子; 加藤 万里絵; 篠原 敏也; 和田 真一郎; 四宮 義貴; 畑中 豊; 笹島 ゆう子; 太田 聡, 日本病理学会会誌, 115, 1, 517, 517, 2026年03月
    (一社)日本病理学会, 日本語
  • ECM1 and KRT6A Mediate Dexamethasone-Induced Tumor Progression and Chemoresistance in pancreatic cancer
    Yoshiki Shinomiya; Yusuke Kouchi; Sakurako Kagitani; Takayuki Ishige; Kanako Hatanaka; Yutaka Hatanaka; Shigetsugu Takano; Masayuki Ohtsuka; Junichiro Ikeda; Takashi Kishimoto, CANCER SCIENCE, 117, 549, 549, 2026年01月
    英語, 研究発表ペーパー・要旨(国際会議)
  • Therapeutic efficacy and immune response of near-infrared photoimmunotherapy for lung cancer in orthotopic murine model
    Hiroshi Yamasaki; Kohei Nakajima; Ryohei Chiba; Haruhiko Shiiya; Kazuto Ohtaka; Hideki Ujiie; Aki Fujiwara; Masato Aragaki; Kanako Hatanaka; Yutaka Hatanaka; Mikako Ogawa; Tatsuya Kato, CANCER SCIENCE, 117, 2088, 2088, 2026年01月
    英語, 研究発表ペーパー・要旨(国際会議)
  • 胆道癌におけるCD73発現とその進行・予後との関連性
    白鳥翔也; 川久保和道; 畑中佳奈子; 桑谷将城; 小田総一郎; 野澤俊一郎; 米村洋輝; 杉浦諒; 畑中豊; 坂本直哉, 日本消化器病学会雑誌(Web), 122, 2025年
  • ASP-1929を用いた光免疫療法の婦人科悪性腫瘍における適用可能性の検討
    山本竜太郎; 畑中佳奈子; 朝野拓史; 四宮義貴; 渡利英道; 畑中豊, 日本がん分子標的治療学会学術集会プログラム・抄録集, 29th, 2025年
  • 細胞検体を用いたゲノム診療の今後
    畑中豊; 四宮義貴; 畑中佳奈子, 日本臨床細胞学会雑誌(Web), 64, 2025年
  • 肝細胞癌における有機アニオントランスポーターOATP1B3の細胞内局在別発現解析
    小林正幸; 相山健; 畑中佳奈子; 畑中豊; 山本葉一; 志智俊介; 藤居勇貴; 藤好直; 旭火華; 長津明久; 川村典生; 渡辺正明; 後藤了一; 柿坂達彦; 深井原; 武冨紹信, 日本外科学会定期学術集会(Web), 125th, 2025年
  • 気管支狭窄拡張術後にALK-TKIを導入したHIP1-ALK陽性肺癌の1例
    佐藤祐麻; 北井秀典; 田上敬太; 石田有莉子; 篠崎鮎香; 佐藤峰嘉; 高橋宏典; 古田恵; 高島雄太; 庄司哲明; 池澤靖元; 榊原純; 品川尚文; 今野哲; 品川尚文; 大川紘弥; 大塚紀幸; 畑中佳奈子; 畑中豊; 横内浩, 肺癌(Web), 65, 1, 2025年
  • 甲状腺癌におけるドライバー変異の免疫組織化学的検出に関する検討
    南家綾江; 畑中佳奈子; 山本万美子; 奥村麻美; 四宮義貴; 田中伸哉; 廣川満良; 加藤良平; 畑中豊, 日本病理学会会誌, 114, 1, 2025年
  • 多機関共同研究による甲状腺乳頭癌の分子病理学的解析
    畑中佳奈子; 山本万美子; 南家綾江; 奥村麻美; 樋口観世子; 天野高志; 四宮義貴; 廣川満良; 加藤良平; 畑中豊, 日本病理学会会誌, 114, 1, 2025年
  • 連続迅速自動固定包埋装置により処理された組織検体の核酸品質に関する検討
    四宮義貴; 村山理子; 田中佑実; 下道真由美; 南家綾江; 石田裕子; 若林健人; 外丸詩野; 畑中豊; 畑中佳奈子, 日本病理学会会誌, 114, 1, 2025年
  • 非小細胞肺癌におけるoligoprogressionの頻度および局所治療が予後に与える影響についての検討
    森永大亮; 榊原純; 北井秀典; 池澤靖元; 加藤達哉; 四宮義貴; 畑中佳奈子; 畑中豊; 田口大志; 今野哲, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 38th, 2025年
  • Preclinical analysis of the efficacy of near-infrared photoimmunotherapy and anti-PD-1 antibody combination therapy for treating CD73-positive lung cancer
    Ryohei Chiba; Kohei Nakajima; Kanako C. Hatanaka; Hideki Ujiie; Masato Aragaki; Takuma Kobayashi; Teppei Konishi; Ichiro Kinoshita; Yutaka Hatanaka; Mikako Ogawa; Tatsuya Kato, JOURNAL OF CLINICAL ONCOLOGY, 42, 16, 2024年06月01日
    英語, 研究発表ペーパー・要旨(国際会議)
  • TP53およびCDKN2Aの変化は節性T濾胞ヘルパー細胞リンパ腫患者における予後不良サブグループを明らかにする
    伊藤勇太; 伊藤勇太; 下埜城嗣; 河本啓介; 畑中佳奈子; 木暮泰寛; 水野洸太; 水野洸太; 古屋淳史; 村上紘一; 村上紘一; 豊嶋崇徳; 畑中豊; 三好寛明; 松野吉宏; 大島孝一; 片岡圭亮; 片岡圭亮; 中川雅夫, 日本リンパ網内系学会会誌, 64, 2024年
  • トリプルネガティブ乳癌(TNBC)におけるTILsやPD-L1のAI解析の有用性
    富岡伸元; 畑中佳奈子; 奧山大; 敷島果林; 太刀川花恵; 前田豪樹; 山本貢; 渡邊健一; 小林拓馬; GRYNKIEWICZ Mateusz; 小西哲平; 清水亜衣; 畑中豊, 日本乳癌学会学術総会(CD-ROM), 32nd, 2024年
  • 肺癌におけるCD73に対する近赤外線免疫療法(NIR-PIT)と抗PD-1抗体の併用療法の有効性
    千葉龍平; 中島孝平; 畑中佳奈子; 氏家秀樹; 新垣雅人; 小林拓馬; 小西哲平; 畑中豊; 加藤達哉; 小川美香子, 日本癌学会学術総会抄録集(Web), 83rd, 2024年
  • KRAS変異陽性大腸癌に対する治療標的分子としてのCD73/NT5E発現に関する分子病理学的検討
    田中佑実; 畑中佳奈子; 奥村麻美; 南家綾江; 南家綾江; 結城敏志; 本間重紀; 木下一郎; 松野吉宏; 畑中豊; 畑中豊; 畑中豊, 日本病理学会会誌, 113, 1, 2024年
  • PD-L1陽性クラスターとその周囲の免疫環境について
    富岡伸元; 山本貢; 前田豪樹; 桑原小百合; 敷島果林; 渡邊健一; 畑中佳奈子; 奧山大; 清水亜衣; 高橋将人; 畑中豊, 北海道外科雑誌, 68, 2, 2023年
  • 腫瘍領域におけるPD-L1の発現状況と免疫環境との関係についての検討
    富岡伸元; 畑中佳奈子; 奧山大; 渡邊健一; 山本貢; 前田豪樹; 桑原小百合; 清水亜衣; 鈴木宏明; 畑中豊; 高橋將人, 日本乳癌学会学術総会(CD-ROM), 31st, 2023年
  • 腋窩リンパ節転移陽性TNBCのPDL1陽性クラスター周囲の微小免疫環境についての検討
    富岡伸元; 渡邊健一; 山本貢; 前田豪樹; 桑原小百合; 畑中佳奈子; 奥山大; 鈴木宏明; 清水亜衣; 畑中豊; 高橋將人, 北海道外科雑誌, 67, 2, 2022年
  • PD-L1(SP142)陽性率が1%未満でも,凝集するクラスター内の陽性細胞数により予後予測が可能である
    富岡伸元; 畑中佳奈子; 奧山大; 桑原小百合; 太刀川花恵; 前田豪樹; 山本貢; 清水亜衣; 鈴木宏明; 渡邊健一; 畑中豊; 高橋將人, 日本乳癌学会学術総会(CD-ROM), 30th, 2022年
  • 子宮頸部すりガラス細胞癌の分子免疫学的検討
    朝野拓史; 村上薫; 長谷部理恵; 石塚泰也; 畑中佳奈子; 畑中豊; 渡利英道; 村上正晃, 日本婦人科腫瘍学会学術講演会プログラム・抄録集(Web), 64th, 2022年
  • リンパ節転移陽性TNBCに対する抗PD-L1抗体の上乗せ効果が得られる機序についての検討
    富岡 伸元; 奥山 大; 畑中 佳奈子; 寺井 小百合; 太刀川 花恵; 前田 豪樹; 山本 貢; 渡邊 健一; 鈴木 宏明; 清水 亜衣; 畑中 豊; 高橋 將人, 日本乳癌学会総会プログラム抄録集, 29回, 18, 18, 2021年07月
    (一社)日本乳癌学会, 日本語
  • 腋窩リンパ節転移を伴うTNBCのPD-L1陽性率が1%未満でも化療効果予測が可能である
    富岡伸元; 寺井小百合; 太刀川花恵; 前田豪樹; 山本貢; 渡邊健一; 高橋將人; 畑中佳奈子; 奥山大; 鈴木宏明; 清水亜衣; 畑中豊, 北海道外科雑誌, 66, 2, 2021年
  • 子宮平滑筋肉腫症例の腫瘍免疫関連遺伝子プロファイル解析
    朝野拓史; 長谷部理絵; 畑中佳奈子; 松岡亮介; 齊藤辰朗; 齊藤辰朗; 野崎綾子; 井平圭; 三田村卓; 金野陽輔; 加藤達矢; 小林範子; 武田真人; 工藤正尊; 松野吉宏; 畑中豊; 渡利英道, 日本婦人科腫瘍学会雑誌, 39, 1, 2021年
  • 【免疫組織化学 実践的な診断・治療方針決定のために】(第1部)免疫組織化学のための病理部門運営 免疫染色の精度管理
    増田 しのぶ; 桑田 健; 畑中 豊; 羽場 礼次; 森井 英一; 鬼島 宏; 白石 泰三, 病理と臨床, 38, 臨増, 24, 31, 2020年04月
    (株)文光堂, 日本語
  • 免疫組織化学 実践的な診断・治療方針決定のために 第1部 免疫組織化学のための病理部門運営 1.病理部門の管理、外注検査の選択
    石田裕子; 安孫子光春; 畑中 豊; 松野吉宏; 丸川活司, 文光堂 病理と臨床【臨時増刊号】, 38, 2, 7, 2020年04月
  • HER2陽性再発・転移唾液腺癌患者に対するトラスツズマブ・ドセタキセル併用療法の第II相試験
    木下 一郎; 加納 里志; 清田 尚臣; 多田 雄一郎; 伊地知 圭; 山崎 知子; 西本 尚樹; 畑中 豊; 松野 吉弘; 秋田 弘俊, 日本内科学会雑誌, 109, Suppl., 230, 230, 2020年02月
    (一社)日本内科学会, 日本語
  • ロルラチニブ治療後にクリゾチニブ再投与が著効したALK融合遺伝子陽性肺腺癌の1例
    辻 康介; 榊原 純; 北井 秀典; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 品川 尚文; 今野 哲; 池澤 靖元; 畑中 豊; 佐々木 高明; 吉田 遼平; 千葉 伸一; 松本 慎吾; 後藤 功一, 肺癌, 59, 7, 1200, 1200, 2019年12月
    (NPO)日本肺癌学会, 日本語
  • 気管支鏡検査におけるFFPE組織検体および細胞検体を用いたROS1融合遺伝子の検査成功率の検証
    辻 康介; 榊原 純; 北井 秀典; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 品川 尚文; 樋田 泰浩; 加賀 基知三; 大井 優子; 中條 聖子; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 今野 哲, 気管支学, 41, 6, 678, 678, 2019年11月
    (NPO)日本呼吸器内視鏡学会, 日本語
  • L1CAMはsurgical stagingを受けた進行子宮体癌症例の独立予後不良因子である
    奥 聡; 朝野 拓史; 畑中 佳奈子; 松岡 亮介; 加藤 達矢; 金野 陽輔; 三田村 卓; 井平 圭; 野崎 綾子; 武田 真人; 小林 範子; 工藤 正尊; 松野 吉宏; 畑中 豊; 渡利 英道, 北日本産科婦人科学会総会・学術講演会プログラム・抄録集, 67回, 49, 49, 2019年09月
    東北連合産科婦人科学会・北日本産科婦人科学会, 日本語
  • Phase II study of trastuzumab and docetaxel therapy in patients with HER2-positive recurrent and/or metastatic salivary gland carcinoma
    Ichiro Kinoshita; Satoshi Kano; Yasushi Shimizu; Naomi Kiyota; Yuichiro Tada; Kei Ijichi; Tmoko Yamazaki; Akihiro Homma; Yoichi M. Ito; Kota Ono; Keiko Kobayashi; Toshiyuki Isoe; Yutaka Hatanaka; Hitoshi Tsuda; Shojiroh Morinaga; Yoshihiro Matsuno; Hirotoshi Dosaka-Akita, CANCER RESEARCH, 79, 13, 2019年07月
    英語, 研究発表ペーパー・要旨(国際会議)
  • FLUORESCENCE IMAGING OF EARLY ADENOCARCINOMA OF THE ESOPHAGOGASTRIC JUNCTION BY TOPICALLY SPRAYING PROBE TARGETING DIPEPTIDYLPEPTIDASE-IV
    Keiko Yamamoto; Shunsuke Ohnishi; Takeshi Mizushima; Junichi Kodaira; Masayoshi Ono; Yutaka Hatanaka; Kanako Hatanaka; Nobuyuki Ehira; Keisuke Shinada; Hiroaki Takahashi; Yugo Kuriki; Mako Kamiya; Yuichi Shimizu; Yasuteru Urano; Naoya Sakamoto, GASTROINTESTINAL ENDOSCOPY, 89, 6, AB624, AB624, 2019年06月
    英語, 研究発表ペーパー・要旨(国際会議)
  • L1CAM陽性子宮体癌の臨床病理学的検討
    朝野 拓史; 畑中 佳奈子; 松岡 亮介; 小林 由佳子; 井平 圭; 野崎 綾子; 三田村 卓; 金野 陽輔; 加藤 達矢; 武田 真人; 小林 範子; 工藤 正尊; 畑中 豊; 松野 吉宏; 渡利 英道, 日本婦人科腫瘍学会雑誌, 37, 3, 499, 499, 2019年06月
    (公社)日本婦人科腫瘍学会, 日本語
  • 当院におけるBRAF遺伝子変異の検査成功率の検討
    山本 岳; 品川 尚文; 辻 康介; 猪狩 智生; 佐藤 峰嘉; 國崎 守; 高橋 宏典; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 木下 一郎; 秋田 弘俊; 畑中 豊; 松野 吉宏; 榊原 純, 気管支学, 41, Suppl., S221, S221, 2019年06月01日
    (NPO)日本呼吸器内視鏡学会, 日本語
  • 気管支鏡検査におけるFFPE検体,細胞診検体を用いたROS1融合遺伝子の検査成功率の検証
    辻 康介; 榊原 純; 北井 秀典; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 大井 優子; 中條 聖子; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 品川 尚文, 気管支学, 41, Suppl., S222, S222, 2019年06月01日
    (NPO)日本呼吸器内視鏡学会, 日本語
  • 当院におけるBRAF遺伝子変異の検査成功率の検討
    山本 岳; 品川 尚文; 辻 康介; 猪狩 智生; 佐藤 峰嘉; 國崎 守; 高橋 宏典; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 木下 一郎; 秋田 弘俊; 畑中 豊; 松野 吉宏; 榊原 純, 気管支学, 41, Suppl., S221, S221, 2019年06月
    (NPO)日本呼吸器内視鏡学会, 日本語
  • 気管支鏡検査におけるFFPE検体,細胞診検体を用いたROS1融合遺伝子の検査成功率の検証
    辻 康介; 榊原 純; 北井 秀典; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 大井 優子; 中條 聖子; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 品川 尚文, 気管支学, 41, Suppl., S222, S222, 2019年06月
    (NPO)日本呼吸器内視鏡学会, 日本語
  • 非小細胞肺癌におけるHER2異常の前向き観察研究(HOT1303-A)
    合田 智宏; 木下 一郎; 秋田 弘俊; 大泉 聡史; 横内 浩; 中野 浩輔; 原田 敏之; 河井 康孝; 榊原 純; 森川 直人; 山田 範幸; 山崎 成夫; 菅原 俊一; 朝比奈 肇; 品川 尚文; 磯部 宏; 天野 虎次; 畑中 豊; 松野 吉宏; 西原 広史, 肺癌, 59, 1, 113, 113, 2019年02月
    (NPO)日本肺癌学会, 日本語
  • 当院におけるFFPE検体、細胞診検体を用いたROS1融合遺伝子の検査成功率の検証
    北井 秀典; 榊原 純; 高橋 宏典; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 品川 尚文; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 大井 優子, 肺癌, 59, 1, 112, 112, 2019年02月
    (NPO)日本肺癌学会, 日本語
  • 気管支鏡下生検検体におけるPD-L1発現評価の後ろ向き検討
    高橋 宏典; 品川 尚文; 畑中 豊; 國崎 守; 古田 恵; 高島 雄太; 庄司 哲明; 北井 秀典; 菊池 創; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 松野 吉宏; 榊原 純, 気管支学, 41, 1, 91, 91, 2019年01月25日
    (NPO)日本呼吸器内視鏡学会, 日本語
  • 自己免疫性疾患患者に発生するびまん性大細胞型B細胞リンパ腫の微小環境の検討
    畑中佳奈子; 畑中佳奈子; 畑中豊; 畑中豊; 藤本勝也; 奥村麻美; 南家綾江; 津矢田明泰; 齋藤辰朗; 豊嶋崇徳; 松野吉宏; 松野吉宏, 日本病理学会会誌, 108, 1, 2019年
  • ロルラチニブ治療後にクリゾチニブ再投与が著効したALK融合遺伝子陽性肺腺癌の1例
    辻康介; 榊原純; 北井秀典; 水柿秀紀; 朝比奈肇; 菊地順子; 菊地英毅; 品川尚文; 今野哲; 池澤靖元; 畑中豊; 佐々木高明; 吉田遼平; 千葉伸一; 松本慎吾; 後藤功一, 肺癌(Web), 59, 7, 2019年
  • 気管支鏡下生検検体におけるPD-L1発現評価の後ろ向き検討
    高橋 宏典; 品川 尚文; 畑中 豊; 國崎 守; 古田 恵; 高島 雄太; 庄司 哲明; 北井 秀典; 菊池 創; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 松野 吉宏; 榊原 純, 気管支学, 41, 1, 91, 91, 2019年01月
    (NPO)日本呼吸器内視鏡学会, 日本語
  • 気管支鏡下生検検体におけるPD-L1発現評価の後ろ向き検討
    高橋 宏典; 品川 尚文; 畑中 豊; 國崎 守; 古田 恵; 高島 雄太; 庄司 哲明; 北井 秀典; 菊池 創; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 松野 吉宏; 榊原 純, 気管支学, 41, 1, 91, 91, 2019年01月
    (NPO)日本呼吸器内視鏡学会, 日本語
  • 肺癌患者におけるEGFR遺伝子変異検査の手引き(第4.0版)
    西野和美; 西尾和人; 畑中豊; 池田貞勝; 菓子井達彦; 木村英晴; 後藤功一; 阪本智宏; 里内美弥子; 清水淳市; 曽田学; 蔦幸治; 豊岡伸一; 西尾和人; 西野和美; 畑中豊; 松本慎吾; 三窪将史; 谷田部恭; 横瀬智之; 秋田弘俊, 日本肺癌学会バイオマーカー委員会, 2018年11月
  • 当院におけるFFPE検体,細胞診検体を用いたROS1融合遺伝子の検査成功率の検証
    北井秀典; 榊原純; 高橋宏典; 國崎守; 庄司哲明; 高島雄太; 古田恵; 水柿秀紀; 朝比奈肇; 菊地英毅; 大井優子; 畑中佳奈子; 畑中豊; 松野吉宏; 品川尚文, 日本肺癌学会総会号, 59th, 584, 2018年10月25日
    日本語
  • NSCLCにおけるHER2異常の前向き観察研究(HOT1303-A)
    横内 浩; 木下 一郎; 合田 智宏; 大泉 聡史; 中野 浩輔; 原田 敏之; 河井 康孝; 榊原 純; 森川 直人; 山田 範幸; 山崎 成夫; 菅原 俊一; 朝比奈 肇; 天野 虎次; 畑中 豊; 松野 吉宏; 西原 広史; 磯部 宏; 西村 正治; 秋田 弘俊; 北海道肺癌臨床研究会(HOT), 肺癌, 58, 6, 511, 511, 2018年10月
    (NPO)日本肺癌学会, 日本語
  • T790M検索を目的とした組織再生検及び血漿検査の後方視的検討
    猪狩 智生; 北井 秀典; 高橋 宏典; 國崎 守; 庄司 哲明; 古田 恵; 高島 雄太; 佐々木 真知子; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 畑中 豊; 松野 吉宏; 品川 尚文, 肺癌, 58, 6, 635, 635, 2018年10月
    (NPO)日本肺癌学会, 日本語
  • 気管支鏡下生検検体におけるPD-L1発現評価の後ろ向き検討
    高橋 宏典; 品川 尚文; 畑中 豊; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 菊池 創; 北井 秀典; 水柿 秀紀; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 松野 吉宏; 西村 正治, 気管支学, 40, Suppl., S241, S241, 2018年05月
    (NPO)日本呼吸器内視鏡学会, 日本語
  • 卵巣明細胞癌におけるγグルタミルトランスペプチダーゼ1の発現と予後との関連性
    松岡亮介; 朝野拓史; 畑中佳奈子; 畑中佳奈子; 畑中佳奈子; 畑中豊; 畑中豊; 南家綾江; 奥村麻美; 遠藤大介; 松野吉宏; 秋田弘俊; 秋田弘俊; 渡利英道, 日本病理学会会誌, 107, 1, 390, 2018年04月26日
    日本語
  • 病理標本染色における核酸抽出の影響の検討
    加瀬谷美幸; 畑中佳奈子; 森こず恵; 葛西瑞穂; 奥村麻美; 南家綾江; 松野吉宏; 松野吉宏; 天野虎次; 天野虎次; 畑中豊; 畑中豊; 佐藤典宏, 日本病理学会会誌, 107, 1, 399, 399, 2018年04月26日
    (一社)日本病理学会, 日本語
  • 肝細胞切除後の予後再発におけるHLA class1分子発現の意義の検討
    岡田 尚樹; 神山 俊哉; 横尾 英樹; 折茂 達也; 若山 顕治; 島田 慎吾; 長津 明久; 蒲池 浩文; 畑中 佳奈子; 畑中 豊; 武冨 紹信, 日本外科学会定期学術集会抄録集, 118回, 1667, 1667, 2018年04月
    (一社)日本外科学会, 日本語
  • 肺癌症例における腫瘍血管内皮マーカーbiglycanの発現解析
    森本 浩史; 間石 奈湖; 樋田 泰浩; 西原 広史; 畑中 豊; 松野 吉宏; 中村 透; 平野 聡; 樋田 京子, 日本病理学会会誌, 107, 1, 293, 293, 2018年04月
    (一社)日本病理学会, 日本語
  • 肺癌症例における腫瘍血管内皮マーカーbiglycanの発現解析
    森本 浩史; 間石 奈湖; 樋田 泰浩; 西原 広史; 畑中 豊; 松野 吉宏; 中村 透; 平野 聡; 樋田 京子, 日本病理学会会誌, 107, 1, 293, 293, 2018年04月
    (一社)日本病理学会, 日本語
  • クリニカルシークエンス施行症例における病理組織標本の腫瘍含有割合の検討
    畑中 佳奈子; 松岡 亮介; 林 秀幸; 藤井 恭子; 畑中 豊; 天野 虎次; 西原 広史; 秋田 弘俊, 日本病理学会会誌, 107, 1, 400, 400, 2018年04月
    (一社)日本病理学会, 日本語
  • 膵管癌分子サブタイピングのIHCサロゲート法の確立に関する検討
    丸川 活司; 三橋 智子; 畑中 豊; 諸岡 亜早美; 佐藤 大介; 奥村 麻美; 南家 綾江; 畑中 佳奈子; 平野 聡; 松野 吉宏, 日本病理学会会誌, 107, 1, 363, 364, 2018年04月
    (一社)日本病理学会, 日本語
  • 肺癌患者におけるBRAF遺伝子変異検査の手引き(第1.0版)
    阪本智宏; 松本慎吾; 後藤功一; 池田貞勝; 菓子井達彦; 木村英晴; 里内美弥子; 清水淳市; 曽田学; 蔦幸治; 豊岡伸一; 西尾和人; 西野和美; 畑中豊; 三窪将史; 谷田部恭; 横瀬智之; 秋田弘俊, 日本肺癌学会バイオマーカー委員会, 2018年04月
  • 肝細胞切除後の予後再発におけるHLA class1分子発現の意義の検討
    岡田 尚樹; 神山 俊哉; 横尾 英樹; 折茂 達也; 若山 顕治; 島田 慎吾; 長津 明久; 蒲池 浩文; 畑中 佳奈子; 畑中 豊; 武冨 紹信, 日本外科学会定期学術集会抄録集, 118回, 1667, 1667, 2018年04月
    (一社)日本外科学会, 日本語
  • VOLTAGE: Multicenter phase 1b/II study of nivolumab monotherapy and subsequent radical surgery after preoperative chemoradiotherapy with capecitabine in patients with locally advanced rectal cancer.
    Yuichiro Tsukada; Hideaki Bando; Koji Inamori; Shota Fukuoka; Takeshi Sasaki; Yuji Nishizawa; Daisuke Kotani; Motohiro Kojima; Yosuke Togashi; Naoki Nakamura; Tetsuo Akimoto; Yoshito Komatsu; Satoshi Yuki; Shigenori Homma; Yutaka Hatanaka; Yoshihiro Matsuno; Akihiro Sato; Hiroyoshi Nishikawa; Masaaki Ito, JOURNAL OF CLINICAL ONCOLOGY, 36, 4, 2018年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • ゲノム診療用病理組織検体取扱い規程:検体検査の品質・精度確保に係る医療法等改正への対応
    畑中 豊, Medical Technology, 印刷中, 2018年
  • 病理における分子診断の医療経済
    畑中 豊, 病理と臨床, 印刷中, 2018年
  • がん遺伝子パネル検査の臨床導入にあたっての日本病理学会の取り組み:ゲノム診療用病理組織検体取扱い規程作成とe-learning教育システムの開発
    畑中 豊; 桑田 健; 菅野 雅人; 小田 義直, 腫瘍内科, 印刷中, 2018年
  • 次世代シークエンサーを用いたマルチプレックス・コンパニオン診断および遺伝子パネル検査における品質管理
    畑中 豊; 齋藤 辰朗; 畑中 佳奈子; 天野 虎次, 別冊 臨床腫瘍プラクティスⅢ:がん治療におけるコンパニオン診断, 印刷中, 2018年
  • 肝細胞切除後の予後再発におけるHLA classI分子発現の意義の検討
    岡田尚樹; 神山俊哉; 横尾英樹; 折茂達也; 若山顕治; 島田慎吾; 長津明久; 蒲池浩文; 畑中佳奈子; 畑中豊; 武冨紹信, 日本外科学会定期学術集会(Web), 118th, ROMBUNNO.PS‐037‐4 (WEB ONLY), 2018年
    日本語
  • ゲノム診療における今後の細胞診の役割と対応
    畑中豊; 畑中豊; 安孫子光春; 清水知浩; 丸川活司; 畑中佳奈子; 畑中佳奈子; 品川尚文; 木下一郎; 松野吉宏; 松野吉宏, 日本臨床細胞学会雑誌(Web), 56, 637, 2017年10月23日
    日本語
  • 呼吸器領域の細胞診の工夫(将来の展望) ゲノム診療における今後の細胞診の役割と対応
    畑中 豊; 安孫子 光春; 清水 知浩; 丸川 活司; 畑中 佳奈子; 品川 尚文; 木下 一郎; 松野 吉宏, 日本臨床細胞学会雑誌, 56, Suppl.2, 637, 637, 2017年10月
    (公社)日本臨床細胞学会, 日本語
  • 肺癌症例における腫瘍血管内皮細胞マーカーbiglycanの発現解析
    森本 浩史; 間石 奈湖; 樋田 泰浩; 西原 広史; 畑中 豊; 松野 吉宏; 中村 透; 平野 聡; 樋田 京子, 日本癌学会総会記事, 76回, P, 2436, 2017年09月
    日本癌学会, 英語
  • 肺癌症例における腫瘍血管内皮細胞マーカーbiglycanの発現解析
    森本 浩史; 間石 奈湖; 樋田 泰浩; 西原 広史; 畑中 豊; 松野 吉宏; 中村 透; 平野 聡; 樋田 京子, 日本癌学会総会記事, 76回, P, 2436, 2017年09月
    日本癌学会, 英語
  • 原発性肺扁平上皮癌におけるPD-L1とNT5E(CD73)の発現と予後に関する検討
    桑原 健; 畑中 豊; 畑中 佳奈子; 清水 知浩; 岡田 宏美; 加賀 基知三; 樋田 泰浩; 秋田 弘俊; 榊原 純; 外丸 詩野; 松野 吉宏, 日本癌学会総会記事, 76回, P, 3259, 2017年09月
    日本癌学会, 英語
  • EGFR-TKI初期耐性非小細胞肺癌の臨床病理学的特徴及び免疫微小環境に関する検討
    高島 雄太; 榊原 純; 畑中 豊; 畑中 佳奈子; 大原 克仁; 大泉 聡史; 樋田 泰浩; 加賀 基知三; 木下 一郎; 秋田 弘俊; 松野 吉宏; 西村 正治, 日本癌学会総会記事, 76回, P, 3264, 2017年09月
    日本癌学会, 英語
  • ホルマリン固定化時間が乳癌のmulti-geneアッセイに与える影響の確認
    齊藤 優莉亜; 松嶋 朋子; 赤井 保正; 奥村 麻美; 畑中 佳奈子; 山下 啓子; 畑中 豊; 松野 吉宏, 日本癌学会総会記事, 76回, P, 3335, 2017年09月
    日本癌学会, 英語
  • 原発性肺扁平上皮癌におけるPD-L1とNT5E(CD73)の発現と予後に関する検討
    桑原 健; 畑中 豊; 畑中 佳奈子; 清水 知浩; 岡田 宏美; 加賀 基知三; 樋田 泰浩; 秋田 弘俊; 榊原 純; 外丸 詩野; 松野 吉宏, 日本癌学会総会記事, 76回, P, 3259, 2017年09月
    日本癌学会, 英語
  • EGFR-TKI初期耐性非小細胞肺癌の臨床病理学的特徴及び免疫微小環境に関する検討
    高島 雄太; 榊原 純; 畑中 豊; 畑中 佳奈子; 大原 克仁; 大泉 聡史; 樋田 泰浩; 加賀 基知三; 木下 一郎; 秋田 弘俊; 松野 吉宏; 西村 正治, 日本癌学会総会記事, 76回, P, 3264, 2017年09月
    日本癌学会, 英語
  • 肺癌症例における腫瘍血管内皮マーカーbiglycanの発現解析
    森本浩史; 間石奈湖; 樋田泰浩; 西原広史; 畑中豊; 松野吉宏; 平野聡; 樋田京子, がんと代謝研究会プログラム&抄録集, 5th, 74, 2017年07月
    日本語
  • 卵巣明細胞癌患者由来異種移植片モデルの樹立と特性解析
    朝野 拓史; 渡利 英道; 遠藤 大介; 國友 美穂子; 本田 弘平; 野村 俊之; 畑中 豊; 畑中 佳奈子, 日本婦人科腫瘍学会雑誌, 35, 3, 529, 529, 2017年06月
    (公社)日本婦人科腫瘍学会, 日本語
  • 卵巣明細胞腺癌に対するcabozantinibの抗腫瘍効果についての検討
    中谷 真紀子; 渡利 英道; 王 磊; 畑中 豊; 畑中 佳奈子; 西原 広史; 朝野 拓史; 遠藤 大介; 三田村 卓; 董 培新; シャロン・ハンリー; 田中 伸哉; 櫻木 範明, 日本婦人科腫瘍学会雑誌, 35, 3, 628, 628, 2017年06月
    (公社)日本婦人科腫瘍学会, 日本語
  • 当施設における肺癌EGFR遺伝子変異検査の現状と課題
    安孫子光春; 清水知浩; 丸川活司; 畑中豊; 松野吉宏, 日本臨床細胞学会雑誌(Web), 56, 183, 2017年04月11日
    日本語
  • 悪性胸膜中皮腫における治療標的遺伝子としてのSORORINおよびPLK1遺伝子の役割
    加藤 達哉; Lee Daiyoon; 氏家 秀樹; 和田 啓伸; 加地 苗人; 松毛 真一; 菅野 宏美; 畑中 豊; 畑中 佳奈子; 松野 吉宏; 加賀 基知三; 松居 喜郎; De Perrot Marc; 安福 和弘, 日本呼吸器外科学会雑誌, 31, 3, P67, 3, 2017年04月
    (NPO)日本呼吸器外科学会, 日本語
  • 新規MUC1糖鎖特異抗体を用いた乳腺組織における癌関連糖鎖の組織局在に関する検討
    清水亜衣; 清水亜衣; 畑中佳奈子; 畑中佳奈子; 畑中豊; 畑中豊; 南家綾江; 奥村麻美; 成地健太郎; 佐藤正治; 山下啓子; 松野吉宏; 松野吉宏; 松野吉宏, 日本病理学会会誌, 106, 1, 487, 487, 2017年03月24日
    (一社)日本病理学会, 日本語
  • 病理領域の外部精度管理 コンパニオン診断の外部精度評価における新たな課題と取り組み
    畑中 豊; 桑田 健; 増田 しのぶ; 酒井 康裕; 坂下 信悟; 南 優子; 元井 紀子; 大林 千穂; 谷田部 恭; 森井 英一, 日本病理学会会誌, 106, 1, 212, 212, 2017年03月
    (一社)日本病理学会, 日本語
  • Prognostic Significance of PD-L1 Expression in Extrahepatic Cholangiocarcinoma
    Takashi Ueno; Tomoko Mitsuhashi; Yutaka Hatanaka; Takahiro Tsuchikawa; Keisuke Okamura; Yoshihiro Matsuno; Satoshi Hirano, LABORATORY INVESTIGATION, 97, 452A, 452A, 2017年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • Prognostic Significance of PD-L1 Expression in Extrahepatic Cholangiocarcinoma
    Takashi Ueno; Tomoko Mitsuhashi; Yutaka Hatanaka; Takahiro Tsuchikawa; Keisuke Okamura; Yoshihiro Matsuno; Satoshi Hirano, MODERN PATHOLOGY, 30, 452A, 452A, 2017年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • 遺伝子関連検査・検体品質管理マニュアル パート2[承認文書]
    畑中 豊, 日本臨床検査標準化協議会・遺伝子関連検査標準化専門委員会編, 2017年
  • ゲノム診療用病理組織検体取扱い規程[初版]
    畑中 豊, 日本病理学会・ゲノム診療用病理組織検体取扱い規程策定ワーキング・グループ, 2017年
  • 肺癌患者における PD-L1 検査の手引き[第1.0版]
    畑中 豊, 日本肺癌学会・バイオマーカー委員会作成, 2017年
  • 遺伝子検査―核酸増幅装置(PCR)(病理組織検体):知っておきたい!臨床検査機器の安全管理とトラブルシューティング
    齋藤 辰朗; 畑中 豊, Medical Technology, 45, 臨時増刊号, 1452, 1455, 2017年
  • 固形腫瘍におけるコンパニオン診断の現状と今後の展開
    畑中 豊; 松野 吉宏, 微研ジャーナル友, 40, 4, 3, 11, 2017年
  • 今後のゲノム診療に求められる病理検体の核酸品質について
    畑中 豊, Histo-Logic Japan, 45, 1, 2, 6, 2017年
  • ER陽性乳癌組織におけるPIK3CA遺伝子変異とAKT,ERαのリン酸化の検討
    石田直子; 馬場基; 萩尾加奈子; 郭家志; 押野智博; 笠原里紗; 奈良美也子; 畑中豊; 岡田宏美; 冨樫謙一; 松野吉宏; 山下啓子, 日本乳癌学会学術総会プログラム・抄録集, 25th, 378, 2017年
    日本語
  • 乳癌における新規MUC1癌関連糖鎖特異抗体の診断有用性の検討
    清水亜衣; 清水亜衣; 畑中佳奈子; 畑中佳奈子; 畑中豊; 畑中豊; 馬場基; 石田直子; 南家綾江; 奥村麻美; 成地健太郎; 佐藤正治; 加瀬廣; 山下啓子; 松野吉宏; 松野吉宏; 松野吉宏, 日本乳癌学会学術総会プログラム・抄録集, 25th, 416, 416, 2017年
    (一社)日本乳癌学会, 日本語
  • 抗メソテリン抗体(MORAb‐009)によるヒト膵癌細胞株に対する抗腫瘍効果の検討
    松澤文彦; 蒲池浩文; 水上達三; 永生高広; 畑中豊; 古内恵司; 神山俊哉; 武冨紹信, 日本外科学会定期学術集会(Web), 117th, ROMBUNNO.PS‐222‐4 (WEB ONLY), 2017年
    日本語
  • 近隣病院との連携強化によるがん患者の開発治験のアクセス向上のための方策 Hub-and-Spokeの実際
    結城 敏志; 畑中 豊; 小松 嘉人, 腫瘍内科, 20, 293, 298, 2017年
  • コンパニオン診断・ゲノム診断を正しく行うために:検体の扱い方を中心に
    畑中 豊, 肺癌(Educational Book), 57, Supplement, 702, 706, 2017年
    特定非営利活動法人 日本肺癌学会, 日本語
  • パラフィン包埋標本を用いたトランスクリプトーム解析
    畑中 豊; 秋山 英雄; 齋藤 辰朗; 丸川 活司; 奥村 麻美; 松野 吉宏, 病理と臨床, 35, 613, 621, 2017年
  • セルブロック作製法の標準化を目指して―セルブロック作製におけるピットフォール―
    丸川活司; 丸川活司; 畑中豊; 松野吉宏; 松野吉宏; 松野吉宏, 日本臨床細胞学会雑誌(Web), 55, 423, 2016年10月19日
    日本語
  • 肺がんのTranslational Science クリニカルシークエンスの臨床実装による肺癌に対する治療標的分子・個別化治療の探索
    西原 広史; 木下 一郎; 畑中 豊; 田中 伸哉; 秋田 弘俊, 日本癌学会総会記事, 75回, SST1, 3, 2016年10月
    日本癌学会, 英語
  • 免疫染色とセルブロック法 セルブロック作製法の標準化を目指して セルブロック作製におけるピットフォール
    丸川 活司; 畑中 豊; 松野 吉宏, 日本臨床細胞学会雑誌, 55, Suppl.2, 423, 423, 2016年10月
    (公社)日本臨床細胞学会, 日本語
  • ALK陽性肺癌細胞株を用いたFFPEセルブロック作製法に関する検討
    丸川 活司; 今川 誠; 中島 真奈美; 小熊 貴光; 東 学; 出口 貴祥; 畑中 豊, 日本医学検査学会抄録集, 65回, 5, 37(228), 2016年09月
    (一社)日本臨床衛生検査技師会, 日本語
  • 低分化肝外胆管癌における臨床病理学的因子の検討
    上野 峰; 三橋 智子; 畑中 豊; 岡村 圭祐; 平野 聡; 松野 吉宏, 日本病理学会会誌, 105, 1, 447, 447, 2016年04月
    (一社)日本病理学会, 日本語
  • 膵管癌におけるNT5E発現における臨床病理学的検討
    諸岡 亜早美; 畑中 豊; 丸川 活司; 上野 峰; 平野 裕子; 奥村 麻美; 畑中 佳奈子; 平野 聡; 松野 吉宏; 三橋 智子, 日本病理学会会誌, 105, 1, 520, 520, 2016年04月
    (一社)日本病理学会, 日本語
  • ALK陽性肺癌細胞株を用いたFFPEセルブロック作製に関する調査研究
    丸川 活司; 畑中 豊; 本多 優奈; 平野 裕子; 東 学; 中島 真奈美; 今川 誠; 小熊 貴光; 東 恭悟; 松野 吉宏, 日本病理学会会誌, 105, 1, 527, 527, 2016年04月
    (一社)日本病理学会, 日本語
  • Clinicopathological Significance of MUC13 Expression in Pancreatic Ductal Adenocarcinoma (PDAC); the Positive Prognostic Marker and Possible Candidate for Molecular Targeted Therapy
    Katsuji Marukawa; Tonzoko Mitsuhashi; Yutaka Hatanaka; Asami Morooka; Daisuke Sato; Takeo Nitta; Toru Nakamura; Satoshi Hirano; Yoshihiro Matsuno, MODERN PATHOLOGY, 29, 444A, 444A, 2016年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • Clinicopathological Significance of MUC13 Expression in Pancreatic Ductal Adenocarcinoma (PDAC); the Positive Prognostic Marker and Possible Candidate for Molecular Targeted Therapy
    Katsuji Marukawa; Tomoko Mitsuhashi; Yutaka Hatanaka; Asami Morooka; Daisuke Sato; Takeo Nitta; Toru Nakamura; Satoshi Hirano; Yoshihiro Matsuno, LABORATORY INVESTIGATION, 96, 444A, 444A, 2016年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • 原発不明癌における分子標的治療の開発を目指したドライバー遺伝子変異解析
    木下 一郎; 畑中 豊; 本間 理央; 辻 靖; 坂井 和子; 鈴木 優介; 秋田 弘俊, 日本内科学会雑誌, 105, Suppl., 272, 272, 2016年02月
    (一社)日本内科学会, 日本語
  • 肺癌患者における EGFR遺伝子変異検査の手引き[第3.05版]
    畑中 豊, 日本肺癌学会・バイオマーカー委員会作成, 2016年
  • 肝細胞癌におけるAdenomatous polyposis coli結合蛋白EB1の機能解析
    相山健; 横尾英樹; 折茂達也; 大畑多嘉宣; 畑中佳奈子; 畑中豊; 松野吉宏; 福原崇介; 高橋秀徳; 若山顕治; 敦賀陽介; 蒲池浩文; 神山俊哉; 武冨紹信, 日本外科学会定期学術集会(Web), 116th, PS‐107‐1 (WEB ONLY), 2016年
    日本語
  • ALDH1の低発現は肝外胆管癌および胆嚢癌の重要な予後因子である
    松澤文彦; 水上達三; 蒲池浩文; 三橋智子; 敦賀陽介; 畑中豊; 神山俊哉; 武冨紹信, 日本外科学会定期学術集会(Web), 116th, OP‐065‐4 (WEB ONLY), 2016年
    日本語
  • 悪性腫瘍に対する分子標的治療薬 現状と今後−消化管がん領域のコンパニオン診断
    畑中 豊, 病理と臨床, 34, 989, 994, 2016年
  • 肺癌における遺伝子変異検査のガイドライン
    大林 千穂; 畑中 豊, 病理と臨床, 34, 249, 255, 2016年
  • Pathology quality assurance in companion diagnosis
    Yoshihiro Matsuno; Katsuji Marukaawa; Yutaka Hatanaka, ANNALS OF ONCOLOGY, 26, 52, 52, 2015年11月
    英語, 研究発表ペーパー・要旨(国際会議)
  • Vp3,4肝細胞癌の門脈腫瘍栓に対する術前放射線治療とAPC-binding protein EB1の発現の意義
    相山 健; 折茂 達也; 横尾 英樹; 大畑 多嘉宣; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 神山 俊哉; 武冨 紹信, 日本癌学会総会記事, 74回, P, 1331, 2015年10月
    日本癌学会, 英語
  • 病理の立場から見たコンパニオン診断薬の開発と評価 (特集 個別化医療とコンパニオン診断薬を取り巻く現状と問題点)
    畑中 豊; 松野 吉宏, 医薬ジャーナル, 51, 8, 76, 82, 2015年08月
    医薬ジャーナル社, 日本語
  • 膵癌局所環境におけるCAFマーカーpalladinの発現は独立した予後因子である
    佐藤 大介; 土川 貴裕; 三橋 智子; 畑中 豊; 野見 武寛; 倉島 庸; 海老原 祐磨; 村上 壮一; 中村 透; 田本 英司; 岡村 圭祐; 七戸 俊明; 松野 吉宏; 平野 聡, 日本肝胆膵外科学会・学術集会プログラム・抄録集, 27回, 567, 567, 2015年06月
    (一社)日本肝胆膵外科学会, 日本語
  • 胆道腺扁平上皮癌の診断におけるp40、p63免疫染色の有用性
    佐藤 大介; 三橋 智子; 畑中 豊; 岡村 圭祐; 平野 聡; 松野 吉宏, 日本病理学会会誌, 104, 1, 325, 325, 2015年03月
    (一社)日本病理学会, 日本語
  • 膵管癌におけるMUC13発現の臨床病理学的検討
    丸川 活司; 畑中 豊; 諸岡 亜早美; 佐藤 大介; 清水 知浩; 畑中 佳奈子; 中村 透; 三橋 智子; 平野 聡; 松野 吉宏, 日本病理学会会誌, 104, 1, 421, 421, 2015年03月
    (一社)日本病理学会, 日本語
  • PHGDH and TRIM29 as Novel Diagnostic Markers for Malignant Pleural Mesothelioma: An Exploring Approach From FFPE Tissue-Based Gene Expression Profiling of a Synchronous Thoracic Tumor
    Tomoaki Naka; Yutaka Hatanaka; Hiromi Kanno; Kanako Hatanaka; Tomoko Mitsuhashi; Yoshihiro Matsuno, MODERN PATHOLOGY, 28, 485A, 486A, 2015年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • PHGDH and TRIM29 as Novel Diagnostic Markers for Malignant Pleural Mesothelioma: An Exploring Approach From FFPE Tissue-Based Gene Expression Profiling of a Synchronous Thoracic Tumor
    Tomoaki Nake; Yutaka Hatanaka; Hiromi Kanno; Kanako Hatanaka; Tomoko Mitsuhashi; Yoshihiro Matsuno, LABORATORY INVESTIGATION, 95, 485A, 486A, 2015年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • Predictive Value of MGMT Gene Promoter and LINE-1 Methylation Status in Primary Central Nervous System Diffuse Large B-Cell Lymphoma Treated With High-Dose MTX and Radiotherapy
    Kanako Hatanaka; Yutaka Hatanaka; Kyoko Fujii; Hiroyuki Kobayashi; Hiromi Kanno; Tomoko Mitsuhashi; Hiroshi Nishihara; Shinya Tanaka; Yoshihiro Matsuno, LABORATORY INVESTIGATION, 95, 431A, 431A, 2015年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • Stromal Palladin Expression Is an Independent Prognostic Factor of Pancreatic Ductal Adenocarcinoma (PDAC)
    Daisuke Sato; Tomoko Mitsuhashi; Takahiro Tsuchikawa; Yutaka Hatanaka; Toru Nakamura; Satoshi Hirano; Yoshihiro Matsuno, LABORATORY INVESTIGATION, 95, 448A, 448A, 2015年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • Stromal Palladin Expression Is an Independent Prognostic Factor of Pancreatic Ductal Adenocarcinoma (PDAC)
    Daisuke Sato; Tomoko Mitsuhashi; Takahiro Tsuchikawa; Yutaka Hatanaka; Toru Nakamura; Satoshi Hirano; Yoshihiro Matsuno, MODERN PATHOLOGY, 28, 448A, 448A, 2015年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • Predictive Value of MGMT Gene Promoter and LINE-1 Methylation Status in Primary Central Nervous System Diffuse Large B-Cell Lymphoma Treated With High-Dose MTX and Radiotherapy
    Kanako Hatanaka; Yutaka Hatanaka; Kyoko Fujii; Hiroyuki Kobayashi; Hiromi Kanno; Tomoko Mitsuhashi; Hiroshi Nishihara; Shinya Tanaka; Yoshihiro Matsuno, MODERN PATHOLOGY, 28, 431A, 431A, 2015年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • 肺癌患者におけるALK融合遺伝子検査の手引き[第2.0版]
    畑中 豊, 日本肺癌学会・バイオマーカー委員会作成, 2015年
  • 固形腫瘍の体細胞遺伝子検査における留意点
    畑中 豊; 松野 吉宏, SRL宝函, 36, 41, 45, 2015年
  • コンパニオン診断におけるIVD承認検査とは何ですか?
    畑中 豊, 検査と技術, 43, 424, 426, 2015年
  • 肝細胞癌におけるAdenomatous polyposis coli結合蛋白EB1と浸潤の関連性
    相山健; 横尾英樹; 折茂達也; 大畑多嘉宣; 柿坂達彦; 畑中佳奈子; 畑中豊; 松野吉宏; 高橋秀徳; 若山顕治; 敦賀陽介; 蒲池浩文; 神山俊哉; 武冨紹信, 日本消化器癌発生学会総会プログラム・抄録集, 26th, 68, 2015年
    日本語
  • CD133の細胞質発現は肝外胆管癌および胆嚢癌の重要な予後因子である。
    水上達三; 蒲池浩文; 三橋智子; 敦賀陽介; 畑中豊; 神山俊哉; 武冨紹信, 日本外科学会定期学術集会(Web), 115th, OP-282-5 (WEB ONLY), 2015年
    日本語
  • 肝細胞癌におけるAdenomatous polyposis coli結合蛋白EB1の新規バイオマーカーとしての可能性
    相山健; 横尾英樹; 折茂達也; 大畑多嘉宣; 畑中佳奈子; 畑中豊; 松野吉宏; 高橋秀徳; 若山顕治; 柿坂達彦; 敦賀陽介; 蒲池浩文; 神山俊哉; 武冨紹信, 日本外科学会定期学術集会(Web), 115th, OP-160-1 (WEB ONLY), 2015年
    日本語
  • Q&Aで学ぶ病理・細胞診領域における遺伝子検査の基本−検体の取り扱い
    畑中 豊, Medical Technology, 43, 1045, 1046, 2015年
  • 病理の立場から見たコンパニオン診断薬の開発と評価
    畑中 豊; 松野 吉宏, 医薬ジャーナル, 51, 1918, 1924, 2015年
  • 乳癌のコンパニオン診断
    畑中 豊; 松野 吉宏, 臨床検査, 59, 459, 465, 2015年
  • 非小細胞肺癌におけるHER2及び関連分子異常の観察研究(HOT1303‐A)とHER2陽性非小細胞肺癌に対するトラスツズマブの第II相試験(HOT1303‐B)の進行状況報告
    合田智宏; 木下一郎; 秋田弘俊; 大泉聡史; 西村正治; 田中伸哉; 原田敏之; 西原広史; 畑中豊; 松野吉宏; 天野虎次; 佐藤典宏; 磯部宏, 肺癌(Web), 54, 7, 992(J‐STAGE), 992, 2014年12月
    (NPO)日本肺癌学会, 日本語
  • 細胞診材料を用いた遺伝子診断の現状と問題点、将来への展望 コンパニオン診断の現状とプレアナリシス段階の重要性
    丸川 活司; 望月 抄苗; 清水 知浩; 渡部 涼子; 宮越 里絵; 山谷 幸恵; 高桑 恵美; 畑中 佳奈子; 畑中 豊; 三橋 智子; 松野 吉宏, 日本臨床細胞学会雑誌, 53, Suppl.2, 492, 492, 2014年10月
    (公社)日本臨床細胞学会, 日本語
  • CTNNB1 Mutational Analysis of Solid-Pseudopapillary Neoplasms of the Pancreas Using Endoscopic Ultrasound-Guided Fine-Needle Aspiration and Next-Generation Deep Sequencing
    Yoshimasa Kubota; Hiroshi Kawakami; Mitsuteru Natsuizaka; Kazumichi Kawakubo; Katsuji Marukawa; Taiki Kudo; Yoko Abe; Kimitoshi Kubo; Masaki Kuwatani; Yutaka Hatanaka; Tomoko Mitsuhashi; Yoshihiro Matsuno; Naoya Sakamoto, GASTROENTEROLOGY, 146, 5, S871, S871, 2014年05月
    英語, 研究発表ペーパー・要旨(国際会議)
  • 肝内胆管癌におけるZEB1、EMT関連分子の臨床病理学的検討
    寺下 勝巳; 畑中 佳奈子; 畑中 豊; 三橋 智子; 横尾 英樹; 大村 卓味; 石津 寛之; 永坂 敦; 山本 義也; 小川 浩司; 倉内 宣明; 豊田 秀徳; 熊田 卓; 金岡 祐次; 堀本 啓大; 荘 拓也; 夏井坂 光輝; 神山 俊哉; 武冨 紹信; 坂本 直哉, 肝臓, 55, Suppl.1, A335, A335, 2014年04月
    (一社)日本肝臓学会, 日本語
  • 体外診断用医薬品承認EGFR変異検出キットのホルマリン固定パラフィン包埋検体における検出感度に関する検討
    丸川 活司; 畑中 豊; 藤井 恭子; 平野 裕子; 恩田 千景; 畑中 佳奈子; 三橋 智子; 松野 吉宏, 日本病理学会会誌, 103, 1, 201, 201, 2014年03月
    (一社)日本病理学会, 日本語
  • Diagnostic Criteria for Intraductal (Intracystic) Papillary Neoplasm of the Bile Duct (IPNB) and the Gallbladder (ICPN): Histological and Immunohistochemical (IHC) Evaluation of 50 Cases
    D. Sato; T. Mitsuhashi; Y. Hatanaka; Y. Nakanishi; S. Hirano; Y. Matsuno, MODERN PATHOLOGY, 27, 454A, 454A, 2014年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • Diagnostic Criteria for Intraductal (Intracystic) Papillary Neoplasm of the Bile Duct (IPNB) and the Gallbladder (ICPN): Histological and Immunohistochemical (IHC) Evaluation of 50 Cases
    D. Sato; T. Mitsuhashi; Y. Hatanaka; Y. Nakanishi; S. Hirano; Y. Matsuno, LABORATORY INVESTIGATION, 94, 454A, 454A, 2014年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • 食道上皮内腫瘍のNBI観察における“background coloration”の出現機序についての検討
    高橋正和; 清水勇一; 吉田武史; 大野正芳; 大森沙織; 松本美櫻; 夏井坂光輝; 森康明; 中川学; 小野尚子; 中川宗一; 間部克裕; 加藤元嗣; 畑中佳奈子; 畑中豊; 坂本直哉, Gastroenterological Endoscopy, 56, Supplement 1, 2014年
  • Adenomatous polyposis coli-binding protein EB1 as an important predictive factor for the prognosis and recurrence in hepatocellular carcinoma
    Takeshi Aiyama; Tatsuya Orimo; Hideki Yokoo; Takanori Ohata; Kanako Hatanaka; Yutaka Hatanaka; Yoshihiro Matsuno; Kenji Wakayama; Tatsuhiko Kakisaka; Yosuke Tsuruga; Hirofumi Kamachi; Toshiya Kamiyama; Akinobu Taketomi, HEPATOLOGY, 60, 802A, 802A, 2014年
    英語, 研究発表ペーパー・要旨(国際会議)
  • 固形腫瘍治療とコンパニオン診断
    丸川 活司; 畑中 豊; 松野 吉宏, 臨床検査, 58, 902, 907, 2014年
  • 病理診断のための検査室運営と免疫組織化学 病理診断のための検査室の運営および管理(免疫組織化学を含めた)
    丸川 活司; 畑中 豊; 松野 吉宏, 病理と臨床, 32, 臨時増刊号, 2, 7, 2014年
  • 経過中に胸腹水細胞像の変化がみられた悪性胸膜中皮腫の一例
    丸川 活司; 恩田 千景; 仁木 涼子; 山谷 幸恵; 森谷 純; 石田 徹; 高桑 恵美; 畑中 佳奈子; 畑中 豊; 三橋 智子; 松野 吉宏, 日本臨床細胞学会北海道支部会報, 22, 42, 45, 2013年10月
    北海道臨床細胞学会, 日本語
  • Erratum: Immunohistochemical molecular expression profile of metastatic brain tumor for potent personalized medicine (Brain Tumor Pathol DOI: 10.1007/s10014-012-0124-y)
    Kato Y; Nishihara H; Yuzawa S; Mohri H; Kanno H; Hatanaka Y; Kimura T; Tanino M; Tanaka S, Brain Tumor Pathology, 30, 4, 266, 267, 2013年10月
    Brain Tumor Pathology
  • コンパニオン診断の現状と今後の課題
    畑中 豊; 西尾 和人; 松野 吉宏, 日本臨床細胞学会雑誌, 52, Suppl.2, 451, 451, 2013年10月
    (公社)日本臨床細胞学会, 日本語
  • 肝外胆管癌における上皮間葉移行(EMT)の臨床病理学的検討
    新田 健雄; 三橋 智子; 畑中 豊; 鈴木 雄太; 大庭 幸治; 畑中 佳奈子; 平野 聡; 松野 吉宏, 日本病理学会会誌, 102, 1, 308, 308, 2013年04月
    (一社)日本病理学会, 日本語
  • ヒトHER2陰性luminalタイプ乳癌におけるNKG2Dリガンドの発現解析
    畑中 豊; 鈴木 雄太; 藤田 裕美; 畑中 佳奈子; 大庭 幸治; 三橋 智子; 山下 啓子; 笠原 正典; 松野 吉宏, 日本病理学会会誌, 102, 1, 333, 333, 2013年04月
    (一社)日本病理学会, 日本語
  • The Significance of Epithelial-Mesenchymal Transition (EMT) in Extrahepatic Bile Duct Carcinoma: A Clinicopathologic Study of 122 Cases
    T. Nitta; T. Mitsuhashi; Y. Hatanaka; K. C. Hatanaka; S. Hirano; Y. Matsuno, MODERN PATHOLOGY, 26, 169A, 169A, 2013年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • The Significance of Epithelial-Mesenchymal Transition (EMT) in Extrahepatic Bile Duct Carcinoma: A Clinicopathologic Study of 122 Cases
    T. Nitta; T. Mitsuhashi; Y. Hatanaka; K. C. Hatanaka; S. Hirano; Y. Matsuno, LABORATORY INVESTIGATION, 93, 169A, 169A, 2013年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • 分子病理学的検索を目的とした新規組織固定法
    鈴木 雄太; 畑中 豊; 松野 吉宏, 検査と技術, 41, 102, 106, 2013年
  • 臓器横断 小細胞癌、高悪性度神経内分泌腫瘍の細胞診断 膵内分泌腫瘍(pancreatic neuroendocrine tumor:PanNET)の細胞所見について
    丸川 活司; 恩田 千景; 仁木 涼子; 山谷 幸恵; 森谷 純; 高桑 恵美; 久保田 佳奈子; 畑中 豊; 三橋 智子; 松野 吉宏, 日本臨床細胞学会雑誌, 51, Suppl.2, 612, 612, 2012年09月
    (公社)日本臨床細胞学会, 日本語
  • ヒト乳癌におけるNKG2Dリガンドの発現に関する検討
    藤田裕美; 畑中豊; 鈴木雄太; 久保田佳奈子; 大庭幸治; 三橋智子; 笠原正典; 松野吉宏, 日本病理学会会誌, 101, 1, 409, 409, 2012年03月26日
    (一社)日本病理学会, 日本語
  • 正確な細胞診断へのアプローチ 日常業務へのアドバイス 胸水中に出現する胸膜悪性中皮腫細胞を正確に診断するために
    丸川 活司; 飯沼 千景; 山谷 幸恵; 宮越 里絵; 森谷 純; 石田 徹; 畑中 豊; 久保田 佳奈子; 三橋 智子; 松野 吉宏, 日本臨床細胞学会雑誌, 51, Suppl.1, 214, 214, 2012年03月
    (公社)日本臨床細胞学会, 日本語
  • Epstein-Barr Virus-Associated Splenic Mesenchymal Tumor - A Proposal of Comprehensive Tumor Entity
    T. Mitsuhashi; Y. Hatanaka; K. Kubota; T. Hasegawa; T. Takahashi; Y. Matsuno, LABORATORY INVESTIGATION, 92, 355A, 356A, 2012年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • Epstein-Barr Virus-Associated Splenic Mesenchymal Tumor - A Proposal of Comprehensive Tumor Entity
    T. Mitsuhashi; Y. Hatanaka; K. Kubota; T. Hasegawa; T. Takahashi; Y. Matsuno, MODERN PATHOLOGY, 25, 355A, 356A, 2012年02月
    英語, 研究発表ペーパー・要旨(国際会議)
  • 遺伝子関連検査・検体品質管理マニュアル[承認文書]
    畑中 豊, 日本臨床検査標準化協議会・遺伝子関連検査標準化専門委員会編, 2012年
  • 固形腫瘍における遺伝子検査
    森谷 純; 山谷 幸恵; 畑中 豊; 松野 吉宏, Medical Technology, 40, 1609, 1614, 2012年
  • コンパニオン診断と病理
    畑中 豊; 西尾 和人; 松野 吉宏, 病理と臨床, 30, 1300, 1308, 2012年
  • 分子標的治療と臨床検査−大腸癌
    畑中 豊; 松野 吉宏, Medical Technology, 40, 36, 43, 2012年
  • ALK陽性を示した若年者肺腺癌の1症例
    丸川 活司; 畑中 豊; 宮越 里絵; 山谷 幸恵; 森谷 純; 山田 洋介; 久保田 佳奈子; 三橋 智子; 松野 吉宏, 日本臨床細胞学会北海道支部会報, 20, 40, 42, 2011年10月
    23歳男。咳嗽、体動時息切れ、右胸水貯留を主訴とした。喫煙歴はなく、X線、CTにて右中葉入口の腫瘤影、中葉の含気不良と右横隔膜挙上、右胸水貯留、両側肺門リンパ節腫大、肝転移、右副腎転移を疑う所見を得た。endobronchial ultrasound guided transbronchial needle aspirationで採取した細胞診標本の細胞像は通常みられる肺腺癌のそれと大差なく、大型核小体明瞭、核不整(切れ込み)、核内細胞質封入体をみる核偏在傾向で粘液産生なく、腺房状構造類似の像であった。また、胸水中に出現していた腺癌細胞について抗ALK抗体を用いた免疫細胞化学染色を行ったところ、顆粒状の陽性像を認め、ALK治療登録候補となった。。, 北海道臨床細胞学会, 日本語
  • 体腔洗浄細胞診の臨床的意義と診断 卵巣腫瘍における腹腔洗浄液細胞診の標本作製と診断
    丸川 活司; 宮越 里絵; 森谷 純; 畑中 豊; 久保田 佳奈子; 首藤 聡子; 武田 真人; 三橋 智子; 櫻木 範明; 松野 吉宏, 日本臨床細胞学会雑誌, 50, Suppl.2, 469, 469, 2011年09月
    (公社)日本臨床細胞学会, 日本語
  • ヒトNKG2Dリガンドの組織発現に関する免疫組織化学検討
    藤田 裕美; 須藤 洋一; 畑中 豊; 富居 一範; 大塚 紀幸; 松野 吉宏; 笠原 正典, 日本病理学会会誌, 100, 1, 367, 367, 2011年03月
    (一社)日本病理学会, 日本語
  • 中皮腫の細胞診を科学する 中皮腫における遺伝子異常検索 細胞診診断応用の可能性
    丸川 活司; 谷野 美智枝; 森谷 純; 山谷 幸恵; 田畑 佑希子; 畑中 豊; 久保田 佳奈子; 田中 伸哉; 松野 吉宏, 日本臨床細胞学会雑誌, 50, Suppl.1, 105, 105, 2011年03月
    (公社)日本臨床細胞学会, 日本語
  • 病理診断に役立つ分子生物学−Ki-67・細胞増殖マーカー・解説編・診断編
    畑中 豊; 長谷川 匡; 松野 吉宏, 病理と臨床, 29, 臨時増刊号, 298, 307, 2011年
  • 診断病理の精度管理−分子病理診断の標準化と精度管理
    畑中 豊; 久保田 佳奈子; 松野 吉宏, 病理と臨床, 29, 346, 352, 2011年
  • 原発性肺癌との衝突が認められた胸膜悪性中皮腫の一例:病理所見および遺伝子発現の解析
    田畑佑希子; 高澤啓; 畑中豊; 谷野美智枝; 丸川活司; 羽賀博典; 樋田泰浩; 加賀基知三; 松野吉宏, 肺癌, 50, 5, 588, 588, 2010年10月05日
    (NPO)日本肺癌学会, 日本語
  • 分子病理学的検査のための新しい検体処理法 "PAXgene Tissue System"の評価
    丸川 活司; 難波 美樹; 望月 抄苗; 清水 知浩; 飯沼 千景; 山谷 幸恵; 森谷 純; 畑中 豊, 北臨技会誌, 8, 2, 55, 55, 2010年09月
    (一社)北海道臨床衛生検査技師会, 日本語
  • トラスツズマブ治療の胃癌適応拡大とHER2検査
    畑中 豊; 森谷 純; 丸川 活司; 久保田 佳奈子; 松野 吉宏, Medical Technology, 38, 1169, 1173, 2010年
  • 分子標的治療と病理−消化管悪性腫瘍の分子標的治療と検査
    畑中 豊; 落合 淳志; 松野 吉宏, 病理技術, 73, 63, 66, 2010年
■ 書籍等出版物
  • 新臨床腫瘍学 改訂第5版
    畑中 豊, 遺伝子変異検査
    南江堂, 2018年07月, 9784524237883, 872, [分担執筆]
  • 免疫染色究極マニュアル
    畑中 豊, コンパニオン診断:Ⅱ 診断編
    金芳堂, 2018年, [分担執筆]
  • リキッドバイオプシー
    畑中 豊; 秋田 弘俊, リキッドバイオプシーによるコンパニオン診断・ゲノム診断の現状と課題
    シーエムシー出版, 2017年08月, 9784781312590, 288, [分担執筆]
  • 病理検査技術教本 (JAMT技術教本シリーズ)
    畑中 豊, 免疫組織化学:マーカー・パネル
    丸善出版, 2017年05月, 341, [分担執筆]
  • Biochemistry and Histochemistry Research Developments
    Hatanaka Y; Imaoka Y; Hashizume K; Osamura RY, Pathological research on molecular-targeted therapy and advanced immunohistochemical approaches
    Nova Scienc Publishers, 2010年, [分担執筆]
  • 体外診断用医薬品の開発と承認申請
    畑中 豊; 松野 吉宏, 治療薬開発およびコンパニオン診断薬との同時開発の現状と今後
    技術情報協会出版, 2010年, 361, 347-361, [分担執筆]
■ 主な担当授業
  • 医学総論, 2024年, 博士後期課程, 医学研究科
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
■ 所属学協会
  • 日本レギュラトリーサイエンス学会
  • 日本肺癌学会
  • 日本臨床腫瘍学会
  • 日本癌学会
  • 日本病理学会
■ 共同研究・競争的資金等の研究課題
  • 細胞外小胞(EV)分子プロファイルに基づく肺がん診断法の開発
    科学研究費助成事業
    2026年04月01日 - 2029年03月31日
    加藤 達哉; 畑中 佳奈子; 畑中 豊; 新垣 雅人; 龍崎 奏
    日本学術振興会, 基盤研究(C), 北海道大学, 26K10227
  • 免疫関連因子CD73のトリプルネガティブ乳癌周術期治療効果・有害事象との関連性の検討
    科学研究費助成事業
    2024年04月01日 - 2027年03月31日
    高橋 將人; 畑中 佳奈子; 畑中 豊; 木下 一郎; 野口 卓郎; 富岡 伸元
    日本学術振興会, 基盤研究(C), 北海道大学, 24K11757
  • 子宮体癌の分子分類診断システムの開発と新規治療標的の探索を志向したゲノム解析研究
    科学研究費助成事業
    2024年04月01日 - 2027年03月31日
    渡利 英道; 畑中 佳奈子; 金野 陽輔; 畑中 豊; 朝野 拓史; 山崎 博之
    日本学術振興会, 基盤研究(B), 北海道大学, 24K02581
  • 心房細動の病態進行における心臓周囲脂肪ミトコンドリア機能の役割
    科学研究費助成事業
    2022年04月01日 - 2025年03月31日
    渡邉 昌也; 畑中 豊; 新宮 康栄; 横田 卓
    日本学術振興会, 基盤研究(C), 北海道大学, 22K08197
  • がん免疫療法の効果予測についての検討
    科学研究費助成事業
    2022年04月01日 - 2025年03月31日
    菊地 順子; 畑中 佳奈子; 天野 虎次; 畑中 豊; 木下 一郎
    日本学術振興会, 基盤研究(C), 北海道大学, 22K07292
  • 肺がん糖鎖抗原を用いた光免疫とiRGDナノ粒子によるsiRNA送達システムの開発
    科学研究費助成事業
    2021年04月01日 - 2024年03月31日
    加藤 達哉; 櫻井 遊; 畑中 佳奈子; 小川 美香子; 樋田 泰浩; 畑中 豊
    本研究はMUC1がん特異的糖鎖抗原のみを選択的に認識する新規モノクローナル抗体(MUC1-Tn抗体)と光感受性物質であるIR700との結合体を用いて、がん細胞のみを特異的に攻撃する新たな治療法を確立し、新規の肺がん治療法の開発を目指すものである。
    今年度は、まず本研究の肝となるMUC1-Tn抗体の供給源である㈱医化学創薬と共同で研究をすすめ、MTAを締結し、本実験で想定される抗体量の確保に努め、動物実験まで含めた十分量の抗体を得ることに成功した。
    さらに今年度は、研究実施計画に則り、まず今後in vitro実験およびin vivo実験に用いる予定のMUC1-Tn高発現の細胞株の選定を行った。乳癌細胞株であるT47DがMUC1-Tnが高発現していることが判明したが、その後21個の肺癌細胞株のセルブロックを作成し、抗MUC1-Tn抗体を用いて免疫染色を行った。うち2株(RERF-LC-KJ, H2228)に高発現が認められ、今後、in vitroおよびin vivo実験に使用可能と判断した。その他、陰性コントロールとしての細胞株も複数選定した。
    また、実験遂行者はすでにIR700と抗MUC1-Tn抗体を合成する技術を習得しており、予備実験として、MUC1-Tn抗体とIR700の結合体を作成し、T47Dに導入後、FACSにて細胞膜表面に抗体が結合していることを確認した。また、タイムラプス顕微鏡でレーザー照射により導入細胞で細胞膜よりブレブが隆起し、細胞死に至ることを確認することができた。したがって今後肺癌細胞株を用いた本実験を開始できる状況にある。
    日本学術振興会, 基盤研究(C), 北海道大学, 21K08876
  • AIを用いた肺癌病変の腫瘍含有割合をリアルタイムに予測するEBUSシステムの開発
    科学研究費助成事業
    2021年04月01日 - 2024年03月31日
    品川 尚文; 畑中 豊
    【背景】肺がん診療において網羅的に遺伝子解析を行うことができる次世代シーケンサー(NGS)の重要性は年々高まっている。本邦で広く普及しているオンコマインDx Target TestマルチCDxシステムを用いた遺伝子解析には腫瘍細胞含有率30%以上の検体が推奨されているが、経気管支生検では腫瘍細胞含有率が低い検体しか採取できないことがある。
    【目的】ガイドシース併用気管支腔内超音波断層法下経気管支生検(EBUS-GS-TBB)検体の腫瘍細胞含有率と関連がある臨床因子を明らかにする。
    【方法】当院で2018年10月から2021年9月の期間にEBUS-GS-TBB 検体を用いてNGS解析を行なった50例を対象とし、腫瘍細胞含有率30%未満(低率群)と30%以上(高率群)の2群に分け、後方視的に検討した。
    【結果】低率群、高率群はそれぞれ13例、37例であった。低率群は高率群と比較して病変が肺門からの距離 “内側1/3” に存在している症例が多い傾向があった(46.2% vs 18.9%, p=.073)。EBUS所見については低率群では高率群と比較してAdjacent toであった症例(38.5% vs 8.1%, p=.021)や栗本分類Type ⅢBであった症例(76.9% vs 37.9%, p=.024)が有意に多かった。一方で生検回数、使用したガイドシースのサイズ、1.5mm鉗子以外のデバイス(1.9mm鉗子やクライオプローブ)使用の有無では含有率に差がなかった。
    【結語】EBUS-GS-TBB検体の腫瘍細胞含有率は病変位置やEBUS所見によって予測できる可能性がある。今後、AIを使ったEBUS画像の解析を開始する。
    日本学術振興会, 基盤研究(C), 北海道大学, 21K08170
  • マウス肺癌モデルを用いたCD73を標的とした赤外光線免疫療法の確立
    科学研究費助成事業
    2021年04月01日 - 2024年03月31日
    畑中 豊; 加藤 達哉; 小川 美香子; 畑中 佳奈子
    がん微小環境において,低酸素状態下ではATPからAMPを介しアデノシンを生成する
    CD39/CD73カスケード分子の発現が誘導され,さらにアデノシンはリンパ球上のA2受容体を介して免疫抑制状態を誘導することから,免疫チェックポイント阻害(ICI)療法に対し抵抗性を示す.
    本研究は,先行研究として実施した非小細胞肺癌(NSCLC)の一部でCD73発現が亢進し,またPD-L1発現と相関する点に着目し,(a) NSCLC組織検体を用いたCD73およびPD-L1発現と腫瘍微小環境との関連性について検討し,次いで(b) ヒトおよびマウス肺癌細胞株を用いたCD73-IR700-Cのがん細胞への集積確認と治療効果のin vitro評価,および(c) ヒトおよびマウス肺癌細胞株の移植腫瘍モデルを用いたCD73抗体-IR700結合体(CD73-IR700-C)の腫瘍集積性の確認および近赤外線免疫療法(NIR-PIT)の抗腫瘍効果のin vivo評価を行う.
    本年度は以下の課題に取り組んだ.肺扁平上皮癌症例を用いた組織マイクロアレイ(TMA)標本123例を用いた低酸素関連タンパクの臨床病理学的検討:CD73,PD-L1およびHIF-1a発現について検討したところ,先行研究同様,CD73とPD-L1発現間に有意な関連性(p=0.019)が認められ,またCD73とHIF-1a発現間にも関連傾向(p=0.0548)が観察された.これら3分子の生存解析においては,低発現群に比べ高発現群で,それぞれ有意な無再発生存期間(RFS)の短縮が認められ,さらにCD73高発現/HIF-1a高発現群ではさらに短縮した(p=0.0187).
    日本学術振興会, 基盤研究(C), 北海道大学, 21K07189
  • ゲノム・遺伝子変異プロファイル解析を用いた膵癌における新規治療戦略の構築
    科学研究費助成事業
    2020年04月01日 - 2023年03月31日
    浅野 賢道; 中村 透; 土川 貴裕; 平野 聡; 畑中 豊; 畑中 佳奈子; 天野 虎次
    令和3年度も新型コロナ感染症によりある程度の制約はあるものの、予定していた研究を進めることができた。
    まず、化学療法前後の遺伝子変異プロファイルを明らかにすべく、生検献体および切除検体の次世代シークエンサーによる遺伝子変異解析を行った。化学療法前の解析にはEUS-FNAにより得られた生検検体を用いることを予定しており、22G針で採取されるため検体量が少ないことは想定していたものの、症例により検体量に大きな差があることが判明した。パイロット的に比較的多く採取されている検体を用いてマイクロダイセクション法によるDNAの抽出・精製を行ったが、ターゲットシークエンスに用いるだけの十分なDNAの抽出が極めて困難であった。技術的要因も多分にあると考えられたが、この状況を鑑みると、他の少量検体ではより一層困難であることは容易に予測でき、生検検体を用いた化学療法前の遺伝子変異解析は断念せざるを得なかった。
    一方、化学療法後の遺伝子変異解析には根治手術により得られた切除検体を用いるため、予定通りDNAの抽出・精製を行うことができ、ライブラリーDNAを作成することが可能であった。生存期間が「1年未満」で再発を認めた症例を早期再発群、「5年以上」の症例を長期生存群とし、各群15症例ずつを解析した。Ion PGMTMシステムを用いたターゲットシークエンスの結果、早期再発群で変異を認めたのは、KRAS、TP53、SMAD4、CDKN2Aの4遺伝子(いわゆるBig 4)であり、特にTP53とSMAD4は長期生存群との間に差を認める傾向にあった(p<0.1)。現在、さらなる解析を進めている。
    また、これに並行してliquid biopsyによる遺伝子変異解析も開始した。現時点では数例にとどまっているものの、術前に採取された血液の血漿からcell-free DNAを抽出し、解析を進めている。
    日本学術振興会, 基盤研究(C), 北海道大学, 20K09094
  • 卵巣がんの血管新生阻害薬耐性の発生を予防するためのCCR2阻害薬併用療法の開発
    科学研究費助成事業
    2019年04月01日 - 2022年03月31日
    三田村 卓; 渡利 英道; 畑中 佳奈子; 天野 虎次; 畑中 豊
    免疫不全マウスを用いて卵巣がん患者の連続した3つの移植腫瘍モデルを作製し、ベバシズマブ単剤治療に対するCCR2阻害薬の上乗せ効果を検証した。ベバシズマブとCCR2阻害薬との併用療法(BEV/CCR2i)は、ベバシズマブ単剤治療(BEV)と比較して有意な腫瘍増殖抑制効果を示し、その機序は血管新生阻害効果の上乗せ効果、あるいは腫瘍細胞CCR2B-MAPK経路の直接的な阻害効果によるものであった。これらの結果はBEV/CCR2iの抗腫瘍免疫非依存的な相乗効果を立証しており、臨床応用が望まれる。特に漿液性がん患者において有用と考えられる。
    日本学術振興会, 基盤研究(C), 北海道大学, 19K09818
  • 早期食道腺癌・接合部腺癌の蛍光プローブによる検出に関する多施設共同研究
    科学研究費助成事業 基盤研究C
    2017年04月 - 2020年03月
    山本 桂子
    日本学術振興会, 競争的資金
  • HER2陽性再発転移の唾液腺癌に対する個別化治療の開発
    臨床研究・治験推進研究事業
    2017年 - 2019年
    秋田 弘俊
    日本医療研究開発機構(AMED), 競争的資金
  • がんゲノム個別化医療の実現に向けた遺伝子診断共通カリキュラム構築と 教育・研修プログラムの実証的開発研究
    革新的がん医療実用化研究事業
    2016年 - 2018年
    西尾 和人
    日本医療研究開発機構(AMED), 競争的資金
  • RHOシグナル経路制御分子群を用いた新規の膵癌分子診断法および標的治療法の開発
    科学研究費助成事業 基盤研究C
    2016年 - 2018年
    三橋 智子
    日本学術振興会, 競争的資金
  • 自己免疫性疾患患者に発生するリンパ増殖性疾患の病態解明と治療効果予測因子の同定
    科学研究費助成事業 基盤研究C
    2016年 - 2018年
    畑中 佳奈子
    日本学術振興会, 競争的資金
  • SCRUM-Japanで組織した遺伝子スクリーニング基盤を利用した多施設他職種専門家から構成されたExpert Panelによる全国共通遺伝子解析・診断システムの構築および研修プログラムの開発
    革新的がん医療実用化研究事業
    2017年
    吉野 孝之
    日本医療研究開発機構(AMED), 競争的資金
  • 先端的がん医療実施のための地域完結型病理診断及び臨床・病理連携ネットワークの構築に関する研究
    厚生労働科学研究費補助金 がん対策推進総合研究事業
    2015年 - 2016年
    桑田 健
    厚生労働省, 競争的資金
  • 遺伝子プロファイリングおよび細胞形態に基づく膵癌分子サブタイピング法の確立
    科学研究費助成事業 基盤研究C
    2013年 - 2016年
    三橋 智子
    日本学術振興会, 競争的資金
  • 中枢神経原発悪性リンパ腫の生物学的特性の解明と治療効果予測因子の同定
    科学研究費助成事業
    2012年04月01日 - 2015年03月31日
    畑中 佳奈子; 松野 吉宏; 畑中 豊; 小林 浩之
    本研究では、大量メソトレキセート/放射線併用療法をうけた中枢神経原発大細胞性B細胞性リンパ腫を対象とし、MGMT、CDKN2A、DAPK1、LINE1のプロモーター領域のメチル化状態を検討し臨床病理学的検討を行った。各遺伝子のメチル化割合はパイロシークエンス法により解析し、割合の中央値をカットオフとして2群化し、統計解析を行い、以下の点が明らかとなった:1)LINE1およびDAPK1の低メチル化は、生存期間の延長と関連していた。2)治療効果との関連性では、CDKN2A及びDAPK1の低メチル化群の治療奏効率が高かった一方、LINE1とMGMTのメチル化状態では奏効率に差は認められなかった。
    日本学術振興会, 若手研究(B), 北海道大学, 24790341
  • NKG2Dリガンドのがん抗体療法における役割解明とこれを用いた治療効果予測
    科学研究費助成事業 基盤研究C
    2012年 - 2015年
    松野 吉宏
    日本学術振興会, 競争的資金
  • 治療効果予測困難な現行のEGFR抗体治療における新規予測検査法の開発
    科学研究費助成事業 基盤研究C
    2012年 - 2015年
    畑中 豊
    日本学術振興会, 研究代表者, 競争的資金
  • 医療用バイオチップ実用化促進に向けたヒト核酸の測定プロセスに関する 国際標準化
    工業標準化推進事業委託費・戦略的国際標準化推進事業委託費
    2012年
    JCCLS/JMAC
    経済産業省, 競争的資金
  • 遺伝子関連検査に係る検体品質管理技術の開発に関するフィージビリティスタディ
    協会委託事業
    2011年 - 2011年
    JCCLS
    財団法人機器システム振興協会, 競争的資金
  • 抗HER2治療抵抗性を示すp95HER2タンパクの測定法確立と検査実用化の試み
    科学研究費補助金・研究活動スタート支援
    2010年 - 2011年
    畑中 豊
    文部科学省, 研究代表者, 競争的資金
■ 産業財産権
  • DNA結合タンパク質の活性測定方法
    特許権, 芦田 均; 畑中 豊; 福田 伊津子; 藪下 善行; 水野 雅史
    特願PCT/ JP 2002/057516, 2002年
  • プローブ試薬および該プローブ試薬を用いたFISH
    特許権, 磯田 武寿; 関口 満; 畑中 豊; 栗原 義一
    特願PCT/JP2015/058612
  • 脂肪性肝疾患の診断方法,診断装置,診断プログラム,診断薬及び脂肪性肝疾患用治療薬のスクリーニング方法
    特許権, 中島 淳; 米田 正人; 藤田 浩司; 中江 大; 高村 岳樹; 高橋 正一; 畑中 豊
    特願PCT/JP2007/067029